{"d48449ff827937b1f17f84eaa5ce9e12e34333a3": [["Durch die wirtschaftliche Globalisierung und erleichterte Urlaubsreisen in alle Kontinente k\u00f6nnen heute bereits leicht Infektionskrankheiten wie virusbedingtes h\u00e4morrhagisches Fieber (Ebola) oder \"severe acute respiratory syndrome\" (SARS) nach Deutschland eingeschleppt werden.", [["acute respiratory syndrome", "DISEASE", 204, 230], ["SARS", "DISEASE", 233, 237], ["severe acute respiratory syndrome", "PROBLEM", 197, 230], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["respiratory syndrome", "OBSERVATION", 210, 230]]], ["In Betracht sind aber auch potenzielle Infektionssituationen zu ziehen, wie avi\u00e4re Influenza (Vogelgrippe) oder Bioterrorismus, z.", [["Influenza (Vogelgrippe)", "TREATMENT", 83, 106]]], ["B. durch Anthraxviren, die sehr schnell und unerwartet ein Krankenhaus tangieren und eine effiziente Notfallplanung erfordern k\u00f6nnen.", [["B. durch Anthraxviren, die sehr schnell und unerwartet ein Krankenhaus tangieren und eine effiziente Notfallplanung erfordern k\u00f6nnen", "SPECIES", 0, 132], ["B. durch Anthraxviren", "TREATMENT", 0, 21]]]], "0924246123956e4b191cd08da4af4b98a465b0f7": [["IntroductionResidency programs invest a significant amount of time and resources on the recruitment process, with a recent surgery publication estimating approximately 100,000 USD \u00b1 87,000 per interview season for university-based programs.", [["a recent surgery", "TREATMENT", 114, 130], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["amount", "OBSERVATION_MODIFIER", 52, 58]]], ["[1] In an era of increasing focus on cost containment, such lavish spending has generated calls for making the process more cost efficient.", [["cost containment", "TREATMENT", 37, 53], ["increasing", "OBSERVATION_MODIFIER", 17, 27], ["focus", "OBSERVATION", 28, 33]]], ["With the interview day playing such a significant role for residents and programs, it is imperative to focus on providing applicants with information they find most useful, but in a safe and cost-effective manner.IntroductionMany university-based residency training programs are faced with providing applicants an accurate portrayal of what their residency experience will be like, but are challenged with the fact that their residents participate in clinical rotations at multiple teaching hospitals.", [["residency training programs", "TREATMENT", 247, 274]]], ["COVID-19 is dramatically changing these traditional strategies as national organizations like the Association of American Medical Colleges (AAMC) are strongly encouraging that interviews and tours be held 'in a virtual settingeither by phone or video conferencing.' [2] Virtual Reality (VR) is a technology that has emerged as a cost-effective and impactful tool for use in medical education.", [["medical education", "TREATMENT", 374, 391]]], ["The primary component of a VR experience typically includes a motion sensitive screen built into a goggle or headset.", [["a motion sensitive screen", "PROBLEM", 60, 85]]], ["By steering the motion sensitive device with head movements, they are able to navigate the virtual environment as if they were actually there.", [["head", "ANATOMY", 45, 49], ["head", "ORGANISM_SUBDIVISION", 45, 49]]], ["The 3Denvironment can range from static images to fullmotion video and can have audio associated with it.", [["static images", "TEST", 33, 46], ["fullmotion video", "TEST", 50, 66]]], ["The technology has become less expensive since its introduction and is now more widely used in different industries ranging from medicine, gaming and education, to tourism and sales.", [["less", "OBSERVATION_MODIFIER", 26, 30]]], ["Some studies show that VR improves post-intervention knowledge scores and health professionals' cognitive skills compared to traditional learning.", [["Some studies", "TEST", 0, 12], ["VR", "PROBLEM", 23, 25]]], ["[5] With the intention to maximize the interview day and provide a cost-effective alternative to off-site hospital tours, the Internal Medicine-Pediatrics (Med-Peds) Residency Program at Rutgers New Jersey Medical School introduced a VR tour of its offsite children's hospital during recruitment and reviewed feedback from the applicants.", [["children", "ORGANISM", 257, 265], ["children", "SPECIES", 257, 265]]], ["While this study was performed prior to COVID-19 pandemic and the new AAMC recommendations, we take the opportunity to discuss the implications of VR technology on the future of the applicant interview process.MethodsThe Med-Peds residency training program interviewed 54 applicants during the 2018-2019 interview season.", [["this study", "TEST", 6, 16], ["COVID", "TEST", 40, 45], ["VR technology", "TREATMENT", 147, 160]]], ["In previous years, applicants would receive an in-person hospital tour of the primary teaching site and then be shuttled to the alternate teaching site where an in-person tour of the children's hospital would follow.", [["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191]]], ["To minimize travel time and costs, the program introduced VR as a substitute for the alternate site, in-person, hospital tour as part of the 2018-2019 interview, but maintained the in-person hospital tour of the primary hospital.", [["person", "SPECIES", 104, 110]]], ["Both tours included several points of interest, ranging from the intensive care units to the cafeteria, but removed the travel required to go from site to site.MethodsTo create the VR experience of the alternate teaching site, a VR headset utilizing Google Cardboard and the Google Cardboard application (app) for VR were used.", [["VR", "PROBLEM", 314, 316]]], ["Photos of the alternate teaching site were taken with a 360-degree camera prior to the start of the recruitment season.", [["alternate teaching site", "DNA", 14, 37], ["a 360-degree camera", "TREATMENT", 54, 73]]], ["On the interview day, applicants were then given a cardboard-constructed goggle that can house the user's smart phone and be worn over the eyes with an elastic headband.", [["eyes", "ANATOMY", 139, 143], ["eyes", "ORGAN", 139, 143], ["eyes", "ANATOMY", 139, 143]]], ["As the user turns the head left, right, up, and down, the viewer's perspective moves accordingly, allowing for 360-degree visualization of the virtual environment.", [["head left", "ANATOMY", 22, 31], ["head", "ORGANISM_SUBDIVISION", 22, 26], ["head", "ANATOMY", 22, 26], ["left", "ANATOMY_MODIFIER", 27, 31], ["right", "ANATOMY_MODIFIER", 33, 38]]], ["A faculty member guided the applicants on a VR tour of the children's hospital, providing an explanation of the different points of interest, while the applicants remained seated at the primary site.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]], ["The applicants were encouraged to browse freely through the images and ask questions.", [["the images", "TEST", 56, 66]]], ["Afterwards, they were given the Google Cardboard set to take home and could access the images for future reference.", [["the images", "TEST", 83, 93]]], ["The cardboard goggles had a purchase price of 3 USD/goggle and a total cost of 175.", [["cardboard goggles", "OBSERVATION", 4, 21]]], ["The survey included specific statements about the use of VR and its potential advantages, and asked applicants to indicate their level of agreement or disagreement.", [["VR", "TREATMENT", 57, 59]]], ["The study protocol was approved as an exempt review by the Rutgers Health Sciences IRB in Newark.ResultsThe online survey was completed by 33 out of the 54 applicants who interviewed.", [["The study protocol", "TEST", 0, 18]]], ["Most applicants (72%, n = 24) agreed or strongly agreed that it was helpful to review the facility images after the interview day and 75% (n = 25) agreed or strongly agreed that they appreciated being able to use the provided VR head set for recreational purposes after the interview day ( Figure 1) .ResultsThe in-person tour of the primary teaching hospital rated an average 4.34 out of 5 and VR tour of the children's hospital was rated an average 3.93 out of 5.", [["head", "ORGANISM_SUBDIVISION", 229, 233], ["children", "ORGANISM", 410, 418], ["person", "SPECIES", 315, 321], ["children", "SPECIES", 410, 418]]], ["The in-person facility and VR tours were ranked 8th and 9th out of 11 respectively ( Table 2) .", [["person", "SPECIES", 7, 13]]], ["Applicants provided a variety of positive and negative comments about the experience (Table 3) .ResultsDuring the previous interview season, applicants spent 1.5 hours at the off-site children's hospital, 1 hour in transport time, and completed the interview day by approximately 3:30 PM.", [["children", "ORGANISM", 184, 192], ["children", "SPECIES", 184, 192]]], ["During the 2018-2019 season, applicants spent 30 minutes touring the children's hospital via VR, and of the time saved from eliminating the transport period and a second walking tour, 1 hour was used towards additional face-to-face time with residents and program leadership at an extended lunch provided at the primary hospital.", [["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77]]], ["The interview day was completed by 2 PM with the 2018-2019 schedule.ResultsDuring the previous season, the Rutgers Med-Peds department spent 2,520 USD USD on transportation between sites.", [["Med", "ANATOMY", 115, 118]]], ["The personalized VR cardboard headsets saved 2,345 USD USD, which was then utilized to fund applicant pre-interview dinners and to support other program activities throughout the year.DiscussionSubstituting a VR tour of the off-site children's hospital in place of an in-person tour significantly impacted the 2018-2019 interview season by saving time and money while improving applicants' perception of the program.", [["children", "ORGANISM", 233, 241], ["children", "SPECIES", 233, 241]]], ["While this study provided a VR experience in-person, it is also possible to provide applicants a similar experience remotely in order to save applicant time and money.DiscussionMost applicants interview at several institutions as part of the matching process, which may result in 'interview fatigue' as exemplified by one of the comments: 'Virtual tour was great!", [["fatigue", "DISEASE", 291, 298], ["person", "SPECIES", 45, 51], ["this study", "TEST", 6, 16]]], ["This could explain why a majority of the applicants preferred VR tours over in-person tours.", [["person", "SPECIES", 79, 85]]], ["Using VR as an alternative to an in-person facility tour is beneficial for the program overall and allows for time to be spent in more 'valuable' parts of the interview process.", [["VR", "TREATMENT", 6, 8]]], ["Saving 2,345 USD in recruitment funds allowed for the program's budget to be spent on other necessary resources like applicant pre-interview dinners, in which current residents spend time with the applicants the night prior to the interview.", [["recruitment funds", "TREATMENT", 20, 37]]], ["Especially in light of the current pandemic and recommendation from the AAMC to do all interviews 'virtually,' one could simply mail the google cardboard headsets to each applicant with directions on its use for a nominal postage fee.", [["a nominal postage fee", "TREATMENT", 212, 233]]], ["Photos and video files can be easily downloaded from any website or share drive for free and interactive tour guides can be pre-recorded or provided to the applicants through teleconferencing.", [["video files", "TEST", 11, 22]]], ["VR in either situation would allow for significant cost savings, while keeping social distancing measures in place.DiscussionThe VR tour also had a favorable impact on more than half of the applicants' perception of the program and almost as many would like to see VR used by other programs.", [["VR", "PROBLEM", 0, 2], ["significant cost savings", "PROBLEM", 39, 63], ["social distancing measures", "TREATMENT", 79, 105]]], ["The current pandemic will likely make it even harder for programs to make a significant impression through virtual media, especially if teleconferencing becomes a standardized approach.", [["virtual media", "TREATMENT", 107, 120], ["a standardized approach", "TREATMENT", 161, 184]]], ["In a highly competitive environment where residency training programs try to increase their appeal to prospective residents, innovative technology, such as VR, can make a difference on the applicants' rank lists.", [["residency training programs", "TREATMENT", 42, 69]]], ["Incorporating VR into a program's interview process can be a tricky process.", [["a tricky process", "PROBLEM", 59, 75], ["tricky", "OBSERVATION", 61, 67]]], ["As nearly half of the applicants had difficulty using the goggles, it is necessary to have dedicated staff or expertise available to the applicants to help troubleshoot the process.", [["the goggles", "TREATMENT", 54, 65]]], ["The ease of the VR tour was largely reliant on the applicant's ability to download the app and photos to their smart phones prior to the interview day, and there seemed to be a large variability of app functionality and phone quality.", [["large", "OBSERVATION_MODIFIER", 177, 182], ["variability", "OBSERVATION", 183, 194]]], ["Some of the comments from the applicants showed how technically challenging the process can be, even in person, and suggest that a poor implementation risks a detrimental impact to the applicant's impression of the program.", [["person", "SPECIES", 104, 110]]], ["Purchasing headsets that include a screen and have the images pre-loaded could overcome these technical difficulties, however, would increase the cost of the technology and would unlikely be offered remotely.", [["a screen", "TEST", 33, 41], ["the images", "TEST", 51, 61], ["the technology", "TREATMENT", 154, 168]]], ["Some individuals even experienced motion sickness while using the headset.", [["motion sickness", "DISEASE", 34, 49], ["Some individuals", "PROBLEM", 0, 16], ["motion sickness", "PROBLEM", 34, 49]]], ["Having an alternative for the VR tour such as a slide show of images from the off-site hospital should be an alternative for applicants who are unable to tolerate VR.", [["images", "TEST", 62, 68], ["VR", "TEST", 163, 165]]], ["This pilot study suggests that VR facility tours have the potential of replacing in-person tours at alternate hospital sites, but a direct comparison between a VR tour done remotely versus inperson of the same site would remain to be validated.", [["person", "SPECIES", 84, 90], ["This pilot study", "TEST", 0, 16], ["a VR tour", "TEST", 158, 167]]], ["Even though 66% of the applicants either somewhat or strongly agree that VR tours are comparable to inperson ones, the in-person tour was rated higher than the VR tour (4.34 vs 3.93), however, these results are difficult to interpret since they evaluate different facilities (main hospital vs alternate hospital).", [["person", "SPECIES", 122, 128]]], ["This lack of a 'randomized-control' trial limits this study's ability to directly compare the quality of the in-person tour of the primary teaching site versus the VR tour of the children's hospital.", [["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187], ["a 'randomized-control' trial", "TREATMENT", 13, 41], ["this study", "TEST", 49, 59]]], ["Performing such a study would require randomizing applicants to either an in-person tour group or a VR tour group of the same site, which would be hard to accomplish during an interview season.", [["a study", "TEST", 16, 23]]], ["Studies would also need to compare the effectiveness of doing VR tours remotely versus receiving VR instruction in-person.ConclusionUse of VR facility tours as an alternative to in-person tours of off-site teaching hospitals during a residency interview day is a viable and innovative option that can save time and money, and favorably impact the applicant's impression of the program.", [["person", "SPECIES", 115, 121], ["VR instruction", "TREATMENT", 97, 111]]], ["Showed respect for our feet, but we were still able to see what it looks like.Conclusion\u2022 I really liked the virtual tour as it saved much time and it was cold outside!", [["feet", "ANATOMY", 23, 27]]], ["Concern for lack of in-person view of the facilities reviewed in virtual tourConclusion\u2022 I thought it was an interesting idea; however, for this really critical decision I would have liked seeing the hospital in person.Conclusion\u2022 I would swap the virtual tour for a real one.", [["person", "SPECIES", 212, 218]]], ["While it isn't very important to see the facilities, if you are going to promote the hospital it would be better to show it via real life tour.ConclusionConcern for difficulty with the implementation and/or utilization of novel technologyConclusion\u2022 Strongly dislike.", [["novel technology", "TREATMENT", 222, 238]]], ["VR has not yet been made properly for people wearing contact lenses and often makes them nauseous or gives them headaches/migrainesConclusion\u2022 Virtual reality tour was a bit complicated; I think a PowerPoint of some images of [the children's hospital] would be an easier alternative.Conclusion\u2022 I think it is a great tool, unfortunately I experienced severe motion sickness.", [["headaches", "DISEASE", 112, 121], ["migraines", "DISEASE", 122, 131], ["motion sickness", "DISEASE", 358, 373], ["people", "ORGANISM", 38, 44], ["children", "ORGANISM", 231, 239], ["people", "SPECIES", 38, 44], ["children", "SPECIES", 231, 239], ["them nauseous", "PROBLEM", 84, 97], ["them headaches", "PROBLEM", 107, 121], ["migraines", "PROBLEM", 122, 131], ["severe motion sickness", "PROBLEM", 351, 373], ["motion sickness", "OBSERVATION", 358, 373]]], ["Unclear if that was a malfunction/issue with the app or not.", [["a malfunction/issue", "PROBLEM", 20, 39]]]], "14d6f0a1a52cf5ab010f2edd89c941c3498f40fb": [["IntroductionThe theory of political survival has proved adept at explaining the behavior of both voters and governments in the wake of disasters.", [["political survival", "TREATMENT", 26, 44]]], ["Risk-averse governments, aware of this, pursue visible and proactive disaster policies -in particular in competitive political settings and close to elections.IntroductionHowever, the great variation in vaccination rates across several western democracies following the 2009 pandemic runs counter to this prediction of political behavior.", [["vaccination rates", "TREATMENT", 203, 220], ["great", "OBSERVATION_MODIFIER", 184, 189], ["variation", "OBSERVATION_MODIFIER", 190, 199]]], ["This paper addresses why the theory of political survival appears to have limited predictive power with respect to government behavior in the case of the 2009 pandemic.IntroductionThe paper's thesis is that pandemic responses are led by national public health agencies (i.e. guided by expertise) rather than government executives (i.e. guided by principles of political survival).", [["political survival", "TREATMENT", 360, 378]]], ["This is important because the source of leadership has critical implications for pandemic vaccination policies.", [["pandemic vaccination policies", "TREATMENT", 81, 110]]], ["In contrast to other disasters, where the logic of political survival usually incites executives to choose a politically precautionary response strategy, public health agencies follow their expert judgments and practice in opting for pandemic responses that could either follow a precautionary or a proportional strategy.", [["a proportional strategy", "TREATMENT", 297, 320]]], ["Hence, national pandemic responses such as vaccine purchases and distribution become highly divergent, depending upon which strategy health authorities use.IntroductionTo identify the source of leadership, the paper assesses expectations of an expertisebased approach to pandemic response with expectations of an approach based on political survival.", [["vaccine purchases", "TREATMENT", 43, 60], ["an expertisebased approach", "TREATMENT", 241, 267], ["an approach", "TREATMENT", 310, 321], ["political survival", "TREATMENT", 331, 349]]], ["The paper supports that, counter to dominant expectations, pandemic responses in mature democracies are led by expertise rather than for political survival.IntroductionThe political survival logical of government responses to disasters Political theory of disaster management generally hypothesizes that democratic governments will go to great lengths to help victims of disasters (Gasper and Reeves, 2011a, b; Morrow et al., 2008; Boin et al., 2008 Boin et al., , 2005 Diamond, 2008; Mesquita et al., 2003; Sen, 1999 Sen, , 2009 .", [["political survival", "TREATMENT", 137, 155], ["disaster management", "TREATMENT", 256, 275]]], ["Government responsiveness in times of crisis is thus not necessarily linked to benevolence but to the fact that governments -fighting for survival (re-election) -will go to great lengths to avoid a humanitarian catastrophe.", [["benevolence", "DISEASE", 79, 90], ["crisis", "PROBLEM", 38, 44], ["a humanitarian catastrophe", "PROBLEM", 196, 222], ["catastrophe", "OBSERVATION", 211, 222]]], ["A free and active media improves conditions for retrospection by performing two basic functions: one as a mediator of information and one as a watchdog scrutinizing the government's disaster management (Sen, 1999; Besley and Burgess, 2002) .", [["free", "OBSERVATION_MODIFIER", 2, 6], ["active", "OBSERVATION_MODIFIER", 11, 17]]], ["The existence of vibrant opposition parties is also important because they present voters with a credible ruling alternative; they might even be able to overturn the government directly though parliamentary procedures (a vote of no-confidence, for instance); and they will generally be highly critical of the government's handling of the disaster.", [["vibrant opposition", "OBSERVATION", 17, 35]]], ["Hence, the opposition, the electorate and the media form a trinity responsible for the political dynamic that spurs the government to respond to disasters (Diamond, 2008; Boin et al., 2005) .DPM 23,1There is ample empirical evidence supporting the two basic assumptions underlying the logic of political survival in response to disasters: first, studies overwhelmingly confirm that voters are retrospective and punish incumbent government for deficient responses to natural hazards (Cole et al., 2012; Malhotra, 2009, 2010; Achen and Bartels, 2004) ; and second, studies also suggest that incumbent governments are well aware of this and that they adjust their disaster responses accordingly (Bechtel and Hainmueller, 2011; Healy and Malhotra, 2009; Reeves, 2011; Gasper and Reeves, 2011a, b) .DPM 23,1The logic of political survival applied to the 2009 pandemic The theory of political survival leads to three specific expectations about government response policies to influenza pandemic disasters.DPM 23,1One is that, all else being equal, mature democracies will respond to influenza pandemics such as the novel \"swine flu\" in 2009 with vaccination policies that are fairly uniform and precautionary.", [[".DPM 23,1", "CHEMICAL", 190, 199], ["influenza pandemics", "DISEASE", 1078, 1097], ["swine flu", "DISEASE", 1117, 1126], ["swine", "SPECIES", 1117, 1122], ["deficient responses", "PROBLEM", 443, 462], ["political survival", "TREATMENT", 815, 833], ["influenza pandemics", "PROBLEM", 1078, 1097], ["vaccination policies", "TREATMENT", 1141, 1161]]], ["The costs of pursuing a precautionary strategy of purchasing and distributing enough vaccines for all citizens are miniscule compared to the political costs of inadequate protection in case of a full-blown epidemic.", [["a precautionary strategy of purchasing", "TREATMENT", 22, 60]]], ["If the disease turns out to be serious, the expected fallout in subsequent elections is likely to be far worse than the fallout over having spent too much on vaccines against a mild disease.DPM 23,1A second expectation is that the response intensity will correlate with the electoral cycle of the individual countries.", [["the disease", "PROBLEM", 3, 14], ["vaccines", "TREATMENT", 158, 166], ["a mild disease", "PROBLEM", 175, 189], ["the response intensity", "PROBLEM", 227, 249], ["disease", "OBSERVATION", 7, 14], ["fallout", "OBSERVATION", 53, 60], ["likely to be", "UNCERTAINTY", 88, 100], ["mild", "OBSERVATION_MODIFIER", 177, 181], ["disease", "OBSERVATION", 182, 189]]], ["The importance of election cycles in retrospective voting behavior is well established, and the timing of the disaster has been shown to have electoral consequences.", [["election cycles", "TREATMENT", 18, 33]]], ["Variations in pluralistic competitiveness and participation should thus be correlated with variations in the pandemic responses.DPM 23,1In order to assess these three hypotheses we have collected data on vaccination responses to the 2009 H1N1 pandemic across nine mature western democracies from which data were available.", [["DPM 23,1", "CHEMICAL", 128, 136], ["H1N1", "DISEASE", 238, 242], ["DPM 23,1", "CHEMICAL", 128, 136], ["vaccination responses", "TREATMENT", 204, 225]]], ["The comparative approach is based on a most-similar case design where different crisis responses take place in otherwise similar socio-political contexts (Przeworski and Teune, 1970; Landmann, 2008 ).", [["different crisis responses", "PROBLEM", 70, 96]]], ["The countries have been purposely selected to constitute a group of critical cases (Eckstein, 1975; George and Bennett, 2005) that have strategic importance: if the political theory of survival fails to predict government responses under the most optimal of conditions (mature and rich democracies), then the same is likely to also hold true in countries with less favorable conditions where centralism, patronage, corruption and red tape are prevalent.", [["centralism", "DISEASE", 392, 402], ["red tape", "TREATMENT", 430, 438]]], ["The data on vaccine purchases and coverage (uptake) are presented in Table I. The first two columns in Table I can be used to assess the first prediction.", [["vaccine purchases", "TREATMENT", 12, 29], ["coverage (uptake)", "TEST", 34, 51]]], ["The table reveals that there were huge variations in both purchased vaccination coverage (government orders of vaccine courses) and actual coverage (uptake by the population of vaccination).", [["huge variations", "PROBLEM", 34, 49], ["both purchased vaccination coverage", "TREATMENT", 53, 88], ["vaccine courses", "TREATMENT", 111, 126], ["actual coverage (uptake", "TREATMENT", 132, 155], ["huge", "OBSERVATION_MODIFIER", 34, 38], ["variations", "OBSERVATION_MODIFIER", 39, 49]]], ["Some countries, such as the UK, Sweden, the Netherlands and Norway,83Pandemic response pursued the precautionary policy predicted by the political survival logic: the governments purchased vaccines to cover the entire electorate.", [["the governments purchased vaccines", "TREATMENT", 163, 197]]], ["But others, such as the USA, Germany and Denmark, pursued something very much at odds -none came close to having vaccine courses available for all residents.", [["vaccine courses", "TREATMENT", 113, 128]]], ["Hence, the first prediction of extensive and uniform vaccination policies across all countries does not hold for the 2009 pandemic.83The second prediction can be evaluated by calculating the number of days to the next election from the day the WHO declared a pandemic on June 11, 2009 (column 3).", [["extensive and uniform vaccination policies", "TREATMENT", 31, 73], ["extensive", "OBSERVATION_MODIFIER", 31, 40], ["uniform", "OBSERVATION_MODIFIER", 45, 52], ["vaccination", "OBSERVATION", 53, 64]]], ["The table reveals no pattern whatsoever between the two indices of vaccination responses and the number of days to the next election.", [["no", "UNCERTAINTY", 18, 20]]], ["This is supported statistically with an insignificant correlation-coefficient (Pearson's) of \u00c00.41 between days to the next election and purchased vaccine coverage.83Column 4 addresses the third prediction by relating vaccination coverage to Vanhanen's democracy index (Vanhanen, 2011 ).", [["purchased vaccine coverage", "TREATMENT", 137, 163], ["vaccination coverage", "TREATMENT", 218, 238]]], ["Vanhanen's democracy index combines proxies for democratic competition (percentage of votes gained by the smaller parties in elections to proxy for the influence of smaller parties) and participation (percentage of the total population who voted in the election to proxy for voter involvement in the political process).", [["Vanhanen", "TREATMENT", 0, 8]]], ["The index is calculated for 2009 as a product of the two variables; a higher index implies greater competition and participation.", [["The index", "TEST", 0, 9], ["a higher index", "TEST", 68, 82], ["index", "OBSERVATION_MODIFIER", 4, 9], ["greater competition", "OBSERVATION", 91, 110]]], ["The table reveals no systematic pattern between purchased vaccine coverage and the level of democratic competition and participation (insignificant correlation-coefficient of \u00c00.089).83All in all, the theory of political survival, which has previously successfully accounted for government responses to disasters in democracies, does not have as much explanatory power when it comes to the behavior of governments during the 2009 pandemic.83The bureaucratized expert sources of disease outbreak response The remainder of this paper probes the plausibility of a bureaucratic logic rather than a political logic to explain variations in national pandemic vaccination policies: the key differentiator between national pandemic responses is the judgment of public health (2010) experts, and of government agencies that employ them as bureaucrats, in national response policy making.", [["systematic pattern", "PROBLEM", 21, 39], ["purchased vaccine coverage", "TREATMENT", 48, 74], ["disease outbreak response", "PROBLEM", 478, 503], ["a bureaucratic logic", "PROBLEM", 559, 579], ["no", "UNCERTAINTY", 18, 20], ["disease", "OBSERVATION", 478, 485]]], ["The outputs of national public health agencies are primarily developed by physicians with public health training and experience and by biomedical research scientists.", [["public health training", "TREATMENT", 90, 112]]], ["In their roles as experts of disease outbreak control, the agencies are likely to be called on to guide and publicly legitimate their governments' pandemic responses.", [["disease outbreak control", "TREATMENT", 29, 53]]], ["Each agency is thus likely in practice to decide within its own bureaucratic expert ranks what the \"best\" course of pandemic vaccination is for a whole nation.", [["pandemic vaccination", "TREATMENT", 116, 136], ["thus likely", "UNCERTAINTY", 15, 26]]], ["Hence, pandemic vaccination policies diverge significantly between countries because expert judgments differ significantly.83To test whether national public health agencies are indeed the locus of leadership and guidance in pandemic response, we have focussed on two deviant cases (Lijphart, 1971 ) (George and Bennett, 2005) , Denmark and the USA, where both governments appear to have followed a proportional response with very limited vaccination coverage.", [["pandemic vaccination policies", "TREATMENT", 7, 36], ["very limited vaccination coverage", "TREATMENT", 425, 458]]], ["Quantitative and qualitative content analyses of media coverage in these two countries are used to assess public perceptions of responsibility and legitimacy in the pandemic response.", [["media coverage", "TREATMENT", 49, 63]]], ["This finding indicates that a bureaucratized expert logic rather than the political survival logic can dictate vaccination policies against pandemic influenza.Expert agencies or elected politicians as leaders of the Danish pandemic response?The Danish pandemic response constitutes an interesting outlier.", [["influenza", "DISEASE", 149, 158], ["vaccination policies", "TREATMENT", 111, 131], ["pandemic influenza", "PROBLEM", 140, 158]]], ["In terms of disaster responses, the countries' emergency and evacuation policies to the 2004 Tsunami were also remarkably similar.", [["evacuation policies", "TREATMENT", 61, 80]]], ["Due to the many vacationing Scandinavians in Thailand, the Tsunami was the most deadly disaster due to a shock occurring in nature for more than a century for both Sweden (543 fatalities) and Denmark (46 fatalities) (EM-DAT, 2012).", [["shock", "DISEASE", 105, 110], ["fatalities", "DISEASE", 176, 186], ["fatalities", "DISEASE", 204, 214], ["a shock", "PROBLEM", 103, 110], ["shock", "OBSERVATION", 105, 110]]], ["The disaster responses were all based on direct Prime Ministerial involvement, and the evacuation efforts were harmonized 85 Pandemic response across the Scandinavian countries (Politiken, 2005b) .", [["the evacuation efforts", "TREATMENT", 83, 105]]], ["With regard to pandemic responses, the institutional setups are also very similar: the countries have strong agencies of pandemic prevention and a great deal of flexibility with regard to the number of vaccines they can purchase (Kristeligt Dagblad, 2009) .", [["pandemic", "DISEASE", 121, 129], ["pandemic prevention", "TREATMENT", 121, 140], ["vaccines", "TREATMENT", 202, 210]]], ["During the 2009 pandemic, however, the Danish Government pursued a much more restrictive vaccination policy based on risk group coverage rather than the universal coverage pursued by the other Scandinavian countries (see Table I ).Expert agencies or elected politicians as leaders of the Danish pandemic response?If indeed the pandemic response was bureaucratized, we would expect the media to primarily focus on the key health organization, the Danish Health and Medicines Authority (DHMA), and not the Danish Government.", [["a much more restrictive vaccination policy", "TREATMENT", 65, 107], ["risk group coverage", "TREATMENT", 117, 136], ["the universal coverage", "TREATMENT", 149, 171]]], ["This expectation is confirmed by the data.", [["the data", "TEST", 33, 41]]], ["To assess the hypothesis, a content analysis was performed of Danish media reports mentioning the terms \"pandemic\" or \"H1N1\" between May 1 and July 31, 2009.", [["a content analysis", "TEST", 26, 44], ["H1N1", "PROBLEM", 119, 123]]], ["Taking advantage of the limited size of the media-landscape in Denmark, we were able to collect articles and features from all of the nine major Danish nationwide newspapers as well as from two major national news broadcasts, using the database Infomedia.Expert agencies or elected politicians as leaders of the Danish pandemic response?In the three months from the first novel swine flu infection of a Danish citizen (May 1-July 31, 2009), the nationwide media carried 952 features and articles mentioning the H1N1 virus (see Table II ) (Infomedia, 2012) .", [["flu infection", "DISEASE", 384, 397], ["swine", "SPECIES", 378, 383], ["swine flu", "SPECIES", 378, 387], ["H1N1 virus", "SPECIES", 511, 521], ["the H1N1 virus", "PROBLEM", 507, 521], ["size", "OBSERVATION_MODIFIER", 32, 36]]], ["Pandemic response resides formally with the national government leaders and the DHMA only has an advisory role.", [["DHMA", "CHEMICAL", 80, 84]]], ["But the mass media focussed almost exclusively on the DHMA.", [["DHMA", "SIMPLE_CHEMICAL", 54, 58], ["the mass media", "PROBLEM", 4, 18], ["mass", "OBSERVATION", 8, 12]]], ["The Prime Minister, who leads the government, was barely mentioned (0.2 percent).Expert agencies or elected politicians as leaders of the Danish pandemic response?Replacing the somewhat sterile medical term \"H1N1\" with the more politically explosive term \"pandemic\" does not alter the general pattern (Table II) .", [["H1N1", "DISEASE", 208, 212], ["H1N1", "PROBLEM", 208, 212]]], ["Of the 221 pandemic stories in the period, the DHMA appeared in 26 percent while the Ministry Denmark USA \"H1N1\" 952 (100%) 233 (100%) \"H1N1\" \u00fe \"DHMA\"/\"CDC\" 317 (33%) 45 (19%) \"H1N1\" \u00fe \"Ministry of Health\"/\"DHHS\" 47 (5%) 2 (1%) \"H1N1\" \u00fe \"DHMA director\"/\"CDC directors\" 118 (12%) 15 (6%) \"H1N1\" \u00fe \"Minister of Health\"/\"DHHS director\" 13 (1%) 2 (1%) \"H1N1\" \u00fe \"Prime Minister\"/\"President\" 8 (1%) 12 (5%) \"pandemic\" 221 (100%) 248 (100%) \"pandemic\" \u00fe \"DHMA\"/\"CDC\" 58 (26%) 38 (15%) \"pandemic\" \u00fe \"Ministry of Health\"/\"DHHS\" 17 (8%) 1 (0%) \"pandemic\" \u00fe \"DHMA director\"/\"CDC directors\" 31 (14%) 11 (4%) \"pandemic\" \u00fe \"Minister of Health\"/\"DHHS director\" 0 (0%) 0 (0%) \"pandemic\" \u00fe \"Prime Minister\"/\"President\" 1 (0%) 14 (6%)Expert agencies or elected politicians as leaders of the Danish pandemic response?Source: Infomedia (2012), EBSCOhost (2012) of Health was mentioned in 8 percent.", [["pandemic", "DISEASE", 780, 788], ["H1N1", "TEST", 107, 111], ["\"", "TEST", 111, 112], ["\"", "TEST", 135, 136], ["H1N1", "TEST", 136, 140], ["\"", "TEST", 140, 141], ["\u00fe", "TEST", 142, 143], ["\"", "TEST", 144, 145], ["DHMA", "TEST", 145, 149], ["\"", "TEST", 149, 150], ["CDC", "TEST", 152, 155], ["\"", "TEST", 155, 156], ["\"", "TEST", 176, 177], ["H1N1", "TEST", 177, 181], ["\"", "TEST", 181, 182], ["\"", "TEST", 204, 205], ["DHHS", "TEST", 207, 211], ["\"", "TEST", 211, 212], ["H1N1", "PROBLEM", 229, 233], ["\"", "PROBLEM", 233, 234], ["H1N1", "PROBLEM", 288, 292], ["H1N1", "PROBLEM", 349, 353]]], ["Hence, the quantitative data on media coverage and pressure strongly support the hypothesis of a decoupling in the general public's perception between the pandemic response and the government leadership.", [["pandemic", "DISEASE", 155, 163], ["media coverage", "TREATMENT", 32, 46], ["pressure", "TREATMENT", 51, 59]]], ["Qualitative analysis of the media story contents in the same period provides additional evidence in support of the hypothesis.", [["Qualitative analysis", "TEST", 0, 20], ["the hypothesis", "PROBLEM", 111, 125], ["hypothesis", "OBSERVATION", 115, 125]]], ["Furthermore, the criticism originated neither from the opposition nor the media but was to a large extent reduced to technocratic disagreements between DHMA and health experts from other institutions such as the Swedish Institute for Communicable Disease Control (Politiken, 2009; Berlingske, 2009a) , a Danish University professor in health economics (Politiken, 2009) and the chairman of the Danish association of local government doctors (BT, 2009) .", [["Communicable Disease", "DISEASE", 234, 254], ["large", "OBSERVATION_MODIFIER", 93, 98], ["extent", "OBSERVATION_MODIFIER", 99, 105], ["reduced", "OBSERVATION_MODIFIER", 106, 113], ["technocratic disagreements", "OBSERVATION", 117, 143]]], ["Only one Member of Parliament publicly questioned the vaccination strategy of not providing universal coverage (Politiken, 2009) , and again the critique was targeted at the DHMA.Expert agencies or elected politicians as leaders of the Danish pandemic response?The attacks gained little significant traction.", [["the vaccination strategy", "TREATMENT", 50, 74], ["The attacks", "PROBLEM", 261, 272], ["little", "OBSERVATION_MODIFIER", 280, 286], ["significant", "OBSERVATION_MODIFIER", 287, 298], ["traction", "OBSERVATION", 299, 307]]], ["While voters' general level of confidence in politicians was low (82 percent of poll respondents had no or very limited confidence in politicians; YouGov, 2009), DHMA enjoyed widespread public approval.", [["DHMA", "CHEMICAL", 162, 166]]], ["A national survey at the end of July 2009 found that 86 percent of respondents approved of how the pandemic was being handled by the DHMA (Berlingske, 2009b) .", [["A national survey", "TEST", 0, 17]]], ["The public accepted and even endorsed that pandemic response was located at the agency rather than among government leaders.Expert agencies or elected politicians as leaders of the Danish pandemic response?The Danish case reveals how the government to a very great extent was insulated from the usual public scrutiny and accountability during the 2009 pandemic response.", [["pandemic response", "PROBLEM", 43, 60]]], ["The health bureaucracy acted as a lightning rod for criticism, and the critique was mainly technical.", [["a lightning rod", "TREATMENT", 32, 47], ["criticism", "PROBLEM", 52, 61]]], ["The key dynamics of the logic of political survival appear to have been disabled in Denmark, allowing for proportional pandemic responses and greater cross-country variations.Expert agencies or elected politicians as leaders of the Danish pandemic response?Expert agencies or elected politicians as leaders of the US pandemic response?", [["proportional pandemic responses", "TEST", 106, 137]]], ["Leadership of pandemic response in the USA resembles the Danish.", [["pandemic", "OBSERVATION_MODIFIER", 14, 22], ["response", "OBSERVATION_MODIFIER", 23, 31]]], ["US healthcare providers and the general public look to the Centers of Disease Control and Prevention (CDC) in Atlanta rather than to the Department of Health and Human Services (DHHS) or to the Presidency for guidance and information on an emerging disease.", [["Human", "ORGANISM", 162, 167], ["Human", "SPECIES", 162, 167], ["Disease Control", "TREATMENT", 70, 85], ["an emerging disease", "PROBLEM", 237, 256], ["Disease", "OBSERVATION", 70, 77], ["disease", "OBSERVATION", 249, 256]]], ["Since its successful handling of polio using mass vaccination in the 1950s, the CDC has been the center of epidemic (and pandemic) response (Etheridge, 1992) .", [["polio", "DISEASE", 33, 38], ["polio using mass vaccination", "TREATMENT", 33, 61], ["epidemic", "PROBLEM", 107, 115], ["successful", "OBSERVATION_MODIFIER", 10, 20], ["mass", "OBSERVATION", 45, 49], ["epidemic", "OBSERVATION_MODIFIER", 107, 115]]], ["To an extent, the executive branch has been particularly discredited as a leader of responses to epidemic influenza due to past mismanagement (Neustadt and Fineberg, 1978) .", [["influenza", "DISEASE", 106, 115], ["epidemic influenza", "PROBLEM", 97, 115], ["extent", "OBSERVATION_MODIFIER", 6, 12], ["branch", "ANATOMY_MODIFIER", 28, 34]]], ["As in Scandinavia, this stands in stark contrast to other disasters, such as the hurricane flooding of New Orleans in 2005 (Katrina), where peak-level, executive (presidential and/or departmental) leadership has been the focus for public guidance and attention (Gerber and Cohen, 2008; Preston, 2008) .Expert agencies or elected politicians as leaders of the Danish pandemic response?Given our expectations about the importance of the national public health agency in setting H1N1 vaccination policies in 2009 and the historical record, the pattern87Pandemic response identified in Denmark should also be found in the US media.", [["H1N1 vaccination policies", "TREATMENT", 476, 501]]], ["To assess the hypothesis, a similar content analysis was conducted on articles mentioning the search terms \"H1N1\" or \"pandemic\" between May 1 and July 31, 2009 in the three major US nationwide daily newspapers, the New York Times, the Wall Street Journal and USA Today.", [["H1N1", "DISEASE", 108, 112], ["the hypothesis", "PROBLEM", 10, 24], ["a similar content analysis", "TEST", 26, 52], ["H1N1", "PROBLEM", 108, 112]]], ["The articles were collected and analyzed using systematic searches of the EBSCOhost databases of news articles and other publications.87All in all, 233 articles in the selection mentioned H1N1 in the title and/or the body (Table II) .", [["body", "ANATOMY", 217, 221], ["H1N1", "DISEASE", 188, 192], ["body", "ORGANISM_SUBDIVISION", 217, 221], ["H1N1", "PROBLEM", 188, 192], ["H1N1", "OBSERVATION", 188, 192], ["body", "ANATOMY", 217, 221]]], ["President Obama was mentioned in 12 (5 percent) of the articles.87In all, 246 articles in the selection mentioned the pandemic in the title and/or the body (Table II) .", [["body", "ANATOMY", 151, 155], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["pandemic", "OBSERVATION", 118, 126], ["body", "ANATOMY", 151, 155]]], ["Of these, 38 (15 percent) mentioned the CDC while just one mentioned the DHHS.", [["DHHS", "DISEASE", 73, 77], ["the CDC", "TEST", 36, 43]]], ["President Obama was mentioned in 14 articles (6 percent).87The quantitative content data thus indicate that the CDC was by far the most referenced public authority in the leading news media in the USA during the summer of 2009.", [["The quantitative content data", "TEST", 59, 88]]], ["Among individuals, the CDC directors were mentioned in similar numbers of articles to the president (more when H1N1 was mentioned, fewer when pandemic was mentioned).", [["H1N1", "PROBLEM", 111, 115]]], ["If mention of the president is treated as equivalent to mention of the executive branch, the CDC was mentioned three to four times more often.87Qualitatively, the selected US newspaper coverage of vaccination and other pandemic response policies treated pandemic response as mostly a medical technical issue.", [["vaccination", "TREATMENT", 197, 208], ["branch", "ANATOMY_MODIFIER", 81, 87]]], ["Vaccination-related articles tended to summarize interviews or press materials from the CDC and other specialized federal agencies, particularly the Food and Drug Administration (New York Times, 2009b; Wall Street Journal, 2009a, b, c d) .", [["Vaccination", "TREATMENT", 0, 11]]], ["The texts focussed on the timelines for developing vaccines, the approval process, the likely timing of the pandemic waves, and risk group assignments.", [["developing vaccines", "TREATMENT", 40, 59]]], ["In relation to vaccines, the president, DHHS secretary and CDC director presented the federal government's vaccine purchasing program in a joint teleconference call on July 9, 2009 (Wall Street Journal, 2009a).", [["vaccines", "TREATMENT", 15, 23], ["joint", "ANATOMY", 139, 144]]], ["This is consistent with the hypothesized importance of the public health agencies, rather than the national government or executive, as the locus of leadership in pandemic response.ConclusionThe disaster literature implies that national leaders will take charge of pandemic response policies.", [["pandemic response policies", "TREATMENT", 265, 291], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Responses such as pandemic vaccination purchasing and distribution will then converge on the \"precautionary\" logic because it carries the lowest political risk.", [["pandemic vaccination purchasing", "TREATMENT", 18, 49]]], ["But this fails to explain why 2009 H1N1 pandemic vaccination varied greatly between countries and why national public health agencies rather than 88 DPM 23,1 national executives were looked to by the Danish and US publics for response guidance and leadership.ConclusionThe evidence instead supports the hypothesis that a key distinction between responses to pandemics and other natural hazards is the role of expertise, and particularly the government agencies constituted of epidemiological and medical experts.", [["pandemic", "DISEASE", 40, 48], ["pandemics", "DISEASE", 358, 367], ["H1N1 pandemic vaccination", "TREATMENT", 35, 60], ["the hypothesis", "PROBLEM", 299, 313], ["pandemics", "PROBLEM", 358, 367]]], ["Pandemics may thus be more likely than other hazards to be overcome with the best of our knowledge.", [["Pandemics", "PROBLEM", 0, 9]]], ["Since experts are elected by no one, the great interventions in society and individual lives that policies such as mass vaccination exemplify are not held to proper account.ConclusionA remaining question is whether the risks to democratic legitimacy from expert-led national pandemic responses are outweighed by the benefits of gaining policies that are legitimated by epidemiological and medical science.", [["mass vaccination", "TREATMENT", 115, 131]]], ["A preliminary hypothesis emerging from this paper's analysis is that the potential gain from expert-led responses may be greater in countries with weaker democratic institutions, ceteris paribus.", [["ceteris paribus", "ORGANISM", 179, 194], ["ceteris paribus", "SPECIES", 179, 194], ["this paper's analysis", "TEST", 39, 60]]], ["Directly strengthening expert communities in countries with weak democratic institutions (e.g. through agency support and training) could boost the likelihood of a more scientific response to pandemics.", [["pandemics", "PROBLEM", 192, 201]]]], "PMC7258630": [["The dominant respiratory feature of coronavirus disease (COVID-19) is arterial hypoxemia greatly exceeding abnormalities in pulmonary mechanics (decreased compliance) (1\u20133).", [["arterial", "ANATOMY", 70, 78], ["pulmonary", "ANATOMY", 124, 133], ["coronavirus disease", "DISEASE", 36, 55], ["hypoxemia", "DISEASE", 79, 88], ["coronavirus", "ORGANISM", 36, 47], ["arterial", "MULTI-TISSUE_STRUCTURE", 70, 78], ["pulmonary", "ORGAN", 124, 133], ["coronavirus", "SPECIES", 36, 47], ["coronavirus disease", "PROBLEM", 36, 55], ["COVID", "TEST", 57, 62], ["arterial hypoxemia greatly exceeding abnormalities in pulmonary mechanics", "PROBLEM", 70, 143], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["respiratory feature", "OBSERVATION", 13, 32], ["coronavirus disease", "OBSERVATION", 36, 55], ["arterial", "ANATOMY", 70, 78], ["hypoxemia", "OBSERVATION", 79, 88], ["greatly", "OBSERVATION_MODIFIER", 89, 96], ["exceeding", "OBSERVATION_MODIFIER", 97, 106], ["abnormalities", "OBSERVATION", 107, 120], ["pulmonary", "ANATOMY", 124, 133], ["mechanics", "ANATOMY_MODIFIER", 134, 143], ["decreased", "OBSERVATION_MODIFIER", 145, 154]]], ["Many patients are intubated and placed on mechanical ventilation early in their course.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["intubated", "TREATMENT", 18, 27], ["mechanical ventilation", "TREATMENT", 42, 64], ["mechanical ventilation", "OBSERVATION", 42, 64]]], ["Projections on usage of ventilators has led to fears that insufficient machines will be available and even to proposals for using a single machine to ventilate four patients.", [["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["ventilators", "TREATMENT", 24, 35], ["insufficient machines", "TREATMENT", 58, 79], ["a single machine", "TREATMENT", 130, 146]]]], "01379b90c1010fd689a5f87efadb1e6abbe4b053": [["Pathophysiology:Mechanism.Pathophysiology:Even though multiple mechanisms of cardiac injury have been postulated, cytokine storm related injury has been uniformly shown to predict several outcomes including acute respiratory distress syndrome, requirement of mechanical ventilation, severity of illness and mortality.", [["cardiac", "ANATOMY", 77, 84], ["respiratory", "ANATOMY", 213, 224], ["cardiac injury", "DISEASE", 77, 91], ["acute respiratory distress syndrome", "DISEASE", 207, 242], ["illness", "DISEASE", 295, 302], ["cardiac", "ORGAN", 77, 84], ["cytokine", "PROTEIN", 114, 122], ["cardiac injury", "PROBLEM", 77, 91], ["cytokine storm related injury", "PROBLEM", 114, 143], ["acute respiratory distress syndrome", "PROBLEM", 207, 242], ["mechanical ventilation", "TREATMENT", 259, 281], ["illness", "PROBLEM", 295, 302], ["mortality", "PROBLEM", 307, 316], ["cardiac", "ANATOMY", 77, 84], ["injury", "OBSERVATION", 85, 91], ["acute", "OBSERVATION_MODIFIER", 207, 212], ["respiratory distress", "OBSERVATION", 213, 233], ["mechanical ventilation", "OBSERVATION", 259, 281]]], ["Patients with elevated inflammatory markers including C-reactive protein, ferritin, procalcitonin, D-Dimer, and IL-6 are consistently reported across patients with poor outcome.", [["Patients", "ORGANISM", 0, 8], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 54, 72], ["ferritin", "GENE_OR_GENE_PRODUCT", 74, 82], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 84, 97], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 99, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["patients", "ORGANISM", 150, 158], ["inflammatory markers", "PROTEIN", 23, 43], ["C-reactive protein", "PROTEIN", 54, 72], ["ferritin", "PROTEIN", 74, 82], ["procalcitonin", "PROTEIN", 84, 97], ["D-Dimer", "PROTEIN", 99, 106], ["IL-6", "PROTEIN", 112, 116], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 150, 158], ["elevated inflammatory markers", "PROBLEM", 14, 43], ["C", "TEST", 54, 55], ["reactive protein", "TEST", 56, 72], ["ferritin", "TEST", 74, 82], ["procalcitonin", "TEST", 84, 97], ["IL", "TEST", 112, 114], ["elevated", "OBSERVATION_MODIFIER", 14, 22], ["inflammatory markers", "OBSERVATION", 23, 43], ["reactive protein", "OBSERVATION", 56, 72]]], ["2Pathology:Involvement of myocardium and pericardium has been reported.", [["myocardium", "ANATOMY", 26, 36], ["pericardium", "ANATOMY", 41, 52], ["myocardium", "MULTI-TISSUE_STRUCTURE", 26, 36], ["pericardium", "ORGAN", 41, 52], ["Involvement of myocardium and pericardium", "PROBLEM", 11, 52], ["myocardium", "ANATOMY", 26, 36], ["pericardium", "ANATOMY", 41, 52]]], ["Acute myocardial injury has been reported as the most common cardiac manifestation of COVID -19 and is reported in 8 -12 % of patients.", [["myocardial", "ANATOMY", 6, 16], ["cardiac", "ANATOMY", 61, 68], ["myocardial injury", "DISEASE", 6, 23], ["myocardial", "MULTI-TISSUE_STRUCTURE", 6, 16], ["cardiac", "ORGAN", 61, 68], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Acute myocardial injury", "PROBLEM", 0, 23], ["COVID", "TEST", 86, 91], ["myocardial", "ANATOMY", 6, 16], ["injury", "OBSERVATION", 17, 23]]], ["3, 4 In a recent review Buja et al summarized the cardiac autopsy findings of 23 COVID-19 patients.", [["cardiac", "ANATOMY", 50, 57], ["cardiac", "ORGAN", 50, 57], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["cardiac", "ANATOMY", 50, 57]]], ["They reported cardiomegaly in 57% (N=13), evidence of individual cardiac myocyte injury in 35% (N=8), lymphocytic pericarditis, and lymphocytic myocarditis in 13% (N=3), 4% (N=1) of patients respectively.", [["cardiac myocyte", "ANATOMY", 65, 80], ["lymphocytic", "ANATOMY", 102, 113], ["lymphocytic", "ANATOMY", 132, 143], ["cardiomegaly", "DISEASE", 14, 26], ["cardiac myocyte injury", "DISEASE", 65, 87], ["lymphocytic pericarditis", "DISEASE", 102, 126], ["lymphocytic myocarditis", "DISEASE", 132, 155], ["cardiac myocyte", "MULTI-TISSUE_STRUCTURE", 65, 80], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["cardiomegaly", "PROBLEM", 14, 26], ["individual cardiac myocyte injury", "PROBLEM", 54, 87], ["lymphocytic pericarditis", "PROBLEM", 102, 126], ["lymphocytic myocarditis", "PROBLEM", 132, 155], ["cardiomegaly", "OBSERVATION", 14, 26], ["cardiac myocyte", "ANATOMY", 65, 80], ["injury", "OBSERVATION", 81, 87], ["lymphocytic pericarditis", "OBSERVATION", 102, 126], ["lymphocytic myocarditis", "OBSERVATION", 132, 155]]], ["5, 6 Myocardial involvement has been reported with elevated cardiac biomarkers, electrocardiography, echocardiography (ECHO), cardiac magnetic resonance imaging and autopsy.", [["Myocardial", "ANATOMY", 5, 15], ["cardiac", "ANATOMY", 60, 67], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 5, 15], ["cardiac", "ORGAN", 60, 67], ["elevated cardiac biomarkers", "PROBLEM", 51, 78], ["electrocardiography", "TEST", 80, 99], ["echocardiography", "TEST", 101, 117], ["ECHO", "TEST", 119, 123], ["cardiac magnetic resonance imaging", "TEST", 126, 160], ["autopsy", "TEST", 165, 172], ["Myocardial", "ANATOMY", 5, 15], ["involvement", "OBSERVATION", 16, 27]]], ["5,7 Among these, elevated cardiac biomarkers like creatinine phosphokinase, lactate dehydrogenase, and high-sensitive troponin have been consistently reported to predict disease severity.", [["cardiac", "ANATOMY", 26, 33], ["creatinine", "CHEMICAL", 50, 60], ["lactate", "CHEMICAL", 76, 83], ["creatinine", "CHEMICAL", 50, 60], ["lactate", "CHEMICAL", 76, 83], ["cardiac", "ORGAN", 26, 33], ["creatinine phosphokinase", "GENE_OR_GENE_PRODUCT", 50, 74], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 76, 97], ["troponin", "GENE_OR_GENE_PRODUCT", 118, 126], ["creatinine phosphokinase", "PROTEIN", 50, 74], ["lactate dehydrogenase", "PROTEIN", 76, 97], ["troponin", "PROTEIN", 118, 126], ["elevated cardiac biomarkers", "PROBLEM", 17, 44], ["creatinine phosphokinase", "TEST", 50, 74], ["lactate dehydrogenase", "TEST", 76, 97], ["high-sensitive troponin", "PROBLEM", 103, 126], ["disease severity", "PROBLEM", 170, 186], ["elevated", "OBSERVATION", 17, 25], ["cardiac", "ANATOMY", 26, 33]]], ["Studies have also shown that a high level, and a rising trend in high-sensitive troponin is predictive of poor outcome.", [["troponin", "GENE_OR_GENE_PRODUCT", 80, 88], ["troponin", "PROTEIN", 80, 88], ["a high level", "PROBLEM", 29, 41], ["a rising trend", "PROBLEM", 47, 61], ["poor outcome", "PROBLEM", 106, 118]]], ["2, 8 Presence of ST segment elevation, and ST-T changes have been reported to be higher among patients with severe illness.", [["illness", "DISEASE", 115, 122], ["ST-T", "GENE_OR_GENE_PRODUCT", 43, 47], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["ST segment elevation", "PROBLEM", 17, 37], ["ST-T changes", "PROBLEM", 43, 55], ["severe illness", "PROBLEM", 108, 122], ["ST segment", "ANATOMY_MODIFIER", 17, 27], ["elevation", "OBSERVATION", 28, 37], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["illness", "OBSERVATION", 115, 122]]], ["Among 19 patients presenting with ST segment elevation on EKG, coronary angiogram revealed the presence of coronary obstruction in only 8 patients, confirming a predominantly non-ischemic pattern of myocardial injury.", [["coronary", "ANATOMY", 63, 71], ["coronary", "ANATOMY", 107, 115], ["myocardial", "ANATOMY", 199, 209], ["coronary obstruction", "DISEASE", 107, 127], ["myocardial injury", "DISEASE", 199, 216], ["patients", "ORGANISM", 9, 17], ["coronary", "MULTI-TISSUE_STRUCTURE", 63, 71], ["coronary obstruction", "PATHOLOGICAL_FORMATION", 107, 127], ["patients", "ORGANISM", 138, 146], ["myocardial", "MULTI-TISSUE_STRUCTURE", 199, 209], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 138, 146], ["ST segment elevation", "PROBLEM", 34, 54], ["EKG", "TEST", 58, 61], ["coronary angiogram", "TEST", 63, 81], ["coronary obstruction", "PROBLEM", 107, 127], ["myocardial injury", "PROBLEM", 199, 216], ["segment", "ANATOMY_MODIFIER", 37, 44], ["elevation", "OBSERVATION", 45, 54], ["coronary", "ANATOMY", 63, 71], ["coronary", "ANATOMY", 107, 115], ["obstruction", "OBSERVATION", 116, 127], ["predominantly", "OBSERVATION_MODIFIER", 161, 174], ["non-ischemic", "OBSERVATION", 175, 187], ["myocardial", "ANATOMY", 199, 209], ["injury", "OBSERVATION", 210, 216]]], ["9 A recent study including 120 patients with COVID -19 showed that the presence of an enlarged right heart diameter, reduced right ventricular function, and right ventricular longitudinal strain pattern on ECHO were predictors of mortality.", [["right heart", "ANATOMY", 95, 106], ["right ventricular", "ANATOMY", 125, 142], ["right ventricular", "ANATOMY", 157, 174], ["patients", "ORGANISM", 31, 39], ["heart", "ORGAN", 101, 106], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 125, 142], ["ventricular", "ORGAN", 163, 174], ["patients", "SPECIES", 31, 39], ["A recent study", "TEST", 2, 16], ["COVID", "TEST", 45, 50], ["an enlarged right heart diameter", "PROBLEM", 83, 115], ["reduced right ventricular function", "PROBLEM", 117, 151], ["right ventricular longitudinal strain pattern", "PROBLEM", 157, 202], ["ECHO", "TEST", 206, 210], ["enlarged", "OBSERVATION", 86, 94], ["right", "ANATOMY_MODIFIER", 95, 100], ["heart", "ANATOMY", 101, 106], ["diameter", "ANATOMY_MODIFIER", 107, 115], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["right ventricular", "ANATOMY", 125, 142], ["function", "OBSERVATION", 143, 151], ["right ventricular", "ANATOMY", 157, 174], ["longitudinal strain", "OBSERVATION", 175, 194]]], ["In another study the development of a new wall motion abnormality, reduced left ventricular ejection fraction, and an increased wall thickness, suggesting a possible myocarditis was statistically higher in patients with severe illness.", [["wall", "ANATOMY", 42, 46], ["left ventricular", "ANATOMY", 75, 91], ["wall", "ANATOMY", 128, 132], ["myocarditis", "DISEASE", 166, 177], ["illness", "DISEASE", 227, 234], ["wall", "TISSUE", 42, 46], ["ventricular", "MULTI-TISSUE_STRUCTURE", 80, 91], ["wall", "TISSUE", 128, 132], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["another study", "TEST", 3, 16], ["a new wall motion abnormality", "PROBLEM", 36, 65], ["reduced left ventricular ejection fraction", "PROBLEM", 67, 109], ["an increased wall thickness", "PROBLEM", 115, 142], ["myocarditis", "PROBLEM", 166, 177], ["severe illness", "PROBLEM", 220, 234], ["new", "OBSERVATION_MODIFIER", 38, 41], ["wall", "ANATOMY_MODIFIER", 42, 46], ["motion abnormality", "OBSERVATION", 47, 65], ["reduced", "OBSERVATION_MODIFIER", 67, 74], ["left ventricular", "ANATOMY", 75, 91], ["ejection fraction", "OBSERVATION", 92, 109], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["wall thickness", "OBSERVATION", 128, 142], ["possible", "UNCERTAINTY", 157, 165], ["myocarditis", "OBSERVATION", 166, 177], ["higher", "OBSERVATION_MODIFIER", 196, 202], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["illness", "OBSERVATION", 227, 234]]], ["10, 11 Pericardial involvement has been reported in less than 5% of patients.", [["Pericardial", "ANATOMY", 7, 18], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Pericardial", "ANATOMY", 7, 18], ["involvement", "OBSERVATION", 19, 30]]], ["In a study by Li et al, computed tomography of chest identified the presence of pericardial effusion in 4.8% of patients.Pathology:Interestingly presence of pericardial effusion was noted to be a predictor of poor outcome.", [["chest", "ANATOMY", 47, 52], ["pericardial effusion", "ANATOMY", 80, 100], ["pericardial effusion", "ANATOMY", 157, 177], ["pericardial effusion", "DISEASE", 80, 100], ["pericardial effusion", "DISEASE", 157, 177], ["chest", "ORGAN", 47, 52], ["pericardial", "ORGAN", 80, 91], ["patients", "ORGANISM", 112, 120], ["pericardial", "ORGAN", 157, 168], ["patients", "SPECIES", 112, 120], ["a study", "TEST", 3, 10], ["computed tomography of chest", "TEST", 24, 52], ["pericardial effusion", "PROBLEM", 80, 100], ["pericardial effusion", "PROBLEM", 157, 177], ["chest", "ANATOMY", 47, 52], ["pericardial", "ANATOMY", 80, 91], ["effusion", "OBSERVATION", 92, 100], ["pericardial", "ANATOMY", 157, 168], ["effusion", "OBSERVATION", 169, 177]]], ["ECHO based studies have also shown that pericardial effusions of more than 5 mm in diameter were significantly higher among those who had severe disease.", [["pericardial effusions", "ANATOMY", 40, 61], ["pericardial effusions", "DISEASE", 40, 61], ["pericardial effusions", "PATHOLOGICAL_FORMATION", 40, 61], ["ECHO based studies", "TEST", 0, 18], ["pericardial effusions", "PROBLEM", 40, 61], ["severe disease", "PROBLEM", 138, 152], ["pericardial", "ANATOMY", 40, 51], ["effusions", "OBSERVATION", 52, 61], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["higher", "OBSERVATION_MODIFIER", 111, 117], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["disease", "OBSERVATION", 145, 152]]], ["2, 8 Endocardial involvement has not been consistently reported yet.", [["Endocardial", "ANATOMY", 5, 16], ["Endocardial", "ANATOMY", 5, 16], ["involvement", "OBSERVATION", 17, 28]]], ["Patients with severe illness are more prone to have rhythm abnormalities and develop cardiogenic shock.", [["illness", "DISEASE", 21, 28], ["rhythm abnormalities", "DISEASE", 52, 72], ["cardiogenic shock", "DISEASE", 85, 102], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["severe illness", "PROBLEM", 14, 28], ["rhythm abnormalities", "PROBLEM", 52, 72], ["cardiogenic shock", "PROBLEM", 85, 102], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["illness", "OBSERVATION", 21, 28], ["cardiogenic shock", "OBSERVATION", 85, 102]]], ["However, involvement of valves, supporting structures including papillary muscles or the conduction system have not been reported.", [["valves", "ANATOMY", 24, 30], ["structures", "ANATOMY", 43, 53], ["papillary muscles", "ANATOMY", 64, 81], ["conduction system", "ANATOMY", 89, 106], ["valves", "TISSUE", 24, 30], ["structures", "TISSUE", 43, 53], ["papillary muscles", "MULTI-TISSUE_STRUCTURE", 64, 81], ["involvement of valves, supporting structures including papillary muscles or the conduction system", "PROBLEM", 9, 106], ["valves", "OBSERVATION", 24, 30], ["papillary muscles", "ANATOMY", 64, 81], ["conduction system", "OBSERVATION", 89, 106]]], ["As mentioned by the authors IL-6 related papillary dysfunction is not yet been reported in the literature.", [["papillary", "ANATOMY", 41, 50], ["papillary dysfunction", "DISEASE", 41, 62], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["papillary", "ORGAN", 41, 50], ["IL-6", "PROTEIN", 28, 32], ["papillary dysfunction", "PROBLEM", 41, 62], ["papillary dysfunction", "OBSERVATION", 41, 62]]], ["Presence of pulmonary artery hypertension has been reported and has been found to be a predictor of a poor outcome.", [["pulmonary artery", "ANATOMY", 12, 28], ["pulmonary artery hypertension", "DISEASE", 12, 41], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 12, 28], ["pulmonary artery hypertension", "PROBLEM", 12, 41], ["pulmonary artery", "ANATOMY", 12, 28], ["hypertension", "OBSERVATION", 29, 41]]], ["8, 11 We agree with the authors on older patients with diabetes being at higher risk of myocardial injury.", [["myocardial", "ANATOMY", 88, 98], ["diabetes", "DISEASE", 55, 63], ["myocardial injury", "DISEASE", 88, 105], ["patients", "ORGANISM", 41, 49], ["myocardial", "MULTI-TISSUE_STRUCTURE", 88, 98], ["patients", "SPECIES", 41, 49], ["diabetes", "PROBLEM", 55, 63], ["myocardial injury", "PROBLEM", 88, 105], ["myocardial", "ANATOMY", 88, 98], ["injury", "OBSERVATION", 99, 105]]], ["The other reported potential contributors of myocardial injury have been hypertension, coronary artery disease, heart failure, and cerebrovascular disease.", [["myocardial", "ANATOMY", 45, 55], ["coronary artery", "ANATOMY", 87, 102], ["heart", "ANATOMY", 112, 117], ["cerebrovascular", "ANATOMY", 131, 146], ["myocardial injury", "DISEASE", 45, 62], ["hypertension", "DISEASE", 73, 85], ["coronary artery disease", "DISEASE", 87, 110], ["heart failure", "DISEASE", 112, 125], ["cerebrovascular disease", "DISEASE", 131, 154], ["myocardial", "MULTI-TISSUE_STRUCTURE", 45, 55], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 87, 102], ["heart", "ORGAN", 112, 117], ["cerebrovascular", "ANATOMICAL_SYSTEM", 131, 146], ["myocardial injury", "PROBLEM", 45, 62], ["hypertension", "PROBLEM", 73, 85], ["coronary artery disease", "PROBLEM", 87, 110], ["heart failure", "PROBLEM", 112, 125], ["cerebrovascular disease", "PROBLEM", 131, 154], ["myocardial", "ANATOMY", 45, 55], ["injury", "OBSERVATION", 56, 62], ["hypertension", "OBSERVATION", 73, 85], ["coronary artery", "ANATOMY", 87, 102], ["disease", "OBSERVATION", 103, 110], ["heart", "ANATOMY", 112, 117], ["failure", "OBSERVATION", 118, 125], ["cerebrovascular disease", "OBSERVATION", 131, 154]]], ["The presence of these comorbidities along with vitals at the time of presentation facilitates patient triage, disposition, and treatment methods.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["these comorbidities", "PROBLEM", 16, 35], ["vitals", "TEST", 47, 53], ["patient triage", "TEST", 94, 108], ["treatment methods", "TREATMENT", 127, 144], ["comorbidities", "OBSERVATION", 22, 35]]], ["Clinical scores like National Early Warning Score [NEWS] have been used to standardize care across multiple facilities.", [["Clinical scores", "PROBLEM", 0, 15]]], ["These scores are neither predictors of myocardial injury nor of mortality.", [["myocardial", "ANATOMY", 39, 49], ["myocardial injury", "DISEASE", 39, 56], ["myocardial", "MULTI-TISSUE_STRUCTURE", 39, 49], ["myocardial injury", "PROBLEM", 39, 56], ["myocardial", "ANATOMY", 39, 49], ["injury", "OBSERVATION", 50, 56]]]], "d8eb3b0bd3a4499bb20e22b8607a264cc40b3e29": [["Introduction 49Coronavirus disease is rapidly spreading across the world and raising severe global health 50 concerns.", [["49Coronavirus disease", "DISEASE", 13, 34], ["Introduction 49Coronavirus disease", "PROBLEM", 0, 34], ["rapidly", "OBSERVATION_MODIFIER", 38, 45], ["spreading", "OBSERVATION_MODIFIER", 46, 55], ["severe", "OBSERVATION_MODIFIER", 85, 91]]], ["Based 51 on the phylogenetic analysis, the identified novel coronavirus is named as Severe Acute 52Introduction 49Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the disease spread by SARS-CoV-2 53 is known as \"COVID-19\", declared as a pandemic by World Health Organization 54 (WHO)(https://www.who.int/emergencies/diseases/novel-coronavirus-55 2019?gclid=EAIaIQobChMI-u-Pz9vW6QIVUyUrCh0kjAlOEAAYASAAEgJ0pvD_BwERemuzzi).", [["coronavirus", "DISEASE", 60, 71], ["SARS", "DISEASE", 189, 193], ["coronavirus", "ORGANISM", 60, 71], ["SARS-CoV-2", "ORGANISM", 150, 160], ["SARS-CoV-2 53", "ORGANISM", 189, 202], ["coronavirus", "SPECIES", 60, 71], ["Severe Acute 52Introduction 49Respiratory Syndrome Coronavirus 2", "SPECIES", 84, 148], ["SARS-CoV-2", "SPECIES", 150, 160], ["SARS-CoV-2 53", "SPECIES", 189, 202], ["the phylogenetic analysis", "TEST", 12, 37], ["novel coronavirus", "PROBLEM", 54, 71], ["Severe Acute 52Introduction 49Respiratory Syndrome", "PROBLEM", 84, 134], ["Coronavirus", "TEST", 135, 146], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["the disease spread", "PROBLEM", 167, 185], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["coronavirus", "OBSERVATION", 60, 71], ["Severe", "OBSERVATION_MODIFIER", 84, 90], ["Acute", "OBSERVATION_MODIFIER", 91, 96], ["disease", "OBSERVATION", 171, 178]]], ["56Introduction 49Despite global massive efforts to control the outbreak of COVID-19, this pandemic is still on the 57 rise.", [["COVID-19", "CHEMICAL", 75, 83], ["global massive efforts", "TREATMENT", 25, 47], ["COVID", "TEST", 75, 80], ["massive", "OBSERVATION_MODIFIER", 32, 39]]], ["To date, lack of approved medicine or vaccine impede escalated the management of the 58 positive patients or IVT RNA.", [["patients", "ORGANISM", 97, 105], ["IVT RNA", "RNA", 109, 116], ["patients", "SPECIES", 97, 105], ["vaccine", "TREATMENT", 38, 45], ["IVT RNA", "PROBLEM", 109, 116]]], ["The RdRp oligo probe (5'-GTGATATGGTCATGTGTGGCGG-3') 126 was used to specifically detect the presence of SARS-CoV-2 RNA in the assay.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["RdRp oligo probe", "DNA", 4, 20], ["SARS-CoV-2 RNA", "RNA", 104, 118], ["The RdRp oligo probe", "TREATMENT", 0, 20], ["GTGATATGGTCATGTGTGGCGG", "TEST", 25, 47], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112]]], ["In parallel, to 127 measure the specificity of the assay, input genomes from different source such nasopharyngeal 128 RNA from COVID negative subjects and HPV DNA from cervical cancer positive samples were 129 used as negative controls.", [["cervical cancer", "ANATOMY", 168, 183], ["samples", "ANATOMY", 193, 200], ["cervical cancer", "DISEASE", 168, 183], ["COVID", "CANCER", 127, 132], ["HPV", "ORGANISM", 155, 158], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["cervical cancer", "CANCER", 168, 183], ["HPV DNA", "DNA", 155, 162], ["HPV", "SPECIES", 155, 158], ["the assay", "TEST", 47, 56], ["COVID", "TEST", 127, 132], ["HPV DNA", "PROBLEM", 155, 162], ["cervical cancer positive samples", "PROBLEM", 168, 200], ["cervical", "ANATOMY", 168, 176], ["cancer", "OBSERVATION", 177, 183]]], ["In addition, to confirm the working principle of the assay, a different 131 RNA template (isolated from pancreas) and pancreas specific REG-3 (Regenerating islet-132 derived protein 3) gene oligo probe (5'-GTGCCTATGGCTCCTATTGCT-3') were used 133 separately.", [["pancreas", "ANATOMY", 104, 112], ["pancreas", "ANATOMY", 118, 126], ["pancreas", "ORGAN", 104, 112], ["pancreas", "ORGAN", 118, 126], ["REG-3", "GENE_OR_GENE_PRODUCT", 136, 141], ["islet-132 derived protein 3", "GENE_OR_GENE_PRODUCT", 156, 183], ["131 RNA template", "DNA", 72, 88], ["pancreas specific REG-3 (Regenerating islet-132 derived protein 3) gene oligo probe", "DNA", 118, 201], ["the assay", "TEST", 49, 58], ["a different 131 RNA template", "PROBLEM", 60, 88], ["pancreas specific REG", "TEST", 118, 139], ["Regenerating islet", "TEST", 143, 161], ["gene oligo probe", "TREATMENT", 185, 201], ["GTGCCTATGGCTCCTATTGCT", "TEST", 206, 227], ["pancreas", "ANATOMY", 104, 112], ["pancreas", "ANATOMY", 118, 126]]], ["134Introduction 49The final reaction mixture with above combinations was then denatured at 95\u00b0C for 30 135 seconds, annealed at 60\u00b0C for 60 seconds and then cooled to room temperature for 10 minutes.", [["above combinations", "TREATMENT", 50, 68]]], ["136Introduction 49Subsequently, 10 nM colloidal AuNPs (~10 nm) were added to the assay mixture and allowed to 137 develop color for 1-2 minute.", [["AuNPs", "CHEMICAL", 48, 53], ["colloidal AuNPs", "SIMPLE_CHEMICAL", 38, 53], ["10 nM colloidal AuNPs", "TREATMENT", 32, 53], ["the assay mixture", "TEST", 77, 94], ["color", "TEST", 122, 127]]], ["138Introduction 49Spectral studies and measurement of sensitivity: Absorption spectrum of the assay mixture 139 was recorded in the range of 300 -700 nm.", [["49Spectral studies", "TEST", 16, 34], ["Absorption spectrum", "TEST", 67, 86], ["the assay mixture", "TEST", 90, 107]]], ["The peak shift from 520 nm (known as red-shift) and 140 peak broadening after 520 nm were measured as a characteristic feature of the salt induced 141 aggregation.", [["salt", "CHEMICAL", 134, 138], ["salt", "SIMPLE_CHEMICAL", 134, 138], ["The peak shift", "TEST", 0, 14], ["the salt induced 141 aggregation", "PROBLEM", 130, 162], ["520 nm", "OBSERVATION_MODIFIER", 20, 26], ["141 aggregation", "OBSERVATION", 147, 162]]], ["Using various combinations of positive and negative controls (as discussed in the 142 previous section) the specificity of reaction and aggregation were compared.", [["reaction", "PROBLEM", 123, 131], ["aggregation", "PROBLEM", 136, 147]]], ["Assay sensitivity 143 was determined by serially diluting the input SARS-CoV-2 RNA from both the IVT synthesized 144 and, synthetic SARS-CoV-2 control (nCov19 control kit by Applied Biosystems) ranging from 5-145 0.1ng and 1-0.1ng concentrations respectively.", [["SARS-CoV-2 RNA", "RNA", 68, 82], ["Assay sensitivity", "TEST", 0, 17], ["the input SARS", "TEST", 58, 72], ["CoV", "TEST", 73, 76], ["the IVT", "TEST", 93, 100], ["synthetic SARS", "TEST", 122, 136], ["CoV", "TEST", 137, 140], ["nCov19 control kit", "TREATMENT", 152, 170]]], ["146Introduction 49Statistical Analysis: Diagnostic accuracy of the new colour test was calculated by assuming 147 RT-PCR as gold standard method.", [["the new colour test", "TEST", 63, 82], ["PCR", "TEST", 117, 120]]], ["Sensitivity (True Positive rate), Specificity (True Negative 148 rate) and overall accuracy (True positive and true negative rate) were calculated with 95% 149 confidence interval.", [["Sensitivity", "TEST", 0, 11], ["Specificity", "TEST", 34, 45], ["rate", "TEST", 65, 69], ["overall accuracy", "TEST", 75, 91]]], ["Likelihood ratio positive (sensitivity / false positive rate), Likelihood ratio 150 negative (false negative rate / specificity), Positive predictive value (True positive value / Total positive results predicted by colour test), Negative predictive value (True negative value / Total 152 negativeresults predicted by colour test) were also calculated.", [["Likelihood ratio", "TEST", 0, 16], ["sensitivity", "TEST", 27, 38], ["false positive rate", "TEST", 41, 60], ["Likelihood ratio", "TEST", 63, 79], ["colour test", "TEST", 215, 226], ["colour test", "TEST", 317, 328]]], ["Measured accuracy was 153 considered statistically significant (p<0.05) when 50% did not falling within the confidence limit 154 for values given in % whereas LR are considered significant when 1 was falling within 155 confidence limit.", [["Measured accuracy", "TEST", 0, 17], ["values", "TEST", 133, 139], ["LR", "TEST", 159, 161], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["significant", "OBSERVATION_MODIFIER", 177, 188]]], ["Statistical analyses were performed using software MedCalc for 156Introduction 49Windows(MedCalc Software, Ostend, Belgium).", [["Statistical analyses", "TEST", 0, 20]]], ["157Result and discussion 158In this study, we report for the first time the development of a rapid and affordable RNA-based 159 assay for the visual detection of the SARS-CoV-2 genome in human samples.", [["samples", "ANATOMY", 193, 200], ["SARS-CoV-2", "ORGANISM", 166, 176], ["human", "ORGANISM", 187, 192], ["samples", "CANCER", 193, 200], ["SARS-CoV-2 genome", "DNA", 166, 183], ["human", "SPECIES", 187, 192], ["SARS-CoV", "SPECIES", 166, 174], ["human", "SPECIES", 187, 192], ["this study", "TEST", 31, 41], ["a rapid and affordable RNA", "PROBLEM", 91, 117], ["the visual detection", "TEST", 138, 158], ["the SARS", "PROBLEM", 162, 170], ["CoV", "PROBLEM", 171, 174], ["rapid", "OBSERVATION_MODIFIER", 93, 98]]], ["Using RT-PCR 160 as gold standard, the developed assay was found to have a sensitivity of 85.29% and 161 sepcififcity of 94.12%.", [["RT-PCR", "TEST", 6, 12], ["assay", "TEST", 49, 54], ["a sensitivity", "TEST", 73, 86], ["sepcififcity", "TEST", 105, 117]]], ["For the assay, we use surface plasmon resonance property of gold 162 nanoparticles/colloids (AuNP) and targeted the RdRp specific gene sequence of SARS-CoV-163 2.", [["gold 162 nanoparticles", "CHEMICAL", 60, 82], ["AuNP", "CHEMICAL", 93, 97], ["gold 162 nanoparticles/colloids", "SIMPLE_CHEMICAL", 60, 91], ["AuNP", "SIMPLE_CHEMICAL", 93, 97], ["RdRp specific gene sequence", "DNA", 116, 143], ["SARS-CoV-163", "SPECIES", 147, 159], ["the assay", "TEST", 4, 13], ["surface plasmon resonance property of gold 162 nanoparticles/colloids (AuNP)", "TREATMENT", 22, 98], ["SARS", "TEST", 147, 151], ["CoV", "TEST", 152, 155]]], ["RdRp is essential for viral replication and has higher analytical power than E (envelope 164 protein) and N (nucleocapsid protein) genes of SARS-CoV-2 (Corman et al. 2020).", [["E (envelope 164 protein", "GENE_OR_GENE_PRODUCT", 77, 100], ["N (nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 106, 129], ["RdRp", "PROTEIN", 0, 4], ["envelope 164 protein", "PROTEIN", 80, 100], ["N (nucleocapsid protein) genes", "DNA", 106, 136], ["SARS-CoV", "SPECIES", 140, 148], ["RdRp", "PROBLEM", 0, 4], ["viral replication", "PROBLEM", 22, 39], ["N (nucleocapsid protein", "TEST", 106, 129], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148], ["essential for", "UNCERTAINTY", 8, 21], ["viral replication", "OBSERVATION", 22, 39]]], ["Our current 165 established assay, salt-induced aggregation and color change of the gold colloids occurs 166Result and discussion 158after RdRp oligo probe hybridizes with its specific target RNA of SARS-CoV-2.", [["salt", "CHEMICAL", 35, 39], ["aggregation", "DISEASE", 48, 59], ["salt", "SIMPLE_CHEMICAL", 35, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 199, 209], ["SARS-CoV", "SPECIES", 199, 207], ["assay", "TEST", 28, 33], ["induced aggregation", "PROBLEM", 40, 59], ["the gold colloids", "TREATMENT", 80, 97], ["RdRp oligo probe hybridizes", "TREATMENT", 139, 166], ["CoV", "TEST", 204, 207], ["gold colloids", "OBSERVATION", 84, 97]]], ["With the current 167 escalated demand of cost effective, easy and sensitive diagnostic for COVID-19, the test was 168 developed using commercially available nCoV19 synthetic DNA and validated further using 169 clinical samples from COVID-19 subjects (as confirmed using Taqman based RT-PCR method, 170 Table S1 ).", [["samples", "ANATOMY", 219, 226], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["nCoV19 synthetic DNA", "DNA", 157, 177], ["COVID", "TEST", 91, 96], ["the test", "TEST", 101, 109], ["COVID", "TEST", 232, 237], ["Taqman", "TEST", 270, 276]]], ["In our study, we demonstrated a visual change in gold colloid color from pink to blue 171 when RNA samples from subjects with clinically diagnosed COVID-19 infection hybridize 172Result and discussion 158with RdRp oligo probe.", [["samples", "ANATOMY", 99, 106], ["infection", "DISEASE", 156, 165], ["our study", "TEST", 3, 12], ["a visual change in gold colloid color", "PROBLEM", 30, 67], ["RNA samples", "TEST", 95, 106], ["clinically diagnosed COVID", "PROBLEM", 126, 152], ["infection hybridize", "PROBLEM", 156, 175], ["RdRp oligo probe", "TREATMENT", 209, 225], ["visual change", "OBSERVATION", 32, 45], ["gold colloid color", "OBSERVATION", 49, 67], ["pink", "OBSERVATION_MODIFIER", 73, 77]]], ["Simultaneously, the color remained pink in SARS-CoV-2 negative 173 samples due to the absence of hybridization.", [["samples", "ANATOMY", 67, 74], ["SARS-CoV", "SPECIES", 43, 51], ["the color", "TEST", 16, 25], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["hybridization", "PROBLEM", 97, 110], ["pink", "OBSERVATION", 35, 39]]], ["174Result and discussion 158In the study, out of 136 samples, 50% samples (n=68) were true positive (COVID-19 Positive) 175 and 50% samples (n=68) true negative (Free from COVID-19 disease) confirmed by gold 176 standard diagnostic test RT-PCR.", [["samples", "ANATOMY", 53, 60], ["samples", "ANATOMY", 66, 73], ["samples", "ANATOMY", 132, 139], ["samples", "CANCER", 53, 60], ["samples", "CANCER", 66, 73], ["samples", "CANCER", 132, 139], ["the study", "TEST", 31, 40], ["COVID", "TEST", 101, 106], ["COVID", "TEST", 172, 177], ["diagnostic test RT-PCR", "TEST", 221, 243]]], ["These true positive and negative samples were again tested by New Colour test to assess the diagnostic accuracy of our new test ( In this assay, SARS-CoV-2 RNA from human patients or IVT synthesized RNA was added into 209 hybridization buffer (containing oligo probe), followed by denaturation and annealing at 95\u00b0C 210 (30s) and 60\u00b0C (60s), respectively.", [["samples", "ANATOMY", 33, 40], ["SARS-CoV-2", "ORGANISM", 145, 155], ["human", "ORGANISM", 165, 170], ["patients", "ORGANISM", 171, 179], ["SARS-CoV-2 RNA", "RNA", 145, 159], ["IVT synthesized RNA", "RNA", 183, 202], ["human", "SPECIES", 165, 170], ["patients", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 145, 153], ["human", "SPECIES", 165, 170], ["New Colour test", "TEST", 62, 77], ["our new test", "TEST", 115, 127], ["this assay", "TEST", 133, 143], ["SARS", "TEST", 145, 149], ["CoV", "TEST", 150, 153], ["IVT synthesized RNA", "TREATMENT", 183, 202], ["hybridization buffer (containing oligo probe", "TREATMENT", 222, 266], ["positive", "OBSERVATION", 11, 19]]], ["After cooling at room temperature, the gold colloid was 211 added into the above reaction mixture.", [["gold colloid", "SIMPLE_CHEMICAL", 39, 51], ["the gold colloid", "TREATMENT", 35, 51], ["the above reaction mixture", "TREATMENT", 71, 97]]], ["The colloid color changes in visible range from pink to 212 blue, indicate the formation of hybridized product (Figure 2b -c, and Figure 3 ).", [["The colloid color changes", "PROBLEM", 0, 25], ["hybridized product", "TREATMENT", 92, 110], ["colloid color", "OBSERVATION", 4, 17], ["visible", "OBSERVATION_MODIFIER", 29, 36], ["range", "OBSERVATION_MODIFIER", 37, 42], ["pink", "OBSERVATION_MODIFIER", 48, 52], ["212 blue", "OBSERVATION_MODIFIER", 56, 64]]], ["Broadening of the 213 peak with red-shift (~30 nm) was observed in the spectrum of aggregated colloids than non-214 aggregated, confirms the success of developed assay for detection of an unamplified target with 215 unmodified colloids in a quick and facile way.", [["red-shift", "TEST", 32, 41], ["aggregated colloids", "PROBLEM", 83, 102], ["unmodified colloids", "TREATMENT", 216, 235], ["213 peak", "OBSERVATION_MODIFIER", 18, 26]]], ["The principle of binding oligo probe to its specific 216 target leading to change in color of the solution was independently verified using a different 217 template RNA (isolated from pancreas tissue) and pancreas specific gene REG3 oligo probe in 218 a separate assay.", [["pancreas tissue", "ANATOMY", 184, 199], ["pancreas", "ANATOMY", 205, 213], ["pancreas tissue", "TISSUE", 184, 199], ["pancreas", "ORGAN", 205, 213], ["216 target", "DNA", 53, 63], ["217 template RNA", "RNA", 152, 168], ["pancreas specific gene REG3 oligo probe", "DNA", 205, 244], ["binding oligo probe", "TREATMENT", 17, 36], ["a different 217 template RNA", "TREATMENT", 140, 168], ["pancreas", "ANATOMY", 184, 192], ["pancreas", "ANATOMY", 205, 213]]], ["This assay also resulted in a similar change in color and absorption spectra 219 as optimized earlier for SARS-CoV-2 RNA and RdRp oligo probe.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["SARS-CoV-2 RNA", "RNA", 106, 120], ["SARS-CoV", "SPECIES", 106, 114], ["This assay", "TEST", 0, 10], ["a similar change in color", "PROBLEM", 28, 53], ["absorption spectra", "TEST", 58, 76], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["RdRp oligo probe", "TREATMENT", 125, 141], ["similar", "OBSERVATION_MODIFIER", 30, 37], ["change", "OBSERVATION", 38, 44], ["oligo probe", "OBSERVATION", 130, 141]]], ["It established the working 220 principle and specificity of the test ( Figure S1 ).", [["the test", "TEST", 60, 68]]], ["221Result and discussion 158We determined the cross-reactivity using a cervical-DNA sample from women diagnosed with 222 HPV infection (non-specific target control).", [["cervical-DNA sample", "ANATOMY", 71, 90], ["HPV infection", "DISEASE", 121, 134], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["women", "ORGANISM", 96, 101], ["HPV", "ORGANISM", 121, 124], ["women", "SPECIES", 96, 101], ["HPV", "SPECIES", 121, 124], ["a cervical-DNA sample", "TEST", 69, 90], ["222 HPV infection", "PROBLEM", 117, 134], ["non-specific target control", "TREATMENT", 136, 163], ["cervical", "ANATOMY", 71, 79], ["infection", "OBSERVATION", 125, 134]]], ["No color change of gold colloids was observed with 223 HPV DNA, indicating no hybridization, and specificity of the developed assay (Figure 3 b, right 224 vial).", [["gold colloids", "SIMPLE_CHEMICAL", 19, 32], ["HPV", "ORGANISM", 55, 58], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["HPV", "SPECIES", 55, 58], ["color change of gold colloids", "PROBLEM", 3, 32], ["223 HPV DNA", "PROBLEM", 51, 62], ["hybridization", "PROBLEM", 78, 91], ["assay", "TEST", 126, 131], ["Figure", "TEST", 133, 139], ["color", "OBSERVATION_MODIFIER", 3, 8], ["change", "OBSERVATION", 9, 15], ["gold colloids", "OBSERVATION", 19, 32], ["no", "UNCERTAINTY", 75, 77]]], ["Contrary to HPV DNA-negative control and NTC, a positive control sample shows 225 development of blue color (Figure 3 b, middle vial).", [["HPV", "ORGANISM", 12, 15], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["HPV DNA", "DNA", 12, 19], ["HPV", "SPECIES", 12, 15], ["HPV DNA", "TEST", 12, 19], ["NTC", "TEST", 41, 44], ["a positive control sample", "TEST", 46, 71], ["blue color", "TEST", 97, 107], ["blue color", "OBSERVATION", 97, 107]]], ["Absorption spectrum (of colloids) with HPV 226 DNA-negative control exhibited characteristics similar to that of NTC, and no red-shift or peak 227 broadening as found with positive samples (Figure 3a ).", [["samples", "ANATOMY", 181, 188], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["HPV 226 DNA", "DNA", 39, 50], ["Absorption spectrum (of colloids", "TREATMENT", 0, 32], ["HPV 226 DNA", "TEST", 39, 50], ["NTC", "TEST", 113, 116], ["red-shift", "PROBLEM", 125, 134], ["positive samples", "PROBLEM", 172, 188], ["no", "UNCERTAINTY", 122, 124]]], ["Cross-reactivity of the developed assay 228 with other respiratory viruses is warranted.", [["respiratory viruses", "DISEASE", 55, 74], ["the developed assay", "TEST", 20, 39], ["other respiratory viruses", "PROBLEM", 49, 74], ["viruses", "OBSERVATION", 67, 74]]], ["However, we do not anticipate the same as the test utilizes the detection of the RdRp gene of the SARS-CoV-2 virus.", [["SARS", "DISEASE", 98, 102], ["SARS-CoV-2 virus", "ORGANISM", 98, 114], ["RdRp gene", "DNA", 81, 90], ["CoV-2 virus", "SPECIES", 103, 114], ["SARS-CoV-2 virus", "SPECIES", 98, 114], ["the test", "TEST", 42, 50], ["the detection", "TEST", 60, 73], ["the SARS", "PROBLEM", 94, 102], ["CoV", "TEST", 103, 106]]], ["The oligo probe sequence 230 used in our assay is not complementary to any human mRNAs and other members of the SARS 231 family, as verified by BLAST using the NCBI database.", [["human", "ORGANISM", 75, 80], ["oligo probe sequence 230", "DNA", 4, 28], ["human mRNAs", "RNA", 75, 86], ["SARS 231 family", "PROTEIN", 112, 127], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["The oligo probe sequence", "TREATMENT", 0, 24]]], ["232Result and discussion 158IVT synthesized SARS-CoV-2 RNA was used to test the sensitivity of the developed assay.", [["SARS-CoV-2 RNA", "RNA", 44, 58], ["CoV-2 RNA", "TREATMENT", 49, 58]]], ["233 RNA ranging from 0.1 to 5ng resulted in a gradual change in colloid color from light pink to blue 234Conclusions 249We have successfully developed an affordable gold nanoparticles-based colorimetric test for the 250 rapid detection of SARS-CoV-2 RNA in humans.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 239, 249], ["humans", "ORGANISM", 257, 263], ["SARS-CoV-2 RNA", "RNA", 239, 253], ["humans", "SPECIES", 257, 263], ["SARS-CoV", "SPECIES", 239, 247], ["humans", "SPECIES", 257, 263], ["RNA", "TEST", 4, 7], ["a gradual change in colloid color", "PROBLEM", 44, 77], ["an affordable gold nanoparticles", "TREATMENT", 151, 183], ["colorimetric test", "TEST", 190, 207], ["SARS", "PROBLEM", 239, 243], ["CoV", "TEST", 244, 247], ["gradual", "OBSERVATION_MODIFIER", 46, 53], ["change", "OBSERVATION_MODIFIER", 54, 60], ["colloid color", "OBSERVATION", 64, 77]]], ["The assay can detect up to 0.5 ng of SARS-251Conclusions 249CoV-2 RNA.", [["249CoV-2", "GENE_OR_GENE_PRODUCT", 57, 65], ["SARS-251Conclusions 249CoV-2 RNA", "RNA", 37, 69], ["The assay", "TEST", 0, 9], ["SARS", "TEST", 37, 41]]], ["The turnaround time of our assay is less than 30 minutes.", [["our assay", "TEST", 23, 32]]], ["Moreover, the 252 developed test will be helpful for mass screening, as it does not require sophisticated 253 equipment.", [["test", "TEST", 28, 32], ["mass screening", "TEST", 53, 67]]], ["However, while analyzing the clinical samples we observed the assay works best 254 with the freshly isolated RNA samples.", [["samples", "ANATOMY", 113, 120], ["the assay", "TEST", 58, 67]]], ["In addition, pH and salt concentration in the elution 255 buffer, used for RNA isolation, may affect the result and hence further optimization may be 256 needed when using a different kit for RNA isolation.", [["salt", "CHEMICAL", 20, 24], ["salt", "SIMPLE_CHEMICAL", 20, 24], ["pH", "TEST", 13, 15], ["salt concentration", "TREATMENT", 20, 38], ["RNA isolation", "TREATMENT", 75, 88], ["a different kit", "TREATMENT", 172, 187], ["RNA isolation", "TREATMENT", 192, 205]]], ["257Acknowledgement 258The study was supported by overhead funds from the extramural grants to ST from DBT, ICMR.", [["DBT", "CHEMICAL", 102, 105], ["The study", "TEST", 22, 31]]], ["Schematic representation of the assay for the visual detection of SARS-CoV-2 RNASchematic illustrates the assay flow to detect RdRp (RNA dependent RNA polymerase) gene sequence of SARS-CoV-2 in the nasopharyngeal RNA sample from subject clinically diagnosed with nCOVID infection (positive control).", [["nasopharyngeal RNA sample", "ANATOMY", 198, 223], ["SARS", "DISEASE", 66, 70], ["nCOVID infection", "DISEASE", 263, 279], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 180, 190], ["nasopharyngeal", "ORGAN", 198, 212], ["RdRp (RNA dependent RNA polymerase) gene sequence", "DNA", 127, 176], ["SARS-CoV-2", "DNA", 180, 190], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 180, 188], ["the assay", "TEST", 28, 37], ["the visual detection", "TEST", 42, 62], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["the assay flow", "TEST", 102, 116], ["RdRp (RNA dependent RNA polymerase", "TEST", 127, 161], ["gene sequence", "TEST", 163, 176], ["SARS", "PROBLEM", 180, 184], ["CoV", "TEST", 185, 188], ["the nasopharyngeal RNA sample", "TEST", 194, 223], ["nCOVID infection", "PROBLEM", 263, 279], ["nasopharyngeal RNA", "ANATOMY", 198, 216], ["infection", "OBSERVATION", 270, 279]]], ["Hybridization buffer with RdRp oligo probe (forward) was mixed with RNA sample.", [["RdRp oligo probe", "DNA", 26, 42], ["Hybridization buffer", "TREATMENT", 0, 20], ["RdRp oligo probe", "TREATMENT", 26, 42], ["RNA sample", "TEST", 68, 78]]], ["The reaction mixture was denatured at 95\u00b0C for 30 seconds, followed by annealing at 60\u00b0 C for 60 seconds.", [["The reaction mixture", "PROBLEM", 0, 20]]], ["After annealing, the tube was kept at room temperature for 10 minutes before colloidal AuNPs were added.", [["tube", "ANATOMY", 21, 25], ["AuNPs", "CHEMICAL", 87, 92], ["tube", "TISSUE", 21, 25], ["colloidal AuNPs", "SIMPLE_CHEMICAL", 77, 92], ["the tube", "TREATMENT", 17, 25], ["colloidal AuNPs", "TREATMENT", 77, 92], ["tube", "OBSERVATION", 21, 25]]], ["A pure colloid is pink in color.", [["pure", "OBSERVATION_MODIFIER", 2, 6], ["colloid", "OBSERVATION", 7, 14], ["pink", "OBSERVATION_MODIFIER", 18, 22], ["color", "OBSERVATION_MODIFIER", 26, 31]]], ["It turns blue in the vial containing RNA sample from positive control due to salt-induced aggregation upon successful hybridization between oligo probe and target RNA.", [["aggregation", "DISEASE", 90, 101], ["salt", "SIMPLE_CHEMICAL", 77, 81], ["oligo probe", "RNA", 140, 151], ["target RNA", "RNA", 156, 166], ["blue", "PROBLEM", 9, 13], ["RNA sample", "TEST", 37, 47], ["positive control", "TREATMENT", 53, 69], ["salt-induced aggregation", "PROBLEM", 77, 101], ["successful hybridization between oligo probe", "TREATMENT", 107, 151], ["target RNA", "PROBLEM", 156, 166], ["blue", "OBSERVATION_MODIFIER", 9, 13], ["aggregation", "OBSERVATION", 90, 101]]], ["The color remained pink in the absence of target RNA, or the presence of a non-specific target. (a) Comparative absorption spectra of unmodified AuNPs (Green curve) and oligo probe stabilized AuNPs i.e., NTC (Grey curve).", [["AuNPs", "CHEMICAL", 145, 150], ["AuNPs", "CHEMICAL", 192, 197], ["AuNPs", "SIMPLE_CHEMICAL", 145, 150], ["AuNPs", "SIMPLE_CHEMICAL", 192, 197], ["target RNA", "RNA", 42, 52], ["target RNA", "PROBLEM", 42, 52], ["a non-specific target", "PROBLEM", 73, 94], ["Comparative absorption spectra of unmodified AuNPs (Green curve)", "TREATMENT", 100, 164], ["oligo probe stabilized AuNPs", "TREATMENT", 169, 197], ["color", "OBSERVATION_MODIFIER", 4, 9], ["pink", "OBSERVATION", 19, 23], ["non-specific", "OBSERVATION_MODIFIER", 75, 87], ["target", "OBSERVATION_MODIFIER", 88, 94]]], ["Both spectra are exhibiting characteristics absorption peak at \u03bbmax 520 nm, however, the reduced peak intensity in NTC is due to dilution of colloid solution.", [["colloid solution", "SIMPLE_CHEMICAL", 141, 157], ["the reduced peak intensity in NTC", "PROBLEM", 85, 118], ["colloid solution", "TREATMENT", 141, 157], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["peak", "OBSERVATION_MODIFIER", 97, 101], ["intensity", "OBSERVATION_MODIFIER", 102, 111]]], ["In NTC, no red-shift in peak position, approve the stabilizing property of single-stranded oligo probe, Optical images of gold colloids (left vial) and NTC (right vial) are shown in the inset. (b) Comparative absorption spectra of NTC (Grey curve) and positive control i.e., nasopharyngeal RNA sample from subject clinically diagnosed with nCOVID infection (Brown curve).", [["nasopharyngeal RNA sample", "ANATOMY", 275, 300], ["nCOVID infection", "DISEASE", 340, 356], ["gold colloids", "SIMPLE_CHEMICAL", 122, 135], ["red-shift in peak position", "PROBLEM", 11, 37], ["single-stranded oligo probe", "TREATMENT", 75, 102], ["gold colloids (left vial) and NTC (right vial)", "TREATMENT", 122, 168], ["NTC (Grey curve", "TEST", 231, 246], ["positive control", "TREATMENT", 252, 268], ["nasopharyngeal RNA sample", "PROBLEM", 275, 300], ["nCOVID infection", "PROBLEM", 340, 356], ["no", "UNCERTAINTY", 8, 10], ["red-shift", "OBSERVATION", 11, 20], ["peak position", "OBSERVATION", 24, 37], ["left", "ANATOMY_MODIFIER", 137, 141], ["right", "ANATOMY_MODIFIER", 157, 162], ["nasopharyngeal", "ANATOMY", 275, 289], ["infection", "OBSERVATION", 347, 356]]], ["Broadening of the peak as well as red-shift in peak position confirm the salt-induced aggregation of AuNP due to successful hybrid formation in control.", [["aggregation", "DISEASE", 86, 97], ["AuNP", "CHEMICAL", 101, 105], ["salt", "SIMPLE_CHEMICAL", 73, 77], ["AuNP", "SIMPLE_CHEMICAL", 101, 105], ["red-shift", "TEST", 34, 43], ["the salt-induced aggregation of AuNP", "TREATMENT", 69, 105], ["successful hybrid formation in control", "TREATMENT", 113, 151], ["peak", "OBSERVATION_MODIFIER", 18, 22], ["hybrid formation", "OBSERVATION", 124, 140]]], ["Optical images shown in inset demonstrate the evident change in the color of the solution from pink to blue in the control vial (right) while no change in color of NTC vial (left). (c) representative absorption spectra, and in the inset shows optical images comparing assay performed with NTC (Grey curves, left vial), RNA from clinically diagnosed nCOVID infected subjects (Brown curve, middle vial), and RNA from subjects without nCOVID infection (Yellow curve, right vial).", [["nCOVID infected", "DISEASE", 349, 364], ["nCOVID infection", "DISEASE", 432, 448], ["Optical images", "TEST", 0, 14], ["the solution", "TREATMENT", 77, 89], ["representative absorption spectra", "TEST", 185, 218], ["optical images comparing assay", "TEST", 243, 273], ["NTC", "TEST", 289, 292], ["Grey curves", "TEST", 294, 305], ["RNA", "PROBLEM", 319, 322], ["nCOVID infected subjects", "PROBLEM", 349, 373], ["Brown curve, middle vial)", "PROBLEM", 375, 400], ["nCOVID infection", "PROBLEM", 432, 448], ["Yellow curve", "TEST", 450, 462], ["evident", "OBSERVATION_MODIFIER", 46, 53], ["change", "OBSERVATION", 54, 60], ["pink", "OBSERVATION_MODIFIER", 95, 99], ["blue", "OBSERVATION", 103, 107], ["right", "ANATOMY_MODIFIER", 129, 134], ["no", "UNCERTAINTY", 142, 144], ["change", "OBSERVATION_MODIFIER", 145, 151], ["NTC", "OBSERVATION", 164, 167], ["left", "ANATOMY_MODIFIER", 174, 178], ["left", "ANATOMY_MODIFIER", 307, 311], ["infection", "OBSERVATION", 439, 448], ["right", "ANATOMY_MODIFIER", 464, 469]]], ["Samples from a total of eighteen infected and eighteen uninfected individuals were analyzed (optical images were attached as supplimentry figure S2) .", [["Samples", "ANATOMY", 0, 7], ["individuals", "ORGANISM", 66, 77], ["Samples", "TEST", 0, 7], ["optical images", "TEST", 93, 107]]], ["Above estimation are based on equal number of disease-and disease-free cases in study samples detected by Gold standard method.", [["samples", "ANATOMY", 86, 93], ["Above estimation", "TEST", 0, 16], ["disease", "PROBLEM", 46, 53], ["disease", "PROBLEM", 58, 65], ["study samples", "TEST", 80, 93], ["disease", "OBSERVATION", 46, 53]]], ["The clinical diagnosis of the subjects based on Taqman RT-PCR analysis.", [["Taqman RT-PCR analysis", "TEST", 48, 70]]], ["RNA from the nasopharyngeal samples were analyzed by the new test (optical images shown in Figure S2 ).", [["nasopharyngeal samples", "ANATOMY", 13, 35], ["nasopharyngeal samples", "CANCER", 13, 35], ["RNA", "RNA", 0, 3], ["the nasopharyngeal samples", "TEST", 9, 35], ["the new test (optical images", "TEST", 53, 81], ["nasopharyngeal", "ANATOMY", 13, 27]]], ["RNA samples received from clinical laboratories were re-elluted in RNAase free water before testing with new method.", [["samples", "ANATOMY", 4, 11], ["RNAase", "PROTEIN", 67, 73], ["RNA samples", "TEST", 0, 11], ["clinical laboratories", "TEST", 26, 47], ["new method", "TREATMENT", 105, 115]]], ["Nasopharyngeal samples Samples were collected and RNA was isolated at RMLIMS (Lucknow).", [["Nasopharyngeal samples", "ANATOMY", 0, 22], ["Nasopharyngeal samples", "CANCER", 0, 22], ["Nasopharyngeal samples Samples", "TEST", 0, 30], ["RNA", "TEST", 50, 53]]]], "PMC7115311": [["Subjects ::: MethodsA total of 50 subjects were invited to participate in this study, including 42 females (nurses and health care assistants) and 8 males (nurses).", [["subjects", "ORGANISM", 34, 42], ["this study", "TEST", 74, 84]]], ["All participants were recruited from a 1,800-bed acute care hospital in Hong Kong, but although we used a convenience sampling method and attempted free sequencing, the sequence was not by randomization.", [["participants", "SPECIES", 4, 16], ["a convenience sampling method", "TREATMENT", 104, 133]]], ["Reflecting the female predominance in the nursing profession, 84% of the subjects were female and 16% were male.", [["subjects", "ORGANISM", 73, 81], ["female", "OBSERVATION_MODIFIER", 15, 21], ["predominance", "OBSERVATION_MODIFIER", 22, 34]]], ["The study included 10 temporary undergraduate nursing students (TUNSs) who had more than 2 years prework experience (ie, a job working in the hospital before promotion to nursing staff) in different departments, including 4-month rotations in surgical, medical, pediatric, orthopedic, neurosurgical, and accident and emergency departments.", [["The study", "TEST", 0, 9]]], ["Because each subject completed the experiment on the same day, the response rate was 100% in this study.", [["the response rate", "TEST", 63, 80], ["this study", "TEST", 93, 103]]], ["Two subjects performed the same glove removal method in the pretest and posttest and were replaced by two subjects who followed the specified processes.", [["the same glove removal method", "TREATMENT", 23, 52]]], ["The total sample size was 50.", [["The total sample size", "TEST", 0, 21], ["total", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["The subjects\u2019 demographic data are summarized in Table 1.Subjects ::: MethodsEthics approval was applied for before the study began, and the experimental protocol was approved by the Human Subjects Ethics Subcommittee of the Hong Kong Polytechnic University before the start of the experiment.", [["Human", "ORGANISM", 183, 188], ["Human", "SPECIES", 183, 188], ["MethodsEthics approval", "TREATMENT", 70, 92], ["the study", "TEST", 116, 125], ["the experimental protocol", "TREATMENT", 137, 162]]], ["Each subject provided written informed consent before taking part in the study and after being familiarized with the study\u2019s nature, purpose, method, and risks.", [["the study", "TEST", 69, 78], ["the study", "TEST", 113, 122]]], ["All subjects were volunteers and could withdraw at any time without any reason.", [["volunteers", "ORGANISM", 18, 28]]], ["The study was completed on the same day, with no subjects returning for follow-up, and no dropouts were noted.Gloves ::: MethodsDisposable latex gloves were used for the test, because latex is the material generally used by Hong Kong Hospital Authority (HKHA).", [["The study", "TEST", 0, 9], ["dropouts", "PROBLEM", 90, 98], ["MethodsDisposable latex gloves", "TREATMENT", 121, 151], ["the test", "TEST", 166, 174], ["no", "UNCERTAINTY", 87, 89], ["latex gloves", "OBSERVATION", 139, 151]]], ["Powder-free latex gloves (Saf-Care PLUS; Careplus (M) Sdn Bhd, Seremban, Negeri Sembilan, Malaysia) were purchased from the HKHA\u2019s supplier.", [["free latex gloves", "TREATMENT", 7, 24], ["Seremban", "TREATMENT", 63, 71]]], ["Powder-free latex gloves carry less risk of leakage compared with vinyl gloves.22, 23 Each subject selected the glove size (small, medium, or large) that he or she uses daily and examined the integrity of the glove by manual checking.", [["vinyl", "CHEMICAL", 66, 71], ["vinyl", "CHEMICAL", 66, 71], ["Powder", "TREATMENT", 0, 6], ["free latex gloves", "TREATMENT", 7, 24], ["leakage", "PROBLEM", 44, 51], ["vinyl gloves", "TREATMENT", 66, 78], ["manual checking", "TEST", 218, 233], ["leakage", "OBSERVATION", 44, 51], ["size", "OBSERVATION_MODIFIER", 118, 122], ["small", "OBSERVATION_MODIFIER", 124, 129]]], ["After the glove integrity was double-checked by the researcher, the fluorescent solution was applied.", [["the glove integrity", "TREATMENT", 6, 25], ["the fluorescent solution", "TREATMENT", 64, 88], ["glove", "OBSERVATION_MODIFIER", 10, 15], ["integrity", "OBSERVATION_MODIFIER", 16, 25]]], ["No leakage or reuse of gloves was allowed, because this might have affected the contaminated fluorescent patch (FP).Fluorescent solution ::: MethodsYellow fluorescent organic dye is used in angiography for the diagnosis and categorization of vascular disorders.30 Many studies use fluorescent stain to represent the contamination caused by pathogens.28, 31, 32, 33 Following Zamora et al,28 a contamination stain larger than 1 cm2 was considered a large patch, and one smaller than 1 cm2 was considered a small patch.", [["vascular", "ANATOMY", 242, 250], ["vascular disorders", "DISEASE", 242, 260], ["vascular", "MULTI-TISSUE_STRUCTURE", 242, 250], ["leakage", "PROBLEM", 3, 10], ["gloves", "TREATMENT", 23, 29], ["MethodsYellow fluorescent organic dye", "TREATMENT", 141, 178], ["angiography", "TEST", 190, 201], ["vascular disorders", "PROBLEM", 242, 260], ["fluorescent stain", "TEST", 281, 298], ["the contamination", "PROBLEM", 312, 329], ["pathogens", "PROBLEM", 340, 349], ["a contamination stain", "TEST", 391, 412], ["a large patch", "TREATMENT", 446, 459], ["a small patch", "TREATMENT", 503, 516], ["leakage", "OBSERVATION", 3, 10], ["gloves", "OBSERVATION", 23, 29], ["organic dye", "OBSERVATION", 167, 178], ["vascular", "ANATOMY", 242, 250], ["pathogens", "OBSERVATION", 340, 349], ["large", "OBSERVATION_MODIFIER", 448, 453], ["patch", "OBSERVATION_MODIFIER", 454, 459], ["smaller", "OBSERVATION_MODIFIER", 469, 476], ["small patch", "OBSERVATION", 505, 516]]], ["Figure 1shows some FPs detected on the edge of the rubbish bin cover and on the cover itself.Fluorescent solution ::: MethodsThe fluorescent solution was diluted from 20 g of free acid fluorescent dye (F2456 free acid dye; Sigma-Aldrich Chemil Gmbh, Munich, Germany) into a 1 M sodium hydroxide solution (Fixamal; Sigma-Aldrich Chemil Gmbh) to form a water-soluble solution of fluorescent sodium.", [["F2456 free acid dye", "CHEMICAL", 202, 221], ["sodium hydroxide", "CHEMICAL", 278, 294], ["Fixamal", "CHEMICAL", 305, 312], ["sodium", "CHEMICAL", 389, 395], ["sodium hydroxide", "CHEMICAL", 278, 294], ["Fixamal", "CHEMICAL", 305, 312], ["sodium", "CHEMICAL", 389, 395], ["free acid fluorescent dye", "SIMPLE_CHEMICAL", 175, 200], ["sodium hydroxide", "SIMPLE_CHEMICAL", 278, 294], ["Fixamal", "SIMPLE_CHEMICAL", 305, 312], ["Sigma-Aldrich Chemil Gmbh", "SIMPLE_CHEMICAL", 314, 339], ["fluorescent sodium", "SIMPLE_CHEMICAL", 377, 395], ["some FPs", "PROBLEM", 14, 22], ["Methods", "TREATMENT", 118, 125], ["The fluorescent solution", "TREATMENT", 125, 149], ["free acid fluorescent dye", "TREATMENT", 175, 200], ["free acid dye", "TREATMENT", 208, 221], ["Sigma-Aldrich Chemil Gmbh", "TREATMENT", 223, 248], ["a 1 M sodium hydroxide solution", "TREATMENT", 272, 303], ["Fixamal", "TREATMENT", 305, 312], ["Sigma-Aldrich Chemil Gmbh", "TREATMENT", 314, 339], ["a water-soluble solution of fluorescent sodium", "TREATMENT", 349, 395], ["some", "OBSERVATION_MODIFIER", 14, 18], ["FPs", "OBSERVATION", 19, 22], ["edge", "OBSERVATION_MODIFIER", 39, 43]]], ["Once the product was completely dissolved, 2 L of water was added to form a suspension.", [["water", "SIMPLE_CHEMICAL", 50, 55], ["water", "TREATMENT", 50, 55], ["a suspension", "TREATMENT", 74, 86]]], ["For the study, 5 mL of the fluorescent solution was sprayed on each gloved palm (a total of 10 mL on both palms) (Fig 2).", [["palms", "ANATOMY", 106, 111], ["palm", "ORGANISM_SUBDIVISION", 75, 79], ["palms", "ORGANISM_SUBDIVISION", 106, 111], ["the study", "TEST", 4, 13], ["the fluorescent solution", "TREATMENT", 23, 47]]], ["As mentioned earlier, fluorescent dye is not known to be harmful to the human body and can be injected into veins in a fundus fluorescein angiogram to safely and effectively diagnose eye problems.31 In the present study, the final fluorescent solution applied to on each gloved palm was similar to that used in fundus fluorescein angiography (0.05 g/5 mL).31 The subjects were instructed to repeat the following procedure 5 times: pull back a plunger to fill a bladder wash syringe with 60 mL of air and then expel all 60 mL of air.", [["body", "ANATOMY", 78, 82], ["veins", "ANATOMY", 108, 113], ["fundus", "ANATOMY", 119, 125], ["eye", "ANATOMY", 183, 186], ["fundus", "ANATOMY", 311, 317], ["bladder", "ANATOMY", 461, 468], ["fluorescein", "CHEMICAL", 126, 137], ["fluorescein", "CHEMICAL", 318, 329], ["fluorescein", "CHEMICAL", 126, 137], ["fluorescein", "CHEMICAL", 318, 329], ["fluorescent dye", "SIMPLE_CHEMICAL", 22, 37], ["human", "ORGANISM", 72, 77], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["veins", "MULTI-TISSUE_STRUCTURE", 108, 113], ["fundus", "MULTI-TISSUE_STRUCTURE", 119, 125], ["fluorescein", "SIMPLE_CHEMICAL", 126, 137], ["eye", "ORGAN", 183, 186], ["fundus", "MULTI-TISSUE_STRUCTURE", 311, 317], ["fluorescein", "SIMPLE_CHEMICAL", 318, 329], ["bladder", "ORGAN", 461, 468], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["fluorescent dye", "TEST", 22, 37], ["a fundus fluorescein angiogram", "TEST", 117, 147], ["diagnose eye problems", "PROBLEM", 174, 195], ["the final fluorescent solution", "TREATMENT", 221, 251], ["fundus fluorescein angiography", "TEST", 311, 341], ["a plunger", "TREATMENT", 441, 450], ["a bladder wash syringe", "TREATMENT", 459, 481], ["veins", "ANATOMY", 108, 113], ["bladder", "ANATOMY", 461, 468]]], ["This procedure was considered a common simulation of a simple daily nursing procedure, such as a Ryle tube feeding or bladder washout.", [["bladder", "ANATOMY", 118, 125], ["bladder", "ORGAN", 118, 125], ["This procedure", "TREATMENT", 0, 14], ["a simple daily nursing procedure", "TREATMENT", 53, 85], ["a Ryle tube feeding", "TREATMENT", 95, 114], ["bladder washout", "TREATMENT", 118, 133], ["bladder", "ANATOMY", 118, 125], ["washout", "OBSERVATION", 126, 133]]], ["This simple procedure was completed before doffing gloves.Fluorescent solution ::: MethodsThree large pieces of white cloth were placed onto the wall in front of and on both sides (left and right) of the subject.", [["wall", "ANATOMY", 145, 149], ["left", "ANATOMY", 181, 185], ["wall", "TISSUE", 145, 149], ["This simple procedure", "TREATMENT", 0, 21], ["Methods", "TREATMENT", 83, 90], ["white cloth", "TREATMENT", 112, 123], ["large", "OBSERVATION_MODIFIER", 96, 101], ["pieces", "OBSERVATION_MODIFIER", 102, 108], ["white cloth", "OBSERVATION", 112, 123], ["wall", "ANATOMY_MODIFIER", 145, 149], ["front", "ANATOMY_MODIFIER", 153, 158], ["both", "ANATOMY_MODIFIER", 169, 173], ["sides", "ANATOMY_MODIFIER", 174, 179], ["left", "ANATOMY_MODIFIER", 181, 185], ["right", "ANATOMY_MODIFIER", 190, 195]]], ["The white cloth was intended to clearly show the FPs.", [["The white cloth", "TREATMENT", 0, 15]]], ["Due to the difficulty in counting the small patches, the researcher drew a grid (30 cm2 squares) on all white cloths to facilitate the counting in each individual grid.Ultraviolent lamp ::: MethodsThe ultraviolet (UV) lamp (Stylish 12\u201d fluorescent lantern; John Manufacture Ltd; Hong Kong, China) is useful for detecting FPs, making the invisible stained patch visible.", [["the difficulty in counting the small patches", "PROBLEM", 7, 51], ["all white cloths", "TREATMENT", 100, 116], ["Ultraviolent lamp", "TREATMENT", 168, 185], ["The ultraviolet (UV) lamp", "TREATMENT", 197, 222], ["small", "OBSERVATION_MODIFIER", 38, 43], ["patches", "OBSERVATION_MODIFIER", 44, 51]]], ["The UV lamp was checked and tested before the study; the same brand of UV lamp was used throughout the study period, to prevent any significant mismatch in the results.", [["The UV lamp", "TEST", 0, 11], ["the study", "TEST", 42, 51], ["UV lamp", "TREATMENT", 71, 78], ["any significant mismatch in the results", "PROBLEM", 128, 167], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["mismatch", "OBSERVATION", 144, 152]]], ["All participants assessed the UV lamp before donning the gloves and protective clothing to ensure that no fluorescent solution was present.Timing ::: MethodsThe researcher recorded the time taken for glove removal in the pretest and posttest periods.Study procedures ::: MethodsIn brief, in an experimental laboratory (ambient temperature, 22\u223c25\u00b0C; relative humidity, 70%), each of the 50 subjects completed the pretest and posttest glove removal at two separate sessions separated by a 30-minute interval after 10 mL of the fluorescent solution was sprayed on both palms.", [["palms", "ANATOMY", 566, 571], ["palms", "ORGANISM_SUBDIVISION", 566, 571], ["participants", "SPECIES", 4, 16], ["the UV lamp", "TEST", 26, 37], ["the gloves", "TREATMENT", 53, 63], ["protective clothing", "TREATMENT", 68, 87], ["fluorescent solution", "TREATMENT", 106, 126], ["Methods", "TREATMENT", 150, 157], ["glove removal", "TREATMENT", 200, 213], ["ambient temperature", "TEST", 319, 338], ["posttest glove removal", "TREATMENT", 424, 446], ["the fluorescent solution", "TREATMENT", 521, 545]]], ["A video demonstrating the CDC\u2019s recommended glove removal method was shown between two sessions.", [["A video", "TEST", 0, 7], ["glove removal method", "TREATMENT", 44, 64]]], ["After glove removal, FPs were counted by a UV scan under dim light.", [["glove removal", "TREATMENT", 6, 19], ["FPs", "TEST", 21, 24], ["a UV scan", "TEST", 41, 50], ["dim light", "OBSERVATION", 57, 66]]], ["Skin testing for allergy to fluorescent dye was performed before the testing to exclude any subject with an allergy and avoid the risk of an allergic reaction.", [["Skin", "ANATOMY", 0, 4], ["allergy", "DISEASE", 17, 24], ["allergy", "DISEASE", 108, 115], ["allergic reaction", "DISEASE", 141, 158], ["Skin", "ORGAN", 0, 4], ["fluorescent dye", "SIMPLE_CHEMICAL", 28, 43], ["Skin testing", "TEST", 0, 12], ["allergy", "PROBLEM", 17, 24], ["fluorescent dye", "TEST", 28, 43], ["the testing", "TEST", 65, 76], ["an allergy", "PROBLEM", 105, 115], ["an allergic reaction", "PROBLEM", 138, 158], ["allergic", "OBSERVATION", 141, 149]]], ["Figure 3shows the procedural sequence.Statistical analysis ::: MethodsAll data were analyzed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL).", [["the procedural sequence", "TEST", 14, 37], ["Methods", "TREATMENT", 63, 70], ["All data", "TEST", 70, 78], ["SPSS", "TEST", 99, 103]]], ["A repeat measurement was made to compare the results of the CDC glove doffing method at two different distances (2 feet and 3 feet) between the subject and the rubbish bin.", [["A repeat measurement", "TEST", 0, 20]]], ["Hotelling\u2019s T2 test of multivariate analysis was used to identify any significant differences in contamination of the front white cloth between the pretest and the posttest.", [["T2", "DNA", 12, 14], ["multivariate analysis", "TEST", 23, 44]]], ["One-way analysis of variance was applied to the data to compare the sample means of ranking of staff and the time of glove removal.", [["glove removal", "TREATMENT", 117, 130]]], ["When a significant difference for a main effect was obtained, the multiple-comparisons method of Bonferroni was used to identify specific differences.", [["significant", "OBSERVATION_MODIFIER", 7, 18]]]], "PMC7441762": [["IntroductionNovel SARS-CoV2 is a pathogenic strain of coronavirus that is raising major concerns over the public health around the world.", [["SARS-CoV2", "DISEASE", 18, 27], ["coronavirus", "DISEASE", 54, 65], ["coronavirus", "ORGANISM", 54, 65], ["coronavirus", "SPECIES", 54, 65], ["a pathogenic strain of coronavirus", "PROBLEM", 31, 65], ["coronavirus", "OBSERVATION", 54, 65]]], ["Coronaviruses are spherical enveloped viruses with positive sense single stranded RNA genome having a place in the Coronaviridae family and they cause respiratory tract infections in humans, animals and birds.", [["respiratory tract", "ANATOMY", 151, 168], ["respiratory tract infections", "DISEASE", 151, 179], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["respiratory tract", "ORGANISM_SUBDIVISION", 151, 168], ["humans", "ORGANISM", 183, 189], ["humans", "SPECIES", 183, 189], ["humans", "SPECIES", 183, 189], ["Coronaviruses", "PROBLEM", 0, 13], ["spherical enveloped viruses", "PROBLEM", 18, 45], ["positive sense single stranded RNA genome", "PROBLEM", 51, 92], ["respiratory tract infections in humans", "PROBLEM", 151, 189], ["spherical", "OBSERVATION_MODIFIER", 18, 27], ["enveloped", "OBSERVATION_MODIFIER", 28, 37], ["viruses", "OBSERVATION", 38, 45], ["RNA genome", "OBSERVATION", 82, 92], ["respiratory tract", "ANATOMY", 151, 168], ["infections", "OBSERVATION", 169, 179]]], ["SARS-like CoVs isolated from bats have 95% genome sequence identity with human SARS-CoVs, allowing them to directly infect humans without any requirement for an intermediate host (Hu et al., 2018).", [["SARS", "DISEASE", 0, 4], ["SARS-CoVs", "DISEASE", 79, 88], ["SARS-like CoVs", "GENE_OR_GENE_PRODUCT", 0, 14], ["bats", "ORGANISM", 29, 33], ["human", "ORGANISM", 73, 78], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 79, 88], ["humans", "ORGANISM", 123, 129], ["SARS-like CoVs", "DNA", 0, 14], ["human", "SPECIES", 73, 78], ["humans", "SPECIES", 123, 129], ["human SARS-CoVs", "SPECIES", 73, 88], ["humans", "SPECIES", 123, 129], ["SARS", "PROBLEM", 0, 4], ["CoVs", "PROBLEM", 10, 14], ["human SARS", "PROBLEM", 73, 83], ["CoVs", "PROBLEM", 84, 88]]], ["The genome of SARS coronaviruses comprise 5\u2032 open reading frame ORF (1a and 1b coding region, S region encodes spike glycoprotein, E region encodes enveloped protein, M region encodes membrane protein, N region encodes nucleocapsid protein, six accessory proteins encoded by ORF 3a, ORF 6, ORF 7a, ORF 7b, ORF 8 and 3\u2032 terminal non-coding region) (Rota et al., 2003).", [["membrane", "ANATOMY", 184, 192], ["SARS coronaviruses", "DISEASE", 14, 32], ["SARS coronaviruses", "ORGANISM", 14, 32], ["membrane", "CELLULAR_COMPONENT", 184, 192], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 219, 239], ["ORF 3a", "GENE_OR_GENE_PRODUCT", 275, 281], ["ORF 6", "GENE_OR_GENE_PRODUCT", 283, 288], ["ORF 7a", "GENE_OR_GENE_PRODUCT", 290, 296], ["ORF 7b", "GENE_OR_GENE_PRODUCT", 298, 304], ["ORF 8", "GENE_OR_GENE_PRODUCT", 306, 311], ["5\u2032 open reading frame ORF", "DNA", 42, 67], ["1a and 1b coding region", "DNA", 69, 92], ["S region", "DNA", 94, 102], ["spike glycoprotein", "PROTEIN", 111, 129], ["E region", "DNA", 131, 139], ["enveloped protein", "PROTEIN", 148, 165], ["M region", "PROTEIN", 167, 175], ["membrane protein", "PROTEIN", 184, 200], ["N region", "PROTEIN", 202, 210], ["nucleocapsid protein", "PROTEIN", 219, 239], ["accessory proteins", "PROTEIN", 245, 263], ["ORF 3a", "DNA", 275, 281], ["ORF 6", "DNA", 283, 288], ["ORF 7a", "DNA", 290, 296], ["ORF 7b", "DNA", 298, 304], ["ORF 8", "DNA", 306, 311], ["3\u2032 terminal non-coding region", "DNA", 316, 345], ["SARS coronaviruses", "SPECIES", 14, 32], ["SARS coronaviruses", "PROBLEM", 14, 32], ["open reading frame ORF", "TEST", 45, 67], ["1b coding region", "PROBLEM", 76, 92], ["S region encodes spike glycoprotein, E region encodes enveloped protein", "PROBLEM", 94, 165], ["membrane protein", "TEST", 184, 200], ["nucleocapsid protein", "TEST", 219, 239], ["six accessory proteins", "TEST", 241, 263], ["ORF", "TEST", 283, 286], ["ORF", "TEST", 290, 293], ["ORF 7b", "TEST", 298, 304], ["ORF", "TEST", 306, 309]]], ["The trimeric S glycoprotein contains two S1 and S2 subunits for interaction with host cell receptor and for fusion with host cell, respectively (Wu et al., 2020).", [["cell", "ANATOMY", 86, 90], ["cell", "ANATOMY", 125, 129], ["trimeric S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 27], ["S1", "GENE_OR_GENE_PRODUCT", 41, 43], ["S2", "GENE_OR_GENE_PRODUCT", 48, 50], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 81, 99], ["host cell", "CELL", 120, 129], ["trimeric S glycoprotein", "PROTEIN", 4, 27], ["S1 and S2 subunits", "PROTEIN", 41, 59], ["host cell receptor", "PROTEIN", 81, 99], ["The trimeric S glycoprotein", "TREATMENT", 0, 27], ["S1 and S2 subunits", "TREATMENT", 41, 59], ["host cell receptor", "TREATMENT", 81, 99], ["fusion", "TREATMENT", 108, 114], ["host cell", "OBSERVATION", 120, 129]]], ["Fan Wu et al. revealed that the receptor-binding domain (RBD) of COVID-19 spike protein is fundamentally the same as that of SARS-CoVs (73.8\u201374.9% amino acid character) and SARS-like CoVs, including strains Rs4874, Rs7327 and Rs4231 (75.9\u201376.9% amino acid) (Wu et al., 2020; Yuan et al., 2017).", [["SARS", "DISEASE", 125, 129], ["amino acid", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 245, 255], ["amino acid", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 245, 255], ["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 125, 134], ["amino acid", "AMINO_ACID", 147, 157], ["SARS-like CoVs", "GENE_OR_GENE_PRODUCT", 173, 187], ["amino acid", "AMINO_ACID", 245, 255], ["receptor-binding domain", "PROTEIN", 32, 55], ["RBD", "PROTEIN", 57, 60], ["COVID-19 spike protein", "PROTEIN", 65, 87], ["SARS-like CoVs", "PROTEIN", 173, 187], ["the receptor-binding domain", "TEST", 28, 55], ["COVID", "TEST", 65, 70], ["spike protein", "TEST", 74, 87], ["SARS", "PROBLEM", 125, 129], ["CoVs", "TEST", 130, 134], ["amino acid character", "TEST", 147, 167], ["SARS", "PROBLEM", 173, 177], ["CoVs", "PROBLEM", 183, 187], ["strains Rs", "TEST", 199, 209], ["Rs", "TEST", 215, 217], ["Rs", "TEST", 226, 228], ["amino acid", "TEST", 245, 255]]], ["Peng Zhou et al. confirmed that SARS-CoV-2 uses human ACE2 receptor for cell entry (Q. Wang et al., 2020; P. Zhou et al., 2020) and this receptor can turn out to be a potential target to block the attachment of SARS-CoV-2 spike protein (Zhang et al., 2020).", [["cell", "ANATOMY", 72, 76], ["SARS", "DISEASE", 32, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["human", "ORGANISM", 48, 53], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 54, 67], ["cell", "CELL", 72, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 211, 221], ["human ACE2 receptor", "PROTEIN", 48, 67], ["SARS-CoV-2 spike protein", "PROTEIN", 211, 235], ["human", "SPECIES", 48, 53], ["SARS-CoV", "SPECIES", 32, 40], ["human", "SPECIES", 48, 53], ["SARS", "PROBLEM", 32, 36], ["human ACE2 receptor", "TREATMENT", 48, 67], ["SARS", "PROBLEM", 211, 215], ["CoV", "TEST", 216, 219], ["SARS", "OBSERVATION", 32, 36]]], ["Among several viral proteins, the main protease of SARS-Cov2 (Mpro) is more potent target due to its vital role in the virus replication and transcription inside the host cells (Jin et al., 2020).", [["cells", "ANATOMY", 171, 176], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 51, 60], ["Mpro", "GENE_OR_GENE_PRODUCT", 62, 66], ["cells", "CELL", 171, 176], ["viral proteins", "PROTEIN", 14, 28], ["protease", "PROTEIN", 39, 47], ["Cov2", "PROTEIN", 56, 60], ["Mpro", "PROTEIN", 62, 66], ["host cells", "CELL_TYPE", 166, 176], ["several viral proteins", "PROBLEM", 6, 28], ["SARS", "PROBLEM", 51, 55], ["the virus replication", "TREATMENT", 115, 136], ["viral proteins", "OBSERVATION", 14, 28], ["host cells", "OBSERVATION", 166, 176]]], ["As the novel coronavirus (SARS-CoV-2) have sequence homology with SARS and MERS thus the existing antiviral drugs seem effective against SARS-CoV-2.", [["SARS", "DISEASE", 66, 70], ["coronavirus", "ORGANISM", 13, 24], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV-2", "ORGANISM", 137, 147], ["SARS-CoV", "SPECIES", 137, 145], ["the novel coronavirus", "PROBLEM", 3, 24], ["sequence homology", "TEST", 43, 60], ["SARS", "PROBLEM", 66, 70], ["MERS", "TREATMENT", 75, 79], ["the existing antiviral drugs", "TREATMENT", 85, 113], ["SARS", "PROBLEM", 137, 141]]], ["Remdesivir, a nucleotide analogue inhibitor of RdRp and antimalarial drug chloroquine effectively inhibited the SARS-CoV-2 infection in vitro (M. Wang et al., 2020).", [["Remdesivir", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 14, 24], ["chloroquine", "CHEMICAL", 74, 85], ["infection", "DISEASE", 123, 132], ["Remdesivir", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 14, 24], ["chloroquine", "CHEMICAL", 74, 85], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["chloroquine", "SIMPLE_CHEMICAL", 74, 85], ["CoV-2", "ORGANISM", 117, 122], ["SARS-CoV-2", "SPECIES", 112, 122], ["Remdesivir", "TREATMENT", 0, 10], ["a nucleotide analogue inhibitor", "TREATMENT", 12, 43], ["RdRp", "TREATMENT", 47, 51], ["antimalarial drug chloroquine", "TREATMENT", 56, 85], ["the SARS", "PROBLEM", 108, 116], ["CoV-2 infection", "PROBLEM", 117, 132]]], ["Hydroxychloroquine, an analogue of chloroquine is also a drug candidate after in vitro (Yao et al., 2020) and clinical investigations (Gautret et al. 2020).", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 35, 46], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 35, 46], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["chloroquine", "SIMPLE_CHEMICAL", 35, 46], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["chloroquine", "TREATMENT", 35, 46], ["clinical investigations", "TEST", 110, 133]]], ["Considering the increase in fatality, there is an urgent requirement to channeled approved drugs and natural active compounds towards fighting the pandemic (Y. Zhou et al., 2020).", [["an urgent requirement", "PROBLEM", 47, 68], ["drugs", "TREATMENT", 91, 96], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["This has led to several computational studies that screened hundreds of small molecules for their binding to key proteins such as spike glycoprotein, envelop protein, membrane protein and nucleocapsid protein (Das et al., 2020; Islam et al., 2020; Farag et al., 2020; Micael et al., 2020; Pandit et al., 2020; Ubani et al., 2020; Tallei et al., 2020; Romulo et al., 2020; Liu et al., 2020).", [["membrane", "ANATOMY", 167, 175], ["spike glycoprotein", "GENE_OR_GENE_PRODUCT", 130, 148], ["envelop protein", "GENE_OR_GENE_PRODUCT", 150, 165], ["membrane", "CELLULAR_COMPONENT", 167, 175], ["spike glycoprotein", "PROTEIN", 130, 148], ["envelop protein", "PROTEIN", 150, 165], ["membrane protein", "PROTEIN", 167, 183], ["nucleocapsid protein", "PROTEIN", 188, 208], ["several computational studies", "TEST", 16, 45], ["small molecules", "PROBLEM", 72, 87], ["their binding", "PROBLEM", 92, 105], ["spike glycoprotein", "TREATMENT", 130, 148]]], ["As natural product repository has overwhelming number of leads that may act as both blocker of receptor mediated host cell uptake of the viral particles and inhibitor of the viral replication.", [["cell", "ANATOMY", 118, 122], ["host cell", "CELL", 113, 122], ["receptor mediated host cell uptake", "TREATMENT", 95, 129], ["the viral particles", "TREATMENT", 133, 152], ["the viral replication", "TREATMENT", 170, 191], ["host cell uptake", "OBSERVATION", 113, 129], ["viral particles", "OBSERVATION", 137, 152], ["viral replication", "OBSERVATION", 174, 191]]], ["In this direction, we have selected two target proteins (viral protein, Mpro and host receptor protein, ACE2) and performed docking studies to screen potential natural products.", [["Mpro", "GENE_OR_GENE_PRODUCT", 72, 76], ["host receptor protein", "GENE_OR_GENE_PRODUCT", 81, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["target proteins", "PROTEIN", 40, 55], ["viral protein", "PROTEIN", 57, 70], ["Mpro", "PROTEIN", 72, 76], ["host receptor protein", "PROTEIN", 81, 102], ["ACE2", "PROTEIN", 104, 108], ["viral protein", "TEST", 57, 70], ["Mpro", "TEST", 72, 76], ["host receptor protein", "TREATMENT", 81, 102], ["ACE2", "TEST", 104, 108], ["docking studies", "TEST", 124, 139], ["natural products", "OBSERVATION", 160, 176]]], ["Further, in silico ADME (Absorption, Distribution, Metabolism, Excretion) analysis has been performed to understand their suitability as a drug candidate.", [["ADME", "CHEMICAL", 19, 23], ["Metabolism, Excretion) analysis", "TEST", 51, 82]]], ["While the top leads, Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid show optimal binding at the active site of both SARS-CoV-2 Mpro and ACE2, ADME calculations show that all these molecules have low bioavailability.Target selection ::: Material and methodsWe selected viral and host targets, SARS CoV-2 main protease (Mpro) and ACE2, respectively to identify effective leads.", [["Delphinidin 3,5-diglucoside", "CHEMICAL", 21, 48], ["Scutellarein 7-glucoside", "CHEMICAL", 50, 74], ["Avicularin", "CHEMICAL", 76, 86], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 91, 120], ["Delphinidin 3,5-diglucoside", "CHEMICAL", 21, 48], ["Scutellarein 7-glucoside", "CHEMICAL", 50, 74], ["Avicularin", "CHEMICAL", 76, 86], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 91, 120], ["Delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 21, 48], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 50, 74], ["Avicularin", "SIMPLE_CHEMICAL", 76, 86], ["3,5-Di-O-galloylshikimic acid", "SIMPLE_CHEMICAL", 91, 120], ["Mpro", "GENE_OR_GENE_PRODUCT", 180, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 189, 193], ["Mpro", "GENE_OR_GENE_PRODUCT", 371, 375], ["ACE2", "GENE_OR_GENE_PRODUCT", 381, 385], ["SARS-CoV-2 Mpro", "PROTEIN", 169, 184], ["ACE2", "PROTEIN", 189, 193], ["SARS CoV-2 main protease", "PROTEIN", 345, 369], ["Mpro", "PROTEIN", 371, 375], ["ACE2", "PROTEIN", 381, 385], ["SARS CoV", "SPECIES", 345, 353], ["Delphinidin", "TEST", 21, 32], ["diglucoside", "TREATMENT", 37, 48], ["Scutellarein", "TEST", 50, 62], ["glucoside", "TREATMENT", 65, 74], ["Avicularin", "TREATMENT", 76, 86], ["Di-O-galloylshikimic acid", "TREATMENT", 95, 120], ["optimal binding", "PROBLEM", 126, 141], ["CoV", "TEST", 174, 177], ["ADME calculations", "TEST", 195, 212], ["SARS CoV", "TEST", 345, 353], ["protease (Mpro)", "TREATMENT", 361, 376], ["ACE2", "TEST", 381, 385]]], ["Mpro is a homodimer with two protomers, each containing three domains (I, II and III) and a CYS-HIS catalytic dyad inside the cleft between domain I and II.", [["Mpro", "GENE_OR_GENE_PRODUCT", 0, 4], ["CYS", "GENE_OR_GENE_PRODUCT", 92, 95], ["Mpro", "PROTEIN", 0, 4], ["I, II and III", "PROTEIN", 71, 84], ["CYS", "PROTEIN", 92, 95], ["HIS catalytic dyad", "PROTEIN", 96, 114], ["domain I and II", "PROTEIN", 140, 155], ["a CYS", "TEST", 90, 95], ["HIS catalytic dyad", "PROBLEM", 96, 114], ["cleft", "OBSERVATION", 126, 131]]], ["This cleft has four subsites (S1, S1\u2032, S2 and S4) that remain conserved in all coronavirus Mpro.", [["cleft", "ORGAN", 5, 10], ["S1\u2032", "GENE_OR_GENE_PRODUCT", 34, 37], ["S2", "GENE_OR_GENE_PRODUCT", 39, 41], ["S4", "GENE_OR_GENE_PRODUCT", 46, 48], ["coronavirus Mpro", "ORGANISM", 79, 95], ["S1", "PROTEIN", 30, 32], ["S1\u2032", "PROTEIN", 34, 37], ["S2", "PROTEIN", 39, 41], ["S4", "PROTEIN", 46, 48], ["coronavirus Mpro", "PROTEIN", 79, 95], ["This cleft", "PROBLEM", 0, 10], ["four subsites (S1, S1\u2032, S2 and S4)", "PROBLEM", 15, 49], ["S2", "ANATOMY", 39, 41], ["S4", "ANATOMY", 46, 48]]], ["The other target is a host protein, ACE2 (angiotensin-converting enzyme-related carboxypeptidase) which is having HEXXH-E zinc-binding consensus sequence.", [["angiotensin", "CHEMICAL", 42, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["angiotensin-converting enzyme-related carboxypeptidase", "GENE_OR_GENE_PRODUCT", 42, 96], ["HEXXH-E", "GENE_OR_GENE_PRODUCT", 114, 121], ["host protein", "PROTEIN", 22, 34], ["ACE2", "PROTEIN", 36, 40], ["angiotensin-converting enzyme", "PROTEIN", 42, 71], ["carboxypeptidase", "PROTEIN", 80, 96], ["HEXXH", "PROTEIN", 114, 119], ["E zinc-binding consensus sequence", "DNA", 120, 153], ["ACE2 (angiotensin", "TREATMENT", 36, 53], ["enzyme-related carboxypeptidase", "TREATMENT", 65, 96]]], ["Extracellular region of ACE2 consist of two domains (I and II), a zinc metallopeptidase (residues 19\u2013611) and C terminus (residues 612\u2013740).", [["Extracellular region", "ANATOMY", 0, 20], ["zinc", "CHEMICAL", 66, 70], ["C", "CHEMICAL", 110, 111], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["\u2013740", "AMINO_ACID", 134, 138], ["ACE2", "PROTEIN", 24, 28], ["I and II", "PROTEIN", 53, 61], ["zinc metallopeptidase", "PROTEIN", 66, 87], ["residues 19\u2013611", "PROTEIN", 89, 104], ["C terminus", "PROTEIN", 110, 120], ["residues 612\u2013740", "PROTEIN", 122, 138], ["ACE2", "TEST", 24, 28], ["a zinc metallopeptidase (residues", "TREATMENT", 64, 97], ["ACE2", "OBSERVATION", 24, 28]]], ["Zinc metallopeptidase further have two domains in which catalytic site for ACE2 inhibitors is present.", [["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc metallopeptidase", "GENE_OR_GENE_PRODUCT", 0, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["Zinc metallopeptidase", "PROTEIN", 0, 21], ["catalytic site", "PROTEIN", 56, 70], ["ACE2", "PROTEIN", 75, 79], ["Zinc metallopeptidase", "TREATMENT", 0, 21], ["ACE2 inhibitors", "TREATMENT", 75, 90]]], ["Along with the presence of residues coordinating with the zinc the catalytic site also have two subsites S1 and S1\u2032 defined by specific residues which occupies major portion providing substrate binding specificity (Towler et al., 2004).Molecular docking and natural products screening ::: Material and methodsMolecular docking was performed, using glide package of Schr\u00f6dinger chemical simulation software (Schr\u00f6dinger, LLC, and New York, NY).", [["zinc", "CHEMICAL", 58, 62], ["zinc", "CHEMICAL", 58, 62], ["catalytic site", "PROTEIN", 67, 81], ["S1", "PROTEIN", 105, 107], ["S1", "PROTEIN", 112, 114], ["the zinc the catalytic site", "PROBLEM", 54, 81], ["residues", "OBSERVATION", 27, 35], ["S1", "ANATOMY", 112, 114], ["specific residues", "OBSERVATION", 127, 144], ["LLC", "ANATOMY", 420, 423]]], ["The crystal structure of SARS-Cov-2 Mpro and ACE2 was sourced from PDB data bank (PDB-ID: 6lu7 (Jin et al., 2020), 1R4L (Towler et al., 2004)).", [["SARS-Cov-2 Mpro", "GENE_OR_GENE_PRODUCT", 25, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["Cov", "PROTEIN", 30, 33], ["Mpro", "PROTEIN", 36, 40], ["ACE2", "PROTEIN", 45, 49], ["SARS", "TEST", 25, 29], ["Cov", "TEST", 30, 33], ["ACE2", "TEST", 45, 49], ["SARS", "OBSERVATION", 25, 29]]], ["The protein preparation wizard was utilized to preprocess the crystal structure which includes removal of water molecules present beyond 5 \u00c5, addition of right bond order, addition of H-atoms and optimization of hydroxyl and amino groups.", [["hydroxyl", "CHEMICAL", 212, 220], ["amino", "CHEMICAL", 225, 230], ["hydroxyl", "CHEMICAL", 212, 220], ["amino", "CHEMICAL", 225, 230], ["H-atoms", "SIMPLE_CHEMICAL", 184, 191], ["hydroxyl", "SIMPLE_CHEMICAL", 212, 220], ["amino", "AMINO_ACID", 225, 230], ["water molecules", "PROTEIN", 106, 121], ["The protein preparation wizard", "TREATMENT", 0, 30], ["removal of water molecules", "TREATMENT", 95, 121], ["H-atoms", "TREATMENT", 184, 191], ["hydroxyl and amino groups", "TREATMENT", 212, 237], ["right", "ANATOMY_MODIFIER", 154, 159]]], ["Restrained minimization was performed using OPLS3 force field until the average root mean square deviation of the non-hydrogen atoms reached 0.3 \u00c5.", [["root", "ANATOMY", 80, 84], ["non-hydrogen", "CHEMICAL", 114, 126], ["non-hydrogen atoms", "SIMPLE_CHEMICAL", 114, 132], ["Restrained minimization", "TREATMENT", 0, 23], ["the non-hydrogen atoms", "TEST", 110, 132]]], ["The receptor grid generation module was employed to generate grid for Mpro and ACE2 co-crystallized with its inhibitors, N3 and MLN4760, respectively.", [["MLN4760", "CHEMICAL", 128, 135], ["Mpro", "GENE_OR_GENE_PRODUCT", 70, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["MLN4760", "SIMPLE_CHEMICAL", 128, 135], ["Mpro", "PROTEIN", 70, 74], ["ACE2", "PROTEIN", 79, 83], ["The receptor grid generation module", "TREATMENT", 0, 35], ["Mpro and ACE2 co-crystallized", "TREATMENT", 70, 99], ["its inhibitors", "TREATMENT", 105, 119], ["N3", "TREATMENT", 121, 123]]], ["Position of N3 and MLN-4760 was set as the primary active site for the docking of selected ligands.", [["MLN-4760", "CHEMICAL", 19, 27], ["N3", "CHEMICAL", 12, 14], ["MLN-4760", "CHEMICAL", 19, 27], ["MLN-4760", "SIMPLE_CHEMICAL", 19, 27], ["N3 and MLN", "TREATMENT", 12, 22], ["N3", "OBSERVATION_MODIFIER", 12, 14], ["MLN", "ANATOMY", 19, 22]]], ["The size of protein grid was optimized by re-docking of co-crystallized ligand within RMSD value < 2 \u00c5.", [["protein grid", "TREATMENT", 12, 24], ["size", "OBSERVATION_MODIFIER", 4, 8], ["protein grid", "OBSERVATION", 12, 24]]], ["Up to 55 molecules (Source: PUBchem) were imported to the LigPrep module of Schr\u00f6dinger software package to generate possible ionization states at the pH range 7 \u00b1 2 using Epik.", [["Schr\u00f6dinger software package", "TREATMENT", 76, 104]]], ["The generated conformers of all the screened ligands were docked to the Mpro using extra precision mode.MM-GBSA dG binding energy calculations ::: Material and methodsOn the basis of binding interaction energies ligand-protein complexes were re-scored by using MM-GB/SA (molecular mechanics energies combined with generalized born and surface area) module of Schr\u00f6dinger software to enhance the binding affinity predictions.ADME parameters calculations ::: Material and methodsIt is vital to explore the pharmacokinetic profile of a molecule to be eligible as an active drug in clinical trial.", [["dG", "CHEMICAL", 112, 114], ["Mpro", "SIMPLE_CHEMICAL", 72, 76], ["Mpro", "PROTEIN", 72, 76], ["protein complexes", "PROTEIN", 219, 236], ["extra precision mode", "TREATMENT", 83, 103], ["protein complexes", "TEST", 219, 236], ["MM", "TEST", 261, 263], ["GB/SA (molecular mechanics energies", "TREATMENT", 264, 299]]], ["Three pharmacokinetic parameters (Lipophilicity, solubility and bioavailability) were considered for the purpose of handling and formulation.", [["Three pharmacokinetic parameters", "TEST", 0, 32], ["Lipophilicity, solubility and bioavailability", "TREATMENT", 34, 79], ["handling and formulation", "TREATMENT", 116, 140]]], ["Lipophilicity (Log P) calculations were based on XLOGP3 model (Cheng et al., 2007) and solubility calculation was based on ESOL model (Delaney, 2004), while bioavailability scores were based on the method developed by Martin (2005).Results and discussionSARS CoV-2 main protease (Mpro) and ACE2 were used as target to identify effective leads.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 259, 264], ["Mpro", "GENE_OR_GENE_PRODUCT", 280, 284], ["ACE2", "GENE_OR_GENE_PRODUCT", 290, 294], ["discussionSARS CoV-2 main protease", "PROTEIN", 244, 278], ["Mpro", "PROTEIN", 280, 284], ["ACE2", "PROTEIN", 290, 294], ["Lipophilicity (Log P) calculations", "TEST", 0, 34], ["solubility calculation", "TEST", 87, 109], ["bioavailability scores", "TEST", 157, 179], ["discussionSARS", "TEST", 244, 258], ["CoV", "TEST", 259, 262], ["protease (Mpro)", "TREATMENT", 270, 285], ["ACE2", "TREATMENT", 290, 294]]], ["Mpro processes polyproteins into 16 non-structural proteins (NSPs), which further generates subgenomic RNAs encoding for four main structural proteins (envelope (E), membrane (M), spike (S) and nucleocapsid (N) proteins) and other additional proteins (Coleman et al., 2014; Lu et al., 2020; Roh, 2012).", [["membrane", "ANATOMY", 166, 174], ["Mpro", "GENE_OR_GENE_PRODUCT", 0, 4], ["NSPs", "GENE_OR_GENE_PRODUCT", 61, 65], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 152, 164], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 194, 219], ["Mpro", "PROTEIN", 0, 4], ["16 non-structural proteins", "PROTEIN", 33, 59], ["NSPs", "PROTEIN", 61, 65], ["subgenomic RNAs", "RNA", 92, 107], ["structural proteins", "PROTEIN", 131, 150], ["envelope (E), membrane (M), spike (S) and nucleocapsid (N) proteins", "PROTEIN", 152, 219], ["Mpro processes polyproteins into 16 non-structural proteins (NSPs)", "PROBLEM", 0, 66], ["subgenomic RNAs", "PROBLEM", 92, 107], ["envelope (E), membrane (M)", "TEST", 152, 178], ["spike (S) and nucleocapsid (N) proteins)", "PROBLEM", 180, 220], ["16 non-structural proteins", "OBSERVATION_MODIFIER", 33, 59], ["subgenomic RNAs", "OBSERVATION", 92, 107]]], ["In the S1 subsite of Mpro, GLN is vital for high cleavage efficiency and is specific to this particular protease.", [["GLN", "CHEMICAL", 27, 30], ["Mpro", "GENE_OR_GENE_PRODUCT", 21, 25], ["GLN", "AMINO_ACID", 27, 30], ["Mpro", "PROTEIN", 21, 25], ["protease", "PROTEIN", 104, 112], ["high cleavage efficiency", "PROBLEM", 44, 68]]], ["There is no known Mpro human homolog with similar cleavage site making it an interesting antiviral target with lower probability of inhibitor toxicity.", [["toxicity", "DISEASE", 142, 150], ["Mpro", "GENE_OR_GENE_PRODUCT", 18, 22], ["human", "ORGANISM", 23, 28], ["Mpro human homolog", "PROTEIN", 18, 36], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["known Mpro human homolog", "PROBLEM", 12, 36], ["similar cleavage site", "PROBLEM", 42, 63], ["inhibitor toxicity", "PROBLEM", 132, 150], ["no", "UNCERTAINTY", 9, 11]]], ["While human ACE2 belongs to the category of type I integral membrane protein having 805 amino acids.", [["membrane", "ANATOMY", 60, 68], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 88, 99], ["human", "ORGANISM", 6, 11], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["type I integral membrane protein", "GENE_OR_GENE_PRODUCT", 44, 76], ["amino acids", "AMINO_ACID", 88, 99], ["human ACE2", "PROTEIN", 6, 16], ["type I integral membrane protein", "PROTEIN", 44, 76], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["amino acids", "TREATMENT", 88, 99]]], ["Despite its role in making a pathway for SARS-CoV2 (Q. Wang et al., 2020), ACE2 prevents lung injuries, resulting in worsening of pathological condition (Zhang et al., 2020).Results and discussionThe catalytic sub domain of human ACE2 in presence of inhibitor undergoes hinge bending movement causing the deep cleft of the subdomain I of enzyme to wrap the inhibitor.", [["lung", "ANATOMY", 89, 93], ["SARS", "DISEASE", 41, 45], ["lung injuries", "DISEASE", 89, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["lung", "ORGAN", 89, 93], ["human", "ORGANISM", 224, 229], ["ACE2", "GENE_OR_GENE_PRODUCT", 230, 234], ["ACE2", "PROTEIN", 75, 79], ["catalytic sub domain", "PROTEIN", 200, 220], ["human ACE2", "PROTEIN", 224, 234], ["subdomain I", "PROTEIN", 323, 334], ["enzyme", "PROTEIN", 338, 344], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 224, 229], ["SARS", "PROBLEM", 41, 45], ["lung injuries", "PROBLEM", 89, 102], ["worsening of pathological condition", "PROBLEM", 117, 152], ["The catalytic sub domain of human ACE2", "TREATMENT", 196, 234], ["inhibitor", "TREATMENT", 250, 259], ["hinge bending movement", "PROBLEM", 270, 292], ["wrap the inhibitor", "TREATMENT", 348, 366], ["lung", "ANATOMY", 89, 93], ["injuries", "OBSERVATION", 94, 102], ["worsening", "OBSERVATION_MODIFIER", 117, 126], ["hinge bending", "OBSERVATION", 270, 283], ["deep", "ANATOMY_MODIFIER", 305, 309], ["cleft", "OBSERVATION", 310, 315]]], ["This closing of subdomain I around inhibitor changes the conformation of the whole receptor making it less susceptible to interact with SARS-CoV2 receptor binding domain.", [["SARS-CoV2 receptor", "GENE_OR_GENE_PRODUCT", 136, 154], ["subdomain I", "PROTEIN", 16, 27], ["SARS-CoV2 receptor binding domain", "PROTEIN", 136, 169], ["This closing of subdomain I around inhibitor", "TREATMENT", 0, 44]]], ["In the free form zinc makes coordination bonds with three residues (HIS374, HIS378 and GLU402) and a water molecule (Towler et al., 2004).", [["zinc", "CHEMICAL", 17, 21], ["zinc", "CHEMICAL", 17, 21], ["HIS374", "CHEMICAL", 68, 74], ["HIS378", "CHEMICAL", 76, 82], ["GLU402", "CHEMICAL", 87, 93], ["zinc", "SIMPLE_CHEMICAL", 17, 21], ["HIS374", "SIMPLE_CHEMICAL", 68, 74], ["GLU402", "SIMPLE_CHEMICAL", 87, 93], ["HIS374", "TEST", 68, 74], ["HIS378", "TEST", 76, 82], ["coordination bonds", "OBSERVATION", 28, 46]]], ["The leads are explored under two key categories (a) drug candidates undergoing clinical evaluation and (b) natural products (Arts et al., 2004; McGhie & Walton, 2007; Okonogi et al., 2016; Paul et al., 2018; Stenlid, 1976; Yuldashev, 2002) (Table 1).", [["clinical evaluation", "TEST", 79, 98]]], ["Glide (Friesner et al., 2004) Extra Precision (XP) approach was used for screening of candidates followed by calculation of MM-GBSA energies to increase accuracy, and reliability of the docking process.", [["Extra Precision (XP) approach", "TREATMENT", 30, 59], ["MM", "TEST", 124, 126], ["GBSA energies", "PROBLEM", 127, 140], ["accuracy", "TEST", 153, 161]]], ["The SARS-CoV2 Mpro crystal structure plays an important role in identifying lead drugs through molecular simulation studies.", [["SARS", "DISEASE", 4, 8], ["The SARS", "TEST", 0, 8], ["lead drugs", "TREATMENT", 76, 86], ["molecular simulation studies", "TEST", 95, 123]]], ["The crystal structure sourced from protein databank has co-crystallized ligand N3, a michael acceptor that act as an irreversible inhibitor (Jin et al., 2020).", [["N3", "CHEMICAL", 79, 81], ["michael", "CHEMICAL", 85, 92], ["ligand N3", "SIMPLE_CHEMICAL", 72, 81], ["michael acceptor", "SIMPLE_CHEMICAL", 85, 101], ["a michael acceptor", "TREATMENT", 83, 101], ["ligand N3", "OBSERVATION", 72, 81]]], ["To validate the methods utilized in this work, N3 was re-docked to its active site in Mpro (RMSD value < 2 \u00c5).", [["N3", "CHEMICAL", 47, 49], ["N3", "SIMPLE_CHEMICAL", 47, 49], ["Mpro", "SIMPLE_CHEMICAL", 86, 90], ["the methods", "TREATMENT", 12, 23], ["N3", "TREATMENT", 47, 49]]], ["The docking yielded similar binding interactions as reported by Zhenming et al. and the MM-GBSA binding energy for N3 was calculated to be \u221280 Kcal/mol.", [["N3", "CHEMICAL", 115, 117], ["N3", "PROBLEM", 115, 117], ["similar binding", "OBSERVATION", 20, 35]]], ["The lactam of N3 embeds into the S1 subsite and forms a hydrogen bond with H163 as reported earlier.", [["lactam", "CHEMICAL", 4, 10], ["lactam", "CHEMICAL", 4, 10], ["N3", "CHEMICAL", 14, 16], ["hydrogen", "CHEMICAL", 56, 64], ["H163", "CHEMICAL", 75, 79], ["H163", "SIMPLE_CHEMICAL", 75, 79], ["S1 subsite", "PROTEIN", 33, 43], ["The lactam", "TEST", 0, 10], ["a hydrogen bond", "TEST", 54, 69], ["S1", "ANATOMY", 33, 35], ["hydrogen bond", "OBSERVATION", 56, 69]]], ["Also, N3 forms multiple hydrogen bonds with the residues in the substrate-binding pocket.", [["N3", "CHEMICAL", 6, 8], ["N3", "CHEMICAL", 6, 8], ["hydrogen", "CHEMICAL", 24, 32], ["N3", "SIMPLE_CHEMICAL", 6, 8], ["substrate-binding pocket", "PROTEIN", 64, 88], ["multiple hydrogen bonds", "PROBLEM", 15, 38], ["the residues in the substrate-binding pocket", "PROBLEM", 44, 88], ["multiple", "OBSERVATION_MODIFIER", 15, 23], ["hydrogen bonds", "OBSERVATION", 24, 38], ["binding pocket", "OBSERVATION", 74, 88]]], ["On the other hand the crystal structure of human ACE2 (PDB ID: 1R4l) Figure 2(i) bound with its inhibitor (MLN-4760) was also validated by re-docking.", [["MLN-4760", "CHEMICAL", 107, 115], ["MLN-4760", "CHEMICAL", 107, 115], ["human", "ORGANISM", 43, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["PDB ID: 1R4l) Figure 2", "GENE_OR_GENE_PRODUCT", 55, 77], ["human ACE2", "PROTEIN", 43, 53], ["PDB ID: 1R4l", "PROTEIN", 55, 67], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["its inhibitor", "TREATMENT", 92, 105]]], ["The residues involved in the binding site showed similar interaction as reported by Towler et al. with the docking score of \u221210.74 Kcal/mol and MM-GBSA score of \u221251.79 Kcal/mol.", [["the docking score", "TEST", 103, 120], ["Kcal", "TEST", 131, 135], ["MM", "TEST", 144, 146], ["GBSA score", "TEST", 147, 157], ["similar interaction", "OBSERVATION", 49, 68]]], ["ACE2 behaves differently with or without the inhibitor.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["the inhibitor", "TREATMENT", 41, 54]]], ["In the presence of its inhibitor subdomain I of zinc matallopeptidase undergo conformational change which could prevents the binding of SARS-CoV2 to its surface.Results and discussionFurther we attempted to dock GS-441524 (active form of remdesivir) and hydrochloroquine, which are being repurposed for treating COVID-19.", [["surface", "ANATOMY", 153, 160], ["zinc", "CHEMICAL", 48, 52], ["SARS", "DISEASE", 136, 140], ["GS-441524", "CHEMICAL", 212, 221], ["remdesivir", "CHEMICAL", 238, 248], ["hydrochloroquine", "CHEMICAL", 254, 270], ["zinc", "CHEMICAL", 48, 52], ["GS-441524", "CHEMICAL", 212, 221], ["remdesivir", "CHEMICAL", 238, 248], ["hydrochloroquine", "CHEMICAL", 254, 270], ["COVID-19", "CHEMICAL", 312, 320], ["zinc matallopeptidase", "SIMPLE_CHEMICAL", 48, 69], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 136, 145], ["surface", "CELLULAR_COMPONENT", 153, 160], ["GS-441524", "SIMPLE_CHEMICAL", 212, 221], ["remdesivir", "SIMPLE_CHEMICAL", 238, 248], ["hydrochloroquine", "SIMPLE_CHEMICAL", 254, 270], ["subdomain I", "PROTEIN", 33, 44], ["zinc matallopeptidase", "PROTEIN", 48, 69], ["CoV2", "PROTEIN", 141, 145], ["zinc matallopeptidase", "TREATMENT", 48, 69], ["conformational change", "PROBLEM", 78, 99], ["the binding of SARS", "PROBLEM", 121, 140], ["dock GS", "TEST", 207, 214], ["remdesivir", "TREATMENT", 238, 248], ["hydrochloroquine", "TREATMENT", 254, 270], ["COVID", "TEST", 312, 317]]], ["The rational for including these molecules is that their principle inhibitory mechanism takes place inside the host cell where viral replication unfolds.", [["cell", "ANATOMY", 116, 120], ["cell", "CELL", 116, 120], ["their principle inhibitory mechanism", "PROBLEM", 51, 87], ["viral replication unfolds", "PROBLEM", 127, 152], ["host cell", "OBSERVATION", 111, 120], ["viral replication", "OBSERVATION", 127, 144]]], ["The possibility for these molecules to bind to off\u2013target proteins that are of viral or host origin cannot be ruled out.", [["off\u2013target", "GENE_OR_GENE_PRODUCT", 47, 57], ["off\u2013target proteins", "PROTEIN", 47, 66], ["these molecules", "PROBLEM", 20, 35], ["proteins", "TREATMENT", 58, 66], ["viral or host origin", "PROBLEM", 79, 99], ["possibility for", "UNCERTAINTY", 4, 19], ["viral", "OBSERVATION", 79, 84]]], ["Recently FDA has issued an Emergency Use Authorization (EUA) for remdesivir to be included in treatment protocol of hospitalized SARS-CoV-2 infected patients (Rhoades, 2020).Results and discussionRemdesivir is a prodrug of adenosine triphosphate (ATP) analog, GS-441524 that interferes with the action of viral RNA-dependent RNA polymerase towards controlling viral RNA production.", [["SARS-CoV-2 infected", "DISEASE", 129, 148], ["discussionRemdesivir", "CHEMICAL", 186, 206], ["adenosine triphosphate", "CHEMICAL", 223, 245], ["ATP", "CHEMICAL", 247, 250], ["GS-441524", "CHEMICAL", 260, 269], ["adenosine triphosphate", "CHEMICAL", 223, 245], ["ATP", "CHEMICAL", 247, 250], ["GS-441524", "CHEMICAL", 260, 269], ["SARS-CoV-2", "ORGANISM", 129, 139], ["patients", "ORGANISM", 149, 157], ["discussionRemdesivir", "SIMPLE_CHEMICAL", 186, 206], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 223, 245], ["ATP", "SIMPLE_CHEMICAL", 247, 250], ["GS-441524", "SIMPLE_CHEMICAL", 260, 269], ["viral RNA", "RNA", 305, 314], ["RNA polymerase", "PROTEIN", 325, 339], ["viral RNA", "RNA", 360, 369], ["CoV-", "SPECIES", 134, 138], ["patients", "SPECIES", 149, 157], ["remdesivir", "TREATMENT", 65, 75], ["adenosine triphosphate (ATP", "TREATMENT", 223, 250], ["GS", "TEST", 260, 262], ["viral RNA", "PROBLEM", 305, 314], ["dependent RNA polymerase", "PROBLEM", 315, 339], ["viral RNA production", "PROBLEM", 360, 380], ["viral RNA", "OBSERVATION", 305, 314], ["viral RNA", "OBSERVATION", 360, 369]]], ["From the present study, the estimated docking scores and MM-GBSA bind energies for GS-441524 are \u22126.24 Kcal/mol and \u221246.51 Kcal/mol for Mpro and \u22125.65 Kcal/mol and \u221240.48 Kcal/mol for ACE2, respectively.", [["GS-441524", "CHEMICAL", 83, 92], ["GS-441524", "CHEMICAL", 83, 92], ["GS-441524", "SIMPLE_CHEMICAL", 83, 92], ["Mpro", "SIMPLE_CHEMICAL", 136, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["ACE2", "PROTEIN", 184, 188], ["the present study", "TEST", 5, 22], ["the estimated docking scores", "TEST", 24, 52], ["MM", "TEST", 57, 59], ["GS", "TEST", 83, 85], ["Mpro", "TREATMENT", 136, 140]]], ["For SARS-CoV2 Mpro the docked poses of GS-441524 shows the hydroxyl groups of oxolan ring are inserted inside the S1 subunit by multiple hydrogen bonds with the CYS145 and ASN142.", [["GS-441524", "CHEMICAL", 39, 48], ["hydroxyl", "CHEMICAL", 59, 67], ["oxolan", "CHEMICAL", 78, 84], ["GS-441524", "CHEMICAL", 39, 48], ["hydroxyl", "CHEMICAL", 59, 67], ["oxolan", "CHEMICAL", 78, 84], ["hydrogen", "CHEMICAL", 137, 145], ["CYS145", "CHEMICAL", 161, 167], ["ASN142", "CHEMICAL", 172, 178], ["GS-441524", "SIMPLE_CHEMICAL", 39, 48], ["oxolan ring", "SIMPLE_CHEMICAL", 78, 89], ["CYS145", "SIMPLE_CHEMICAL", 161, 167], ["ASN142", "SIMPLE_CHEMICAL", 172, 178], ["SARS-CoV2 Mpro", "PROTEIN", 4, 18], ["S1 subunit", "PROTEIN", 114, 124], ["CYS145", "PROTEIN", 161, 167], ["ASN142", "PROTEIN", 172, 178], ["GS", "TEST", 39, 41], ["the hydroxyl groups of oxolan ring", "TREATMENT", 55, 89], ["the CYS145", "TREATMENT", 157, 167], ["S1", "ANATOMY_MODIFIER", 114, 116], ["multiple", "OBSERVATION_MODIFIER", 128, 136], ["hydrogen bonds", "OBSERVATION", 137, 151]]], ["The nitrogen of the nitrile group was found to form a hydrogen bond with the GLU166 of the side chain of S1 subunit.", [["nitrogen", "CHEMICAL", 4, 12], ["nitrile", "CHEMICAL", 20, 27], ["nitrogen", "CHEMICAL", 4, 12], ["nitrile", "CHEMICAL", 20, 27], ["hydrogen", "CHEMICAL", 54, 62], ["GLU166", "CHEMICAL", 77, 83], ["nitrile", "SIMPLE_CHEMICAL", 20, 27], ["GLU166", "SIMPLE_CHEMICAL", 77, 83], ["S1", "GENE_OR_GENE_PRODUCT", 105, 107], ["S1 subunit", "PROTEIN", 105, 115], ["a hydrogen bond", "TEST", 52, 67], ["hydrogen bond", "OBSERVATION", 54, 67], ["S1", "ANATOMY", 105, 107]]], ["However for ACE2 multiple hydrogen bonds were formed by hydroxyl groups of the oxolane ring with PRO346, ARG273 of S1 subsite, and ARG518 of the side chain.", [["hydroxyl", "CHEMICAL", 56, 64], ["oxolane", "CHEMICAL", 79, 86], ["PRO346", "CHEMICAL", 97, 103], ["hydrogen", "CHEMICAL", 26, 34], ["hydroxyl", "CHEMICAL", 56, 64], ["oxolane", "CHEMICAL", 79, 86], ["PRO346", "CHEMICAL", 97, 103], ["ARG273", "CHEMICAL", 105, 111], ["ARG518", "CHEMICAL", 131, 137], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["hydroxyl", "SIMPLE_CHEMICAL", 56, 64], ["oxolane", "SIMPLE_CHEMICAL", 79, 86], ["PRO346", "SIMPLE_CHEMICAL", 97, 103], ["ARG273", "SIMPLE_CHEMICAL", 105, 111], ["ARG518", "SIMPLE_CHEMICAL", 131, 137], ["ACE2", "PROTEIN", 12, 16], ["ACE2 multiple hydrogen bonds", "TREATMENT", 12, 40], ["the oxolane ring", "TREATMENT", 75, 91], ["S1 subsite", "TREATMENT", 115, 125], ["hydrogen bonds", "OBSERVATION", 26, 40]]], ["The oxygen of the oxolane ring was found forming hydrogen bond with the THR371 residue of the side chain.", [["oxygen", "CHEMICAL", 4, 10], ["oxolane", "CHEMICAL", 18, 25], ["oxygen", "CHEMICAL", 4, 10], ["oxolane", "CHEMICAL", 18, 25], ["hydrogen", "CHEMICAL", 49, 57], ["THR371", "CHEMICAL", 72, 78], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["oxolane ring", "SIMPLE_CHEMICAL", 18, 30], ["the oxolane ring", "TREATMENT", 14, 30], ["oxygen", "OBSERVATION_MODIFIER", 4, 10], ["hydrogen bond", "OBSERVATION", 49, 62]]], ["The free amine group interacts with the ASP367 residue of the S1\u2032 subsite through hydrogen bonding.", [["amine", "CHEMICAL", 9, 14], ["amine", "CHEMICAL", 9, 14], ["ASP367", "CHEMICAL", 40, 46], ["hydrogen", "CHEMICAL", 82, 90], ["free amine", "SIMPLE_CHEMICAL", 4, 14], ["hydrogen", "SIMPLE_CHEMICAL", 82, 90], ["S1\u2032 subsite", "PROTEIN", 62, 73], ["hydrogen bonding", "OBSERVATION", 82, 98]]], ["Non-specific binding to Mpro might be also contribute to the overall CoV inhibitory potential of the drug, which has shown encouraging results in terms of reduced time to clinical recovery but with insignificant clinical benefits in COVID-19 patients.", [["Mpro", "GENE_OR_GENE_PRODUCT", 24, 28], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["Non-specific binding", "PROBLEM", 0, 20]]], ["However, further in vitro target-ligand interaction studies are required to assess concentration dependence of its inhibitory effect via Mpro binding.", [["Mpro", "CHEMICAL", 137, 141], ["Mpro", "SIMPLE_CHEMICAL", 137, 141], ["Mpro", "PROTEIN", 137, 141], ["ligand interaction studies", "TEST", 33, 59], ["concentration dependence", "PROBLEM", 83, 107], ["Mpro binding", "PROBLEM", 137, 149]]], ["Similar to remdesivir, Hydroxychloroqine has also been assigned for EUA from FDA (2020) to treat hospitalized, severely ill SARS-CoV2 infected patients.Results and discussionThe MM-GBSA binding energy for HCQ with Mpro and ACE2 was found to be \u221267.53 Kcal/mol and \u221259.03 Kcal/mol.", [["remdesivir", "CHEMICAL", 11, 21], ["Hydroxychloroqine", "CHEMICAL", 23, 40], ["SARS-CoV2 infected", "DISEASE", 124, 142], ["HCQ", "CHEMICAL", 205, 208], ["Mpro", "CHEMICAL", 214, 218], ["remdesivir", "CHEMICAL", 11, 21], ["Hydroxychloroqine", "CHEMICAL", 23, 40], ["HCQ", "CHEMICAL", 205, 208], ["remdesivir", "SIMPLE_CHEMICAL", 11, 21], ["Hydroxychloroqine", "SIMPLE_CHEMICAL", 23, 40], ["patients", "ORGANISM", 143, 151], ["HCQ", "SIMPLE_CHEMICAL", 205, 208], ["Mpro", "SIMPLE_CHEMICAL", 214, 218], ["ACE2", "GENE_OR_GENE_PRODUCT", 223, 227], ["Mpro", "PROTEIN", 214, 218], ["ACE2", "PROTEIN", 223, 227], ["patients", "SPECIES", 143, 151], ["remdesivir", "TREATMENT", 11, 21], ["Hydroxychloroqine", "TREATMENT", 23, 40], ["severely ill SARS", "PROBLEM", 111, 128], ["HCQ", "TREATMENT", 205, 208], ["Mpro", "TREATMENT", 214, 218], ["ACE2", "TEST", 223, 227]]], ["In the Mpro catalytic site it forms \u03c0-\u03c0 stacking interaction between quinolin and HIE41 of the hydrophobic S2 subunit.", [["quinolin", "CHEMICAL", 69, 77], ["quinolin", "CHEMICAL", 69, 77], ["HIE41", "CHEMICAL", 82, 87], ["quinolin", "SIMPLE_CHEMICAL", 69, 77], ["HIE41", "SIMPLE_CHEMICAL", 82, 87], ["Mpro catalytic site", "PROTEIN", 7, 26], ["HIE41", "PROTEIN", 82, 87], ["hydrophobic S2 subunit", "PROTEIN", 95, 117], ["quinolin", "TREATMENT", 69, 77], ["hydrophobic S2", "ANATOMY", 95, 109]]], ["The hydrogen of the two amine groups was showing interaction with the GLN189 and CYS145 through hydrogen bond and non-covalent ionic interaction (salt bridge).", [["hydrogen", "CHEMICAL", 4, 12], ["amine", "CHEMICAL", 24, 29], ["GLN189", "CHEMICAL", 70, 76], ["CYS145", "CHEMICAL", 81, 87], ["hydrogen", "CHEMICAL", 4, 12], ["amine", "CHEMICAL", 24, 29], ["GLN189", "CHEMICAL", 70, 76], ["CYS145", "CHEMICAL", 81, 87], ["hydrogen", "CHEMICAL", 96, 104], ["hydrogen", "SIMPLE_CHEMICAL", 4, 12], ["amine", "SIMPLE_CHEMICAL", 24, 29], ["GLN189", "SIMPLE_CHEMICAL", 70, 76], ["CYS145", "SIMPLE_CHEMICAL", 81, 87], ["hydrogen bond and non-covalent ionic interaction (salt bridge", "TREATMENT", 96, 157], ["hydrogen", "OBSERVATION_MODIFIER", 4, 12]]], ["The hydroxyl group of the alkyl chain was found to interact through hydrogen bond with GLY143 residue of the S1 subunit.", [["hydroxyl", "CHEMICAL", 4, 12], ["alkyl", "CHEMICAL", 26, 31], ["hydroxyl", "CHEMICAL", 4, 12], ["hydrogen", "CHEMICAL", 68, 76], ["GLY143", "CHEMICAL", 87, 93], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["GLY143", "SIMPLE_CHEMICAL", 87, 93], ["S1 subunit", "PROTEIN", 109, 119], ["S1", "ANATOMY", 109, 111]]], ["While this drug shows good binding to Mpro catalytic site, it is also labeled for possible cardiac injury (FDA, 2020).", [["cardiac", "ANATOMY", 91, 98], ["cardiac injury", "DISEASE", 91, 105], ["cardiac", "ORGAN", 91, 98], ["Mpro catalytic site", "DNA", 38, 57], ["this drug", "TEST", 6, 15], ["cardiac injury", "PROBLEM", 91, 105], ["cardiac", "ANATOMY", 91, 98], ["injury", "OBSERVATION", 99, 105]]], ["While in the catalytic site of ACE2 the free hydroxyl group of alkyl chain and the hydrogen of tertiary amine group interact with the side chain residue ASP367 through hydrogen bonds and one non-covalent ionic interaction was also formed between ASP367 and hydrogen of tertiary amine group.", [["hydroxyl", "CHEMICAL", 45, 53], ["alkyl", "CHEMICAL", 63, 68], ["hydrogen", "CHEMICAL", 83, 91], ["amine", "CHEMICAL", 104, 109], ["ASP367", "CHEMICAL", 153, 159], ["ASP367", "CHEMICAL", 246, 252], ["hydrogen", "CHEMICAL", 257, 265], ["amine", "CHEMICAL", 278, 283], ["hydroxyl", "CHEMICAL", 45, 53], ["hydrogen", "CHEMICAL", 83, 91], ["tertiary amine", "CHEMICAL", 95, 109], ["ASP367", "CHEMICAL", 153, 159], ["hydrogen", "CHEMICAL", 168, 176], ["ASP367", "CHEMICAL", 246, 252], ["hydrogen", "CHEMICAL", 257, 265], ["tertiary amine", "CHEMICAL", 269, 283], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["alkyl chain", "SIMPLE_CHEMICAL", 63, 74], ["hydrogen", "SIMPLE_CHEMICAL", 83, 91], ["ASP367", "SIMPLE_CHEMICAL", 153, 159], ["hydrogen bonds", "SIMPLE_CHEMICAL", 168, 182], ["ASP367", "SIMPLE_CHEMICAL", 246, 252], ["hydrogen of tertiary amine", "SIMPLE_CHEMICAL", 257, 283], ["catalytic site", "PROTEIN", 13, 27], ["ACE2", "PROTEIN", 31, 35], ["ACE2 the free hydroxyl group of alkyl chain", "TREATMENT", 31, 74], ["the hydrogen of tertiary amine group", "TREATMENT", 79, 115]]], ["The side chain residue HIE345 was found to interact through couple of \u03c0-\u03c0 stacking interaction with the two rings of quinolin nucleus.", [["HIE345", "CHEMICAL", 23, 29], ["HIE345", "CHEMICAL", 23, 29], ["quinolin", "CHEMICAL", 117, 125], ["HIE345", "AMINO_ACID", 23, 29], ["quinolin", "SIMPLE_CHEMICAL", 117, 125], ["nucleus", "CELLULAR_COMPONENT", 126, 133], ["The side chain residue", "PROBLEM", 0, 22], ["the two rings of quinolin nucleus", "TREATMENT", 100, 133], ["quinolin nucleus", "ANATOMY", 117, 133]]], ["The 2D and 3D docking pose of both remdesivir and hydroxychloroquine in SARS-CoV-2 Mpro and ACE2 is presented in Figure 1(ii) and (iii) and Figure 2 (ii) and (iii).Results and discussionAmong the 30 natural secondary metabolites screened, the top four leads exhibiting highest binding affinity were re-scored for their MM-GB/SA dG bind energies and predict their docking poses (Guimar\u00e3es & Cardozo, 2008).", [["remdesivir", "CHEMICAL", 35, 45], ["hydroxychloroquine", "CHEMICAL", 50, 68], ["SARS", "DISEASE", 72, 76], ["dG", "CHEMICAL", 328, 330], ["remdesivir", "CHEMICAL", 35, 45], ["hydroxychloroquine", "CHEMICAL", 50, 68], ["remdesivir", "SIMPLE_CHEMICAL", 35, 45], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 50, 68], ["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 72, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["SA dG", "SIMPLE_CHEMICAL", 325, 330], ["ACE2", "PROTEIN", 92, 96], ["both remdesivir", "TREATMENT", 30, 45], ["hydroxychloroquine", "TREATMENT", 50, 68], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["ACE2", "TEST", 92, 96], ["highest binding affinity", "PROBLEM", 269, 293], ["GB/SA dG bind energies", "TREATMENT", 322, 344]]], ["All these four natural secondary metabolites were found to fit perfectly at the active site pockets of SARS-CoV-2 Mpro and human ACE2.", [["SARS-CoV-2 Mpro", "GENE_OR_GENE_PRODUCT", 103, 118], ["human", "ORGANISM", 123, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["SARS-CoV-2 Mpro and human ACE2", "PROTEIN", 103, 133], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["CoV", "TEST", 108, 111], ["human ACE2", "TREATMENT", 123, 133], ["active", "OBSERVATION_MODIFIER", 80, 86], ["site", "OBSERVATION_MODIFIER", 87, 91], ["pockets", "OBSERVATION_MODIFIER", 92, 99]]], ["By analysis of the interactions it can be inferred that the active site of Mpro is polar in nature and shows good binding energies with ligands having polar functional groups.", [["Mpro", "CHEMICAL", 75, 79], ["Mpro", "CHEMICAL", 75, 79], ["Mpro", "SIMPLE_CHEMICAL", 75, 79], ["Mpro", "PROTEIN", 75, 79], ["active", "OBSERVATION_MODIFIER", 60, 66], ["polar", "OBSERVATION_MODIFIER", 83, 88]]], ["All the top four leads are presented in Table 1 with corresponding docking scores, MM-GB/SA dG bind energies, and pharmacokinetic descriptors for both the targets.", [["dG", "CHEMICAL", 92, 94], ["MM", "TEST", 83, 85], ["pharmacokinetic descriptors", "TEST", 114, 141], ["top", "OBSERVATION_MODIFIER", 8, 11]]], ["For SARS-CoV-2 Mpro, similar to N3, the screened leads also engaged through multiple H-bond with the residues present in the cleft between domain I and II of Mpro of SARS-CoV-2.", [["H", "CHEMICAL", 85, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 166, 176], ["domain I and II", "PROTEIN", 139, 154], ["Mpro", "PROTEIN", 158, 162], ["SARS-CoV", "SPECIES", 166, 174], ["SARS", "PROBLEM", 4, 8], ["CoV", "TEST", 9, 12], ["the residues", "PROBLEM", 97, 109], ["SARS", "TEST", 166, 170], ["CoV", "TEST", 171, 174]]], ["The key residues involved in the binding interaction are GLN166, HIS163, THR190, CYS145, GLN189 of main chain bonded through H-bonding and H41 of the hydrophobic pocket through \u03c0 stacking interaction.", [["GLN166", "CHEMICAL", 57, 63], ["HIS163", "CHEMICAL", 65, 71], ["THR190", "CHEMICAL", 73, 79], ["CYS145", "CHEMICAL", 81, 87], ["GLN166", "GENE_OR_GENE_PRODUCT", 57, 63], ["HIS163", "GENE_OR_GENE_PRODUCT", 65, 71], ["THR190", "GENE_OR_GENE_PRODUCT", 73, 79], ["CYS145", "GENE_OR_GENE_PRODUCT", 81, 87], ["GLN166", "PROTEIN", 57, 63], ["HIS163", "PROTEIN", 65, 71], ["THR190", "PROTEIN", 73, 79], ["CYS145", "PROTEIN", 81, 87], ["GLN189", "PROTEIN", 89, 95], ["HIS163", "TEST", 65, 71], ["CYS145", "TEST", 81, 87], ["the hydrophobic pocket", "PROBLEM", 146, 168], ["hydrophobic pocket", "OBSERVATION", 150, 168]]], ["Delphinidin 3,5-diglucoside is an anthocyanin mainly found in high concentration in pomegranates.", [["Delphinidin 3,5-diglucoside", "CHEMICAL", 0, 27], ["Delphinidin 3,5-diglucoside", "CHEMICAL", 0, 27], ["anthocyanin", "CHEMICAL", 34, 45], ["Delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 0, 27], ["anthocyanin", "SIMPLE_CHEMICAL", 34, 45], ["pomegranates", "SIMPLE_CHEMICAL", 84, 96], ["Delphinidin", "TREATMENT", 0, 11], ["an anthocyanin", "TREATMENT", 31, 45], ["high concentration", "OBSERVATION_MODIFIER", 62, 80]]], ["It is a phenolic compound formed of anthocyanidin unit which is linked to carbohydrate moiety with O-glycoside at the C5-position.", [["anthocyanidin", "CHEMICAL", 36, 49], ["O-glycoside", "CHEMICAL", 99, 110], ["anthocyanidin", "CHEMICAL", 36, 49], ["carbohydrate", "CHEMICAL", 74, 86], ["O-glycoside", "CHEMICAL", 99, 110], ["anthocyanidin unit", "SIMPLE_CHEMICAL", 36, 54], ["carbohydrate moiety", "SIMPLE_CHEMICAL", 74, 93], ["O-glycoside", "SIMPLE_CHEMICAL", 99, 110], ["C5", "PROTEIN", 118, 120], ["anthocyanidin unit", "TREATMENT", 36, 54], ["glycoside", "TREATMENT", 101, 110], ["phenolic compound", "OBSERVATION", 8, 25], ["anthocyanidin unit", "OBSERVATION", 36, 54], ["C5", "ANATOMY", 118, 120]]], ["There are few reports on the therapeutic potential of this anthocyanin as an anticancer agent against colon and fibrosarcoma cancer.", [["anticancer", "ANATOMY", 77, 87], ["colon", "ANATOMY", 102, 107], ["fibrosarcoma cancer", "ANATOMY", 112, 131], ["anthocyanin", "CHEMICAL", 59, 70], ["colon and fibrosarcoma cancer", "DISEASE", 102, 131], ["anthocyanin", "CHEMICAL", 59, 70], ["anthocyanin", "SIMPLE_CHEMICAL", 59, 70], ["anticancer", "CANCER", 77, 87], ["colon", "CANCER", 102, 107], ["fibrosarcoma cancer", "CANCER", 112, 131], ["this anthocyanin", "TREATMENT", 54, 70], ["an anticancer agent", "TREATMENT", 74, 93], ["colon and fibrosarcoma cancer", "PROBLEM", 102, 131], ["few", "OBSERVATION_MODIFIER", 10, 13], ["colon", "ANATOMY", 102, 107], ["fibrosarcoma cancer", "OBSERVATION", 112, 131]]], ["One of them reported that it significantly inhibited the HCT 116 and HT-29 human colon cancer cells (Mazewski et al., 2019).", [["HCT 116", "ANATOMY", 57, 64], ["HT-29", "ANATOMY", 69, 74], ["colon cancer cells", "ANATOMY", 81, 99], ["HT", "DISEASE", 69, 71], ["colon cancer", "DISEASE", 81, 93], ["HCT 116", "CELL", 57, 64], ["HT-29 human colon cancer cells", "CELL", 69, 99], ["HCT 116", "CELL_LINE", 57, 64], ["HT-29 human colon cancer cells", "CELL_LINE", 69, 99], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["the HCT", "TEST", 53, 60], ["HT", "TEST", 69, 71], ["human colon cancer cells", "PROBLEM", 75, 99], ["colon", "ANATOMY", 81, 86], ["cancer", "OBSERVATION", 87, 93]]], ["In another study, delphinidin-3,5-glucoside showed cytotoxicity in combination with other anthocyanins (gallic acid, delphinidin and pelargonidin3-glucosides) (Filipiak et al., 2014).Results and discussionPresent in silico analysis showed its highest binding affinity against for both the targets, Mpro and ACE2.", [["delphinidin-3,5-glucoside", "CHEMICAL", 18, 43], ["gallic acid", "CHEMICAL", 104, 115], ["delphinidin", "CHEMICAL", 117, 128], ["pelargonidin3-glucosides", "CHEMICAL", 133, 157], ["delphinidin-3,5-glucoside", "CHEMICAL", 18, 43], ["anthocyanins", "CHEMICAL", 90, 102], ["gallic acid", "CHEMICAL", 104, 115], ["delphinidin", "CHEMICAL", 117, 128], ["pelargonidin3-glucosides", "CHEMICAL", 133, 157], ["delphinidin-3,5-glucoside", "SIMPLE_CHEMICAL", 18, 43], ["anthocyanins", "SIMPLE_CHEMICAL", 90, 102], ["gallic acid", "SIMPLE_CHEMICAL", 104, 115], ["delphinidin", "SIMPLE_CHEMICAL", 117, 128], ["pelargonidin3-glucosides", "SIMPLE_CHEMICAL", 133, 157], ["Mpro", "GENE_OR_GENE_PRODUCT", 298, 302], ["ACE2", "GENE_OR_GENE_PRODUCT", 307, 311], ["Mpro", "PROTEIN", 298, 302], ["ACE2", "PROTEIN", 307, 311], ["another study", "TEST", 3, 16], ["delphinidin", "TEST", 18, 29], ["cytotoxicity", "PROBLEM", 51, 63], ["other anthocyanins", "TREATMENT", 84, 102], ["gallic acid", "TREATMENT", 104, 115], ["delphinidin", "TREATMENT", 117, 128], ["pelargonidin3-glucosides", "TREATMENT", 133, 157], ["silico analysis", "TEST", 216, 231]]], ["The estimated docking scores were \u221212.2 Kcal/mol for Mpro and \u221213.6 Kcal/mol for ACE2 and MM-GBSA dG binding energies came out be \u221274 Kcal/mol and \u221279.47 Kcal/mol, respectively, which are lowest among all the screened ligands for both the targets.", [["Mpro", "SIMPLE_CHEMICAL", 53, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["MM-GBSA dG", "SIMPLE_CHEMICAL", 90, 100], ["ACE2", "PROTEIN", 81, 85], ["The estimated docking scores", "TEST", 0, 28], ["Mpro", "TEST", 53, 57], ["ACE2", "TEST", 81, 85], ["MM", "TEST", 90, 92]]], ["The 2D and 3D generated docking poses in Mpro (Figure 2(i)) shows that the hydroxyl groups of the glycone participate in H-bond interaction with GLU166 and ASN142 of the main chain, and with LEU141 of S1 subunit.", [["hydroxyl", "CHEMICAL", 75, 83], ["glycone", "CHEMICAL", 98, 105], ["H", "CHEMICAL", 121, 122], ["hydroxyl", "CHEMICAL", 75, 83], ["glycone", "CHEMICAL", 98, 105], ["H", "CHEMICAL", 121, 122], ["GLU166", "CHEMICAL", 145, 151], ["ASN142", "CHEMICAL", 156, 162], ["Mpro", "SIMPLE_CHEMICAL", 41, 45], ["glycone", "SIMPLE_CHEMICAL", 98, 105], ["GLU166", "SIMPLE_CHEMICAL", 145, 151], ["ASN142", "SIMPLE_CHEMICAL", 156, 162], ["LEU141 of S1 subunit", "GENE_OR_GENE_PRODUCT", 191, 211], ["GLU166", "PROTEIN", 145, 151], ["ASN142", "PROTEIN", 156, 162], ["LEU141", "PROTEIN", 191, 197], ["S1 subunit", "PROTEIN", 201, 211], ["GLU166", "TEST", 145, 151], ["main chain", "ANATOMY", 170, 180]]], ["The hydroxyl groups of benzene ring interact with CYS145 of the catalytic site and HIS164 of the S2 subunit through H-bond.", [["hydroxyl", "CHEMICAL", 4, 12], ["benzene", "CHEMICAL", 23, 30], ["hydroxyl", "CHEMICAL", 4, 12], ["benzene", "CHEMICAL", 23, 30], ["H", "CHEMICAL", 116, 117], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["benzene ring", "SIMPLE_CHEMICAL", 23, 35], ["CYS145", "SIMPLE_CHEMICAL", 50, 56], ["HIS164", "AMINO_ACID", 83, 89], ["CYS145", "PROTEIN", 50, 56], ["catalytic site", "PROTEIN", 64, 78], ["HIS164", "PROTEIN", 83, 89], ["S2 subunit", "PROTEIN", 97, 107], ["The hydroxyl groups of benzene ring", "TREATMENT", 0, 35], ["the catalytic site", "TREATMENT", 60, 78], ["hydroxyl", "OBSERVATION_MODIFIER", 4, 12], ["benzene ring", "OBSERVATION", 23, 35]]], ["Docking results also exposed the \u03c0-\u03c0 interaction between the benzene ring and the HIE41 of the hydrophobic cavity of S2 subunit.", [["benzene", "CHEMICAL", 61, 68], ["benzene", "CHEMICAL", 61, 68], ["HIE41", "CHEMICAL", 82, 87], ["HIE41", "SIMPLE_CHEMICAL", 82, 87], ["HIE41", "PROTEIN", 82, 87], ["S2 subunit", "PROTEIN", 117, 127], ["the benzene ring", "TREATMENT", 57, 73], ["benzene ring", "OBSERVATION", 61, 73], ["hydrophobic cavity", "OBSERVATION", 95, 113], ["S2 subunit", "ANATOMY_MODIFIER", 117, 127]]], ["The hydroxyl group of flavylium nucleus found to be interacting with the THR190 of S4 subunit.", [["hydroxyl", "CHEMICAL", 4, 12], ["flavylium", "CHEMICAL", 22, 31], ["hydroxyl", "CHEMICAL", 4, 12], ["flavylium", "CHEMICAL", 22, 31], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["flavylium nucleus", "SIMPLE_CHEMICAL", 22, 39], ["THR190", "GENE_OR_GENE_PRODUCT", 73, 79], ["S4", "GENE_OR_GENE_PRODUCT", 83, 85], ["THR190", "PROTEIN", 73, 79], ["S4 subunit", "PROTEIN", 83, 93], ["flavylium nucleus", "PROBLEM", 22, 39]]], ["On the contrary 2D and 3D refined poses of delphinidin-3,5-glucoside (Figure 3(i)) in the catalytic site of ACE2 flag up pi-cation interaction between the rings of flavylium nucleus and the side chain residues ARG273 and HIE345 of the catalytic site.", [["delphinidin-3,5-glucoside", "CHEMICAL", 43, 68], ["delphinidin-3,5-glucoside", "CHEMICAL", 43, 68], ["flavylium", "CHEMICAL", 164, 173], ["ARG273", "CHEMICAL", 210, 216], ["delphinidin-3,5-glucoside", "SIMPLE_CHEMICAL", 43, 68], ["Figure 3(i)", "SIMPLE_CHEMICAL", 70, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["flavylium", "SIMPLE_CHEMICAL", 164, 173], ["nucleus", "CELLULAR_COMPONENT", 174, 181], ["HIE345", "AMINO_ACID", 221, 227], ["catalytic site", "PROTEIN", 90, 104], ["ACE2", "PROTEIN", 108, 112], ["catalytic site", "PROTEIN", 235, 249], ["delphinidin", "TEST", 43, 54], ["ACE2 flag", "PROBLEM", 108, 117], ["the rings of flavylium nucleus", "TREATMENT", 151, 181], ["ACE2 flag", "OBSERVATION", 108, 117], ["rings", "ANATOMY_MODIFIER", 155, 160], ["flavylium nucleus", "ANATOMY", 164, 181], ["catalytic site", "OBSERVATION", 235, 249]]], ["Flavylium rings were also showing \u03c0-\u03c0 interaction with the residues HIE345 and HIS374and its hydroxyl was bonded through hydrogen bond to the GLU375.", [["Flavylium", "CHEMICAL", 0, 9], ["HIE345", "CHEMICAL", 68, 74], ["HIS374and", "CHEMICAL", 79, 88], ["hydroxyl", "CHEMICAL", 93, 101], ["GLU375", "CHEMICAL", 142, 148], ["Flavylium", "CHEMICAL", 0, 9], ["HIE345", "CHEMICAL", 68, 74], ["HIS374and", "CHEMICAL", 79, 88], ["hydroxyl", "CHEMICAL", 93, 101], ["hydrogen", "CHEMICAL", 121, 129], ["GLU375", "CHEMICAL", 142, 148], ["Flavylium rings", "SIMPLE_CHEMICAL", 0, 15], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 34, 37], ["HIE345", "SIMPLE_CHEMICAL", 68, 74], ["HIS374and", "SIMPLE_CHEMICAL", 79, 88], ["hydroxyl", "SIMPLE_CHEMICAL", 93, 101], ["GLU375", "SIMPLE_CHEMICAL", 142, 148], ["GLU375", "PROTEIN", 142, 148], ["Flavylium rings", "TREATMENT", 0, 15]]], ["In addition to this the hydroxyls of the sugar moiety were found to have multiple hydrogen bond interaction with GLU406, THR371, ASH368, and ASP367.", [["hydroxyls", "CHEMICAL", 24, 33], ["sugar", "CHEMICAL", 41, 46], ["hydrogen", "CHEMICAL", 82, 90], ["GLU406", "CHEMICAL", 113, 119], ["THR371", "CHEMICAL", 121, 127], ["ASH368", "CHEMICAL", 129, 135], ["ASP367", "CHEMICAL", 141, 147], ["sugar moiety", "SIMPLE_CHEMICAL", 41, 53], ["GLU406", "SIMPLE_CHEMICAL", 113, 119], ["THR371", "SIMPLE_CHEMICAL", 121, 127], ["ASH368", "GENE_OR_GENE_PRODUCT", 129, 135], ["ASP367", "GENE_OR_GENE_PRODUCT", 141, 147], ["ASP367", "PROTEIN", 141, 147], ["multiple hydrogen bond interaction", "PROBLEM", 73, 107], ["GLU406", "TEST", 113, 119], ["ASP367", "TEST", 141, 147], ["multiple", "OBSERVATION_MODIFIER", 73, 81], ["hydrogen bond", "OBSERVATION", 82, 95]]], ["Likewise hydroxyls of the phenyl ring were bonded to TYR127 with multiple hydrogen bonds.Results and discussionThe second lead compound is a flavonoid glycoside, Scutellarein 7-glucoside isolated from plants like Verbena officinalis L (Rehecho et al., 2011), Buddleja madagascariensis Lam (Emam et al., 1998), Plantago asiatica L, Scutellaria immaculate (Yuldashev, 2002), Plantago asiatica L and Polygonum odoratum (Okonogi et al., 2016).", [["hydroxyls of the phenyl", "CHEMICAL", 9, 32], ["TYR127", "CHEMICAL", 53, 59], ["flavonoid glycoside", "CHEMICAL", 141, 160], ["Scutellarein 7-glucoside", "CHEMICAL", 162, 186], ["hydroxyls", "CHEMICAL", 9, 18], ["phenyl", "CHEMICAL", 26, 32], ["TYR127", "CHEMICAL", 53, 59], ["hydrogen", "CHEMICAL", 74, 82], ["flavonoid glycoside", "CHEMICAL", 141, 160], ["Scutellarein 7-glucoside", "CHEMICAL", 162, 186], ["phenyl ring", "SIMPLE_CHEMICAL", 26, 37], ["TYR127", "SIMPLE_CHEMICAL", 53, 59], ["flavonoid glycoside", "SIMPLE_CHEMICAL", 141, 160], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 162, 186], ["Verbena officinalis L", "ORGANISM", 213, 234], ["Buddleja madagascariensis", "ORGANISM", 259, 284], ["Plantago asiatica L", "ORGANISM", 310, 329], ["Scutellaria immaculate", "ORGANISM", 331, 353], ["Plantago asiatica L", "ORGANISM", 373, 392], ["Polygonum odoratum", "ORGANISM", 397, 415], ["Verbena officinalis", "SPECIES", 213, 232], ["Buddleja madagascariensis", "SPECIES", 259, 284], ["Plantago asiatica", "SPECIES", 310, 327], ["Scutellaria immaculate", "SPECIES", 331, 353], ["Plantago asiatica", "SPECIES", 373, 390], ["Polygonum odoratum", "SPECIES", 397, 415], ["Verbena officinalis", "SPECIES", 213, 232], ["Buddleja madagascariensis Lam (Emam et al., 1998)", "SPECIES", 259, 308], ["Plantago asiatica", "SPECIES", 310, 327], ["Scutellaria immaculate", "SPECIES", 331, 353], ["Plantago asiatica", "SPECIES", 373, 390], ["Polygonum odoratum", "SPECIES", 397, 415], ["hydroxyls of the phenyl ring", "TREATMENT", 9, 37], ["multiple hydrogen bonds", "PROBLEM", 65, 88], ["a flavonoid glycoside", "TREATMENT", 139, 160], ["Scutellarein", "TREATMENT", 162, 174], ["glucoside", "TREATMENT", 177, 186], ["Plantago asiatica", "PROBLEM", 310, 327], ["Plantago asiatica L", "TREATMENT", 373, 392], ["hydrogen bonds", "OBSERVATION", 74, 88], ["Scutellaria", "ANATOMY", 331, 342], ["Plantago asiatica", "ANATOMY", 373, 390], ["Polygonum odoratum", "ANATOMY", 397, 415]]], ["Biologically scutellarein 7-glucoside shows anti-inflammatory activity by decreasing the IL-6 and TNF-\u03b1 production as reported by Okonogi et al. (2016).", [["scutellarein 7-glucoside", "CHEMICAL", 13, 37], ["scutellarein 7-glucoside", "CHEMICAL", 13, 37], ["scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 13, 37], ["IL-6", "GENE_OR_GENE_PRODUCT", 89, 93], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-6", "PROTEIN", 89, 93], ["TNF", "PROTEIN", 98, 101], ["anti-inflammatory activity", "PROBLEM", 44, 70], ["the IL", "TREATMENT", 85, 91], ["anti-inflammatory activity", "OBSERVATION", 44, 70], ["decreasing", "OBSERVATION_MODIFIER", 74, 84]]], ["Another study reported by Goran et al., shows its certain inhibitory activity against indole-3-acetic acid oxidase there by inhibiting ATP formation inside the plant mitochondria (Stenlid, 1976).", [["mitochondria", "ANATOMY", 166, 178], ["indole-3-acetic acid", "CHEMICAL", 86, 106], ["ATP", "CHEMICAL", 135, 138], ["indole-3-acetic acid", "CHEMICAL", 86, 106], ["ATP", "CHEMICAL", 135, 138], ["indole-3-acetic acid oxidase", "SIMPLE_CHEMICAL", 86, 114], ["ATP", "SIMPLE_CHEMICAL", 135, 138], ["mitochondria", "CELLULAR_COMPONENT", 166, 178], ["Another study", "TEST", 0, 13], ["indole", "TEST", 86, 92], ["acetic acid oxidase", "TREATMENT", 95, 114], ["plant mitochondria", "OBSERVATION", 160, 178]]], ["In addition to these properties Rehecho et al. (2011) reported that it also shows free radical scavenging activity.", [["free", "OBSERVATION_MODIFIER", 82, 86], ["radical", "OBSERVATION", 87, 94], ["scavenging activity", "OBSERVATION", 95, 114]]], ["The binding affinity docking scores of Scutellarein 7-glucoside against Mpro and ACE2 are \u22129.3 Kcal/mol and \u221210.6 Kcal/mol.", [["Scutellarein 7-glucoside", "CHEMICAL", 39, 63], ["Scutellarein 7-glucoside", "CHEMICAL", 39, 63], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 39, 63], ["Mpro", "SIMPLE_CHEMICAL", 72, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["Mpro", "PROTEIN", 72, 76], ["ACE2", "PROTEIN", 81, 85], ["Scutellarein", "TEST", 39, 51], ["ACE2", "TEST", 81, 85]]], ["The MM-GBSA dG binding energies are \u221268.55 Kcal/mol and \u221259.1 Kcal/mol.", [["dG", "CHEMICAL", 12, 14]]], ["In Mpro all the hydroxyl groups of sugar moiety are involved in H-bonding with the CYS145, His163 and GLU166 which are the main residues of the catalytic site.", [["hydroxyl", "CHEMICAL", 16, 24], ["H", "CHEMICAL", 64, 65], ["hydroxyl", "CHEMICAL", 16, 24], ["sugar", "CHEMICAL", 35, 40], ["H", "CHEMICAL", 64, 65], ["CYS145", "CHEMICAL", 83, 89], ["His", "CHEMICAL", 91, 94], ["GLU166", "CHEMICAL", 102, 108], ["sugar moiety", "SIMPLE_CHEMICAL", 35, 47], ["H", "SIMPLE_CHEMICAL", 64, 65], ["CYS145", "SIMPLE_CHEMICAL", 83, 89], ["His163", "GENE_OR_GENE_PRODUCT", 91, 97], ["GLU166", "AMINO_ACID", 102, 108], ["catalytic site", "PROTEIN", 144, 158], ["the CYS145", "TEST", 79, 89], ["main residues", "OBSERVATION", 123, 136], ["catalytic site", "OBSERVATION", 144, 158]]], ["Moreover hydroxyl group of phenyl ring also interacts with the GLN192 residue of S4 subunit through hydrogen bonding that further secures scutellarein 7-glucoside binding to Mpro (Figure 3(ii)).", [["hydroxyl", "CHEMICAL", 9, 17], ["phenyl", "CHEMICAL", 27, 33], ["scutellarein 7-glucoside", "CHEMICAL", 138, 162], ["hydroxyl", "CHEMICAL", 9, 17], ["phenyl", "CHEMICAL", 27, 33], ["GLN192", "CHEMICAL", 63, 69], ["hydrogen", "CHEMICAL", 100, 108], ["scutellarein 7-glucoside", "CHEMICAL", 138, 162], ["hydroxyl", "SIMPLE_CHEMICAL", 9, 17], ["phenyl ring", "SIMPLE_CHEMICAL", 27, 38], ["S4", "AMINO_ACID", 81, 83], ["hydrogen", "SIMPLE_CHEMICAL", 100, 108], ["scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 138, 162], ["Mpro", "SIMPLE_CHEMICAL", 174, 178], ["S4 subunit", "PROTEIN", 81, 91], ["hydroxyl group of phenyl ring", "TREATMENT", 9, 38], ["S4 subunit through hydrogen bonding", "TREATMENT", 81, 116], ["further secures scutellarein", "TREATMENT", 122, 150]]], ["While in case of the ACE2 enzyme the hydroxyls of the sugar moiety were locking the Scutellarein 7-glucoside by forming multiple hydrogen bonds with GLU375, HIE345 and HIE505.", [["Scutellarein 7-glucoside", "CHEMICAL", 84, 108], ["hydroxyls", "CHEMICAL", 37, 46], ["sugar", "CHEMICAL", 54, 59], ["Scutellarein 7-glucoside", "CHEMICAL", 84, 108], ["hydrogen", "CHEMICAL", 129, 137], ["GLU375", "CHEMICAL", 149, 155], ["HIE345", "CHEMICAL", 157, 163], ["HIE505", "CHEMICAL", 168, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["sugar moiety", "SIMPLE_CHEMICAL", 54, 66], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 84, 108], ["GLU375", "SIMPLE_CHEMICAL", 149, 155], ["HIE345", "SIMPLE_CHEMICAL", 157, 163], ["HIE505", "SIMPLE_CHEMICAL", 168, 174], ["ACE2 enzyme", "PROTEIN", 21, 32], ["the ACE2 enzyme", "TEST", 17, 32], ["the sugar moiety", "TREATMENT", 50, 66], ["locking the Scutellarein", "TREATMENT", 72, 96], ["hydrogen bonds", "OBSERVATION", 129, 143]]], ["The phenyl ring was shown to make \u03c0-\u03c0 stacking interaction with the phenyl ring of HIE345.", [["phenyl", "CHEMICAL", 4, 10], ["HIE345", "CHEMICAL", 83, 89], ["phenyl", "CHEMICAL", 4, 10], ["\u03c0-\u03c0", "CHEMICAL", 34, 37], ["phenyl", "CHEMICAL", 68, 74], ["HIE345", "CHEMICAL", 83, 89], ["phenyl ring", "SIMPLE_CHEMICAL", 4, 15], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 34, 37], ["HIE345", "SIMPLE_CHEMICAL", 83, 89], ["The phenyl ring", "TREATMENT", 0, 15], ["the phenyl ring of HIE345", "TREATMENT", 64, 89], ["phenyl ring", "OBSERVATION", 4, 15]]], ["The carbonyl oxygen and hydroxyl group of chromone nucleus were displaying hydrogen bond interaction with the THR371 and ASH368 (Figure 4(ii)).Results and discussionAvicularin is a flavonoid isolated from Polygonum aviculare, Rhododendron aureum and Taxillus kaempferi (Fukunaga et al., 1989; Zhang et al., 1989).", [["carbonyl", "CHEMICAL", 4, 12], ["oxygen", "CHEMICAL", 13, 19], ["hydroxyl", "CHEMICAL", 24, 32], ["chromone", "CHEMICAL", 42, 50], ["discussionAvicularin", "CHEMICAL", 155, 175], ["flavonoid", "CHEMICAL", 181, 190], ["carbonyl", "CHEMICAL", 4, 12], ["oxygen", "CHEMICAL", 13, 19], ["hydroxyl", "CHEMICAL", 24, 32], ["chromone", "CHEMICAL", 42, 50], ["hydrogen", "CHEMICAL", 75, 83], ["THR371", "CHEMICAL", 110, 116], ["ASH368", "CHEMICAL", 121, 127], ["discussionAvicularin", "CHEMICAL", 155, 175], ["flavonoid", "CHEMICAL", 181, 190], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 4, 19], ["hydroxyl", "SIMPLE_CHEMICAL", 24, 32], ["chromone nucleus", "SIMPLE_CHEMICAL", 42, 58], ["THR371", "SIMPLE_CHEMICAL", 110, 116], ["discussionAvicularin", "SIMPLE_CHEMICAL", 155, 175], ["flavonoid", "SIMPLE_CHEMICAL", 181, 190], ["Polygonum aviculare", "ORGANISM", 205, 224], ["Rhododendron aureum", "ORGANISM", 226, 245], ["Taxillus kaempferi", "ORGANISM", 250, 268], ["Polygonum aviculare", "SPECIES", 205, 224], ["Rhododendron aureum", "SPECIES", 226, 245], ["Taxillus kaempferi", "SPECIES", 250, 268], ["Polygonum aviculare", "SPECIES", 205, 224], ["Rhododendron aureum", "SPECIES", 226, 245], ["Taxillus kaempferi", "SPECIES", 250, 268], ["The carbonyl oxygen", "TREATMENT", 0, 19], ["hydroxyl group of chromone nucleus", "TREATMENT", 24, 58], ["carbonyl oxygen", "OBSERVATION", 4, 19], ["chromone nucleus", "OBSERVATION", 42, 58], ["hydrogen bond", "OBSERVATION", 75, 88]]], ["A derivative of quercetin, it possesses biological properties including anti-cancer, anti-inflammatory, anti-oxidant, anti-allergic properties.", [["quercetin", "CHEMICAL", 16, 25], ["quercetin", "CHEMICAL", 16, 25], ["quercetin", "SIMPLE_CHEMICAL", 16, 25], ["A derivative of quercetin", "TREATMENT", 0, 25], ["anti-cancer", "TREATMENT", 72, 83], ["anti-inflammatory", "TREATMENT", 85, 102], ["anti-oxidant", "TREATMENT", 104, 116], ["anti-allergic properties", "TREATMENT", 118, 142], ["anti-inflammatory", "OBSERVATION_MODIFIER", 85, 102]]], ["Van Anh Vo et al., demonstrated the anti-inflammatory activity of avicularin by LPS-induced suppression of ERK signaling pathway in RAW 264.7 macrophage cells (Determination of Avicularin in Polygonum Aviculare L. by Square Wave Polarography. - PubMed - NCBI, n.d.).", [["RAW 264.7 macrophage cells", "ANATOMY", 132, 158], ["avicularin", "CHEMICAL", 66, 76], ["LPS", "CHEMICAL", 80, 83], ["avicularin", "CHEMICAL", 66, 76], ["avicularin", "SIMPLE_CHEMICAL", 66, 76], ["LPS", "SIMPLE_CHEMICAL", 80, 83], ["ERK", "GENE_OR_GENE_PRODUCT", 107, 110], ["RAW 264.7 macrophage cells", "CELL", 132, 158], ["Avicularin", "SIMPLE_CHEMICAL", 177, 187], ["Polygonum Aviculare L.", "ORGANISM", 191, 213], ["ERK", "PROTEIN", 107, 110], ["RAW 264.7 macrophage cells", "CELL_LINE", 132, 158], ["Polygonum", "SPECIES", 191, 200], ["Aviculare L.", "SPECIES", 201, 213], ["Polygonum Aviculare L.", "SPECIES", 191, 213], ["avicularin", "TREATMENT", 66, 76], ["LPS", "TEST", 80, 83], ["ERK signaling pathway", "TEST", 107, 128], ["macrophage cells", "TEST", 142, 158], ["Avicularin in Polygonum", "TREATMENT", 177, 200], ["Square Wave Polarography", "TEST", 217, 241], ["anti-inflammatory activity", "OBSERVATION", 36, 62], ["macrophage cells", "OBSERVATION", 142, 158]]], ["Avicularin elevated the sensitivity of cisplatin in drug resistant gastric cancer cells in in vitro and in vivo studies by enhancing the Bax and Bak expressions (Guo et al., 2018).", [["gastric cancer cells", "ANATOMY", 67, 87], ["Avicularin", "CHEMICAL", 0, 10], ["cisplatin", "CHEMICAL", 39, 48], ["gastric cancer", "DISEASE", 67, 81], ["Avicularin", "CHEMICAL", 0, 10], ["cisplatin", "CHEMICAL", 39, 48], ["Avicularin", "SIMPLE_CHEMICAL", 0, 10], ["cisplatin", "SIMPLE_CHEMICAL", 39, 48], ["gastric cancer cells", "CELL", 67, 87], ["Bax", "GENE_OR_GENE_PRODUCT", 137, 140], ["Bak", "GENE_OR_GENE_PRODUCT", 145, 148], ["gastric cancer cells", "CELL_TYPE", 67, 87], ["Bax", "PROTEIN", 137, 140], ["Bak", "PROTEIN", 145, 148], ["Avicularin", "PROBLEM", 0, 10], ["cisplatin", "TREATMENT", 39, 48], ["drug resistant gastric cancer cells", "PROBLEM", 52, 87], ["elevated", "OBSERVATION_MODIFIER", 11, 19], ["gastric", "ANATOMY", 67, 74], ["cancer cells", "OBSERVATION", 75, 87]]], ["In another study, avicularin suppressed the intracellular accumulation of lipids by suppressing C/EBP\u03b1-mediated activation of GLUT4 expression in 3T3-L1 cells (Fujimori & Shibano, 2013).", [["intracellular", "ANATOMY", 44, 57], ["3T3-L1 cells", "ANATOMY", 146, 158], ["avicularin", "CHEMICAL", 18, 28], ["avicularin", "CHEMICAL", 18, 28], ["avicularin", "SIMPLE_CHEMICAL", 18, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 57], ["lipids", "SIMPLE_CHEMICAL", 74, 80], ["C/EBP\u03b1", "GENE_OR_GENE_PRODUCT", 96, 102], ["GLUT4", "GENE_OR_GENE_PRODUCT", 126, 131], ["3T3-L1 cells", "CELL", 146, 158], ["Fujimori & Shibano", "CELL", 160, 178], ["EBP\u03b1", "PROTEIN", 98, 102], ["GLUT4", "PROTEIN", 126, 131], ["3T3-L1 cells", "CELL_LINE", 146, 158], ["another study", "TEST", 3, 16], ["avicularin", "TREATMENT", 18, 28], ["the intracellular accumulation of lipids", "PROBLEM", 40, 80], ["suppressing C/EBP", "PROBLEM", 84, 101], ["GLUT4 expression", "PROBLEM", 126, 142], ["intracellular accumulation", "OBSERVATION", 44, 70], ["GLUT4 expression", "OBSERVATION", 126, 142], ["L1 cells", "ANATOMY", 150, 158]]], ["Present computational analysis showed that it has good affinity to Mpro with a docking score of \u22129.6 Kcal/mol and MM-GBSA dG binding energy \u221266.6 Kcal/mol.", [["Mpro", "SIMPLE_CHEMICAL", 67, 71], ["Present computational analysis", "TEST", 0, 30], ["a docking score", "TEST", 77, 92], ["MM", "TEST", 114, 116]]], ["Similar to Delphinidin 3,5-diglucoside and scutellarein 7-glucoside, the alpha-L-arabinofuranosy moiety of avicularin is majorly involved in interaction with the main residues (CYS145 and GLU166) of the catalytic site via hydrogen bonding.", [["Delphinidin 3,5-diglucoside", "CHEMICAL", 11, 38], ["scutellarein 7-glucoside", "CHEMICAL", 43, 67], ["alpha-L-arabinofuranosy", "CHEMICAL", 73, 96], ["avicularin", "CHEMICAL", 107, 117], ["Delphinidin 3,5-diglucoside", "CHEMICAL", 11, 38], ["scutellarein 7-glucoside", "CHEMICAL", 43, 67], ["alpha-L-arabinofuranosy", "CHEMICAL", 73, 96], ["avicularin", "CHEMICAL", 107, 117], ["hydrogen", "CHEMICAL", 222, 230], ["Delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 11, 38], ["scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 43, 67], ["alpha-L-arabinofuranosy", "SIMPLE_CHEMICAL", 73, 96], ["avicularin", "SIMPLE_CHEMICAL", 107, 117], ["hydrogen", "SIMPLE_CHEMICAL", 222, 230], ["alpha-L-arabinofuranosy moiety", "PROTEIN", 73, 103], ["GLU166", "PROTEIN", 188, 194], ["catalytic site", "PROTEIN", 203, 217], ["Delphinidin", "TEST", 11, 22], ["diglucoside", "TREATMENT", 27, 38], ["scutellarein", "TREATMENT", 43, 55], ["glucoside", "TREATMENT", 58, 67], ["the alpha-L-arabinofuranosy moiety of avicularin", "TREATMENT", 69, 117], ["hydrogen bonding", "OBSERVATION", 222, 238]]], ["To further increase the binding affinity, the benzene ring forms \u03c0-\u03c0 stacking with the HIE41 of the hydrophobic subsite.", [["benzene", "CHEMICAL", 46, 53], ["benzene", "CHEMICAL", 46, 53], ["\u03c0-\u03c0", "CHEMICAL", 65, 68], ["HIE41", "CHEMICAL", 87, 92], ["benzene", "SIMPLE_CHEMICAL", 46, 53], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 65, 68], ["HIE41", "SIMPLE_CHEMICAL", 87, 92], ["HIE41", "PROTEIN", 87, 92], ["hydrophobic subsite", "PROTEIN", 100, 119], ["the binding affinity", "TREATMENT", 20, 40], ["the benzene ring forms", "TREATMENT", 42, 64]]], ["Also the hydroxyl group of chromone nucleus and benzene ring were found to interact with the THR190 and HIS164, CYS145, respectively through hydrogen bonding, enhancing the fit into the active site (Figure 3(iii)).", [["hydroxyl", "CHEMICAL", 9, 17], ["chromone", "CHEMICAL", 27, 35], ["benzene", "CHEMICAL", 48, 55], ["hydroxyl", "CHEMICAL", 9, 17], ["chromone", "CHEMICAL", 27, 35], ["benzene", "CHEMICAL", 48, 55], ["THR190", "CHEMICAL", 93, 99], ["HIS164", "CHEMICAL", 104, 110], ["CYS145", "CHEMICAL", 112, 118], ["hydrogen", "CHEMICAL", 141, 149], ["hydroxyl", "SIMPLE_CHEMICAL", 9, 17], ["chromone nucleus", "SIMPLE_CHEMICAL", 27, 43], ["benzene ring", "SIMPLE_CHEMICAL", 48, 60], ["THR190", "GENE_OR_GENE_PRODUCT", 93, 99], ["CYS145", "GENE_OR_GENE_PRODUCT", 112, 118], ["THR190", "PROTEIN", 93, 99], ["HIS164", "PROTEIN", 104, 110], ["CYS145", "PROTEIN", 112, 118], ["benzene ring", "PROBLEM", 48, 60], ["chromone nucleus", "OBSERVATION", 27, 43], ["benzene ring", "OBSERVATION", 48, 60], ["active", "OBSERVATION_MODIFIER", 186, 192], ["site", "OBSERVATION_MODIFIER", 193, 197]]], ["On the other hand avicularin has highest MM-GBSA dG binding energy of \u221244.50 Kcal/mol among all top leads for ACE2 enzyme.", [["avicularin", "CHEMICAL", 18, 28], ["dG", "CHEMICAL", 49, 51], ["avicularin", "CHEMICAL", 18, 28], ["avicularin", "SIMPLE_CHEMICAL", 18, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["ACE2 enzyme", "PROTEIN", 110, 121], ["Kcal/mol", "TREATMENT", 77, 85], ["ACE2 enzyme", "TEST", 110, 121]]], ["The hydroxyls of the alpha-L-arabinofuranosy moiety and phenyl ring shows binding interaction with residues GLU406, THR445, ASP367 and ASH368 of domain I. Docking poses also reveals the presence of multiple \u03c0-cation interaction between chromone nucleus and ARG273.", [["hydroxyls", "CHEMICAL", 4, 13], ["alpha-L-arabinofuranosy", "CHEMICAL", 21, 44], ["phenyl", "CHEMICAL", 56, 62], ["ARG273", "CHEMICAL", 257, 263], ["hydroxyls", "CHEMICAL", 4, 13], ["alpha-L-arabinofuranosy", "CHEMICAL", 21, 44], ["phenyl", "CHEMICAL", 56, 62], ["GLU406", "CHEMICAL", 108, 114], ["chromone", "CHEMICAL", 236, 244], ["ARG273", "CHEMICAL", 257, 263], ["alpha-L-arabinofuranosy moiety", "SIMPLE_CHEMICAL", 21, 51], ["phenyl ring", "SIMPLE_CHEMICAL", 56, 67], ["GLU406", "GENE_OR_GENE_PRODUCT", 108, 114], ["THR445", "GENE_OR_GENE_PRODUCT", 116, 122], ["ASP367", "GENE_OR_GENE_PRODUCT", 124, 130], ["\u03c0-cation", "SIMPLE_CHEMICAL", 207, 215], ["chromone", "SIMPLE_CHEMICAL", 236, 244], ["nucleus", "CELLULAR_COMPONENT", 245, 252], ["ARG273", "SIMPLE_CHEMICAL", 257, 263], ["alpha-L", "PROTEIN", 21, 28], ["THR445", "PROTEIN", 116, 122], ["ASP367", "PROTEIN", 124, 130], ["ASH368", "PROTEIN", 135, 141], ["The hydroxyls", "TREATMENT", 0, 13], ["the alpha-L-arabinofuranosy moiety", "TREATMENT", 17, 51], ["phenyl ring", "TREATMENT", 56, 67], ["multiple \u03c0-cation interaction between chromone nucleus", "PROBLEM", 198, 252], ["hydroxyls", "OBSERVATION_MODIFIER", 4, 13], ["multiple", "OBSERVATION_MODIFIER", 198, 206], ["\u03c0-cation", "OBSERVATION", 207, 215], ["chromone nucleus", "OBSERVATION", 236, 252]]], ["The carbonyl group of main nucleus was found to be bonded with ARG518 through hydrogen bonding (Figure 4(iii)).Results and discussionOut of top 4 screened leads 3,5-Di-O-galloylshikimic acid have the highest MM-GBSA dG binding energy of \u221235.09 Kcal/mol with docking score of \u221210.3 kcal/mol for Mpro.", [["nucleus", "ANATOMY", 27, 34], ["carbonyl", "CHEMICAL", 4, 12], ["ARG518", "CHEMICAL", 63, 69], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 161, 190], ["dG", "CHEMICAL", 216, 218], ["carbonyl", "CHEMICAL", 4, 12], ["ARG518", "CHEMICAL", 63, 69], ["hydrogen", "CHEMICAL", 78, 86], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 161, 190], ["carbonyl", "SIMPLE_CHEMICAL", 4, 12], ["nucleus", "CELLULAR_COMPONENT", 27, 34], ["ARG518", "SIMPLE_CHEMICAL", 63, 69], ["hydrogen", "SIMPLE_CHEMICAL", 78, 86], ["3,5-Di-O-galloylshikimic acid", "SIMPLE_CHEMICAL", 161, 190], ["Mpro", "SIMPLE_CHEMICAL", 294, 298], ["Mpro", "PROTEIN", 294, 298], ["galloylshikimic acid", "TEST", 170, 190], ["docking score", "TEST", 258, 271], ["Mpro", "TREATMENT", 294, 298], ["main nucleus", "ANATOMY", 22, 34]]], ["It is also the only lead among top four that lacks a sugar moiety.", [["sugar", "CHEMICAL", 53, 58], ["sugar moiety", "SIMPLE_CHEMICAL", 53, 65], ["sugar moiety", "OBSERVATION", 53, 65]]], ["To fit inside the Mpro cavity, the hydroxyl groups of benzoyl moiety are involved in H-bonding with the S4 subsite residues (THR190), and S1 subsite residues (HIS163, ASN142).", [["hydroxyl", "CHEMICAL", 35, 43], ["benzoyl", "CHEMICAL", 54, 61], ["H", "CHEMICAL", 85, 86], ["Mpro", "CHEMICAL", 18, 22], ["hydroxyl", "CHEMICAL", 35, 43], ["benzoyl", "CHEMICAL", 54, 61], ["H", "CHEMICAL", 85, 86], ["HIS163", "CHEMICAL", 159, 165], ["benzoyl moiety", "SIMPLE_CHEMICAL", 54, 68], ["H", "SIMPLE_CHEMICAL", 85, 86], ["HIS163", "SIMPLE_CHEMICAL", 159, 165], ["the Mpro cavity", "TREATMENT", 14, 29], ["the hydroxyl groups of benzoyl moiety", "TREATMENT", 31, 68]]], ["The hydroxyl group and the oxygen atoms of both the benzoyl groups are found to interact with the LEU167, GLY143 and GLU166 (Figure 3(iv)).Results and discussionHowever for ACE2, 3,5-Di-O-galloylshikimic acid has the 3rd lowest MM-GBSA dG binding energy of \u221251.7 Kcal/mol with docking score of \u221211.16 kcal/mol.", [["hydroxyl", "CHEMICAL", 4, 12], ["oxygen", "CHEMICAL", 27, 33], ["benzoyl", "CHEMICAL", 52, 59], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 179, 208], ["dG", "CHEMICAL", 236, 238], ["hydroxyl", "CHEMICAL", 4, 12], ["oxygen", "CHEMICAL", 27, 33], ["benzoyl", "CHEMICAL", 52, 59], ["LEU167", "CHEMICAL", 98, 104], ["GLY143", "CHEMICAL", 106, 112], ["GLU166", "CHEMICAL", 117, 123], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 179, 208], ["hydroxyl", "SIMPLE_CHEMICAL", 4, 12], ["oxygen atoms", "SIMPLE_CHEMICAL", 27, 39], ["benzoyl", "SIMPLE_CHEMICAL", 52, 59], ["LEU167", "SIMPLE_CHEMICAL", 98, 104], ["GLY143", "SIMPLE_CHEMICAL", 106, 112], ["GLU166", "SIMPLE_CHEMICAL", 117, 123], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["3,5-Di-O-galloylshikimic acid", "SIMPLE_CHEMICAL", 179, 208], ["ACE2", "PROTEIN", 173, 177], ["The hydroxyl group", "TREATMENT", 0, 18], ["the oxygen atoms", "TREATMENT", 23, 39], ["GLY143", "TEST", 106, 112], ["ACE2", "TEST", 173, 177], ["galloylshikimic acid", "TEST", 188, 208], ["docking score", "TEST", 277, 290]]], ["From the docked poses inside ACE2 catalytic site, it can be concluded that oxygen of the carboxylate was found to interact with HIE505 and HIE345 through hydrogen bonding and with ARG273 through non-covalent ionic interaction (salt bridge).", [["oxygen", "CHEMICAL", 75, 81], ["carboxylate", "CHEMICAL", 89, 100], ["HIE505", "CHEMICAL", 128, 134], ["HIE345", "CHEMICAL", 139, 145], ["ARG273", "CHEMICAL", 180, 186], ["oxygen", "CHEMICAL", 75, 81], ["carboxylate", "CHEMICAL", 89, 100], ["HIE505", "CHEMICAL", 128, 134], ["HIE345", "CHEMICAL", 139, 145], ["hydrogen", "CHEMICAL", 154, 162], ["ARG273", "CHEMICAL", 180, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["carboxylate", "SIMPLE_CHEMICAL", 89, 100], ["HIE505", "SIMPLE_CHEMICAL", 128, 134], ["HIE345", "SIMPLE_CHEMICAL", 139, 145], ["ARG273", "SIMPLE_CHEMICAL", 180, 186], ["ACE2", "PROTEIN", 29, 33], ["ARG273 through non-covalent ionic interaction (salt bridge", "TREATMENT", 180, 238]]], ["The hydroxyls of the benzoyl moiety were displaying hydrogen bonding interaction with the TYR127 and GLU406.", [["benzoyl", "CHEMICAL", 21, 28], ["hydroxyls", "CHEMICAL", 4, 13], ["benzoyl", "CHEMICAL", 21, 28], ["hydrogen", "CHEMICAL", 52, 60], ["TYR127", "CHEMICAL", 90, 96], ["GLU406", "CHEMICAL", 101, 107], ["benzoyl moiety", "SIMPLE_CHEMICAL", 21, 35], ["hydrogen", "SIMPLE_CHEMICAL", 52, 60], ["TYR127", "SIMPLE_CHEMICAL", 90, 96], ["GLU406", "SIMPLE_CHEMICAL", 101, 107], ["TYR127", "PROTEIN", 90, 96], ["GLU406", "PROTEIN", 101, 107], ["The hydroxyls of the benzoyl moiety", "TREATMENT", 0, 35], ["hydrogen bonding interaction", "PROBLEM", 52, 80], ["hydrogen bonding", "OBSERVATION", 52, 68]]], ["HIE345 of the side chain was involved in the \u03c0-\u03c0 stacking interaction with one of the benzoyl ring (Figure 4(iv)).", [["HIE345", "CHEMICAL", 0, 6], ["benzoyl", "CHEMICAL", 86, 93], ["benzoyl", "CHEMICAL", 86, 93], ["HIE345", "SIMPLE_CHEMICAL", 0, 6], ["benzoyl ring", "SIMPLE_CHEMICAL", 86, 98], ["Figure 4(iv)", "SIMPLE_CHEMICAL", 100, 112], ["the benzoyl ring (Figure 4(iv)", "TREATMENT", 82, 112]]], ["The docking score of all the screened natural secondary metabolites is shown in Figure 5.Results and discussionTo be eligible for clinical evaluation, pharmacokinetic profile of a drug plays pivotal role.", [["The docking score", "TEST", 0, 17], ["clinical evaluation", "TEST", 130, 149]]], ["Based on the results of ADME calculations all the investigated leads have low bioavailability score.", [["ADME calculations", "TEST", 24, 41], ["low bioavailability score", "PROBLEM", 74, 99]]], ["The bioavailability score (ABS) depends on passing or violating Lipinski\u2019s rule of five.", [["The bioavailability score", "TEST", 0, 25]]], ["At biological pH, a compound is expected to have >10% bioavailability (F) in rat only if it pass Lipinski\u2019s rule of five with ABS 0.55 (i.e. 55% chances of F > 10% in rat).", [["rat", "ORGANISM", 77, 80], ["rat", "ORGANISM", 167, 170], ["rat", "SPECIES", 77, 80], ["rat", "SPECIES", 167, 170], ["ABS", "TEST", 126, 129], ["F", "TEST", 156, 157]]], ["However if it fails, ABS is only 0.17 i.e. 17% chance for a molecule to have bioavailability >10% in rat (Martin, 2005).", [["rat", "ORGANISM", 101, 104], ["rat", "SPECIES", 101, 104], ["rat", "SPECIES", 101, 104], ["ABS", "TEST", 21, 24], ["bioavailability", "TEST", 77, 92]]], ["With ABS-0.17, delphinidin 3,5-diglucoside (an anthocyanin), the bioavailability through gastro intestinal tract (GIT) is reported to be very low.", [["gastro intestinal tract", "ANATOMY", 89, 112], ["GIT", "ANATOMY", 114, 117], ["delphinidin 3,5-diglucoside", "CHEMICAL", 15, 42], ["anthocyanin", "CHEMICAL", 47, 58], ["delphinidin 3,5-diglucoside", "CHEMICAL", 15, 42], ["anthocyanin", "CHEMICAL", 47, 58], ["delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 15, 42], ["anthocyanin", "SIMPLE_CHEMICAL", 47, 58], ["gastro intestinal tract", "MULTI-TISSUE_STRUCTURE", 89, 112], ["GIT", "MULTI-TISSUE_STRUCTURE", 114, 117], ["ABS", "TEST", 5, 8], ["delphinidin", "TREATMENT", 15, 26], ["diglucoside", "TREATMENT", 31, 42], ["an anthocyanin", "TREATMENT", 44, 58], ["gastro", "ANATOMY", 89, 95], ["intestinal tract", "ANATOMY", 96, 112], ["low", "OBSERVATION", 142, 145]]], ["A study reported by McGhie and Walton (2007) concluded that in animals and humans low anthocyanins levels are absorbed in the circulation and excreted in urine, but high levels are found in the gastrointestinal (GI) tract.", [["urine", "ANATOMY", 154, 159], ["gastrointestinal (GI) tract", "ANATOMY", 194, 221], ["anthocyanins", "CHEMICAL", 86, 98], ["gastrointestinal (GI) tract", "DISEASE", 194, 221], ["anthocyanins", "CHEMICAL", 86, 98], ["humans", "ORGANISM", 75, 81], ["anthocyanins", "SIMPLE_CHEMICAL", 86, 98], ["urine", "ORGANISM_SUBSTANCE", 154, 159], ["gastrointestinal", "ORGANISM_SUBDIVISION", 194, 210], ["(GI) tract", "ORGANISM_SUBDIVISION", 211, 221], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["A study", "TEST", 0, 7], ["humans low anthocyanins levels", "PROBLEM", 75, 105], ["high levels", "PROBLEM", 165, 176], ["circulation", "ANATOMY", 126, 137], ["gastrointestinal", "ANATOMY", 194, 210], ["GI", "ANATOMY", 212, 214]]], ["Another investigation by Paul et al. (2018) suggests that anthocyanins in the form of crude extract have less bioavailability as compared to encapsulated spray dried formulations.", [["extract", "ANATOMY", 92, 99], ["anthocyanins", "CHEMICAL", 58, 70], ["anthocyanins", "CHEMICAL", 58, 70], ["anthocyanins", "SIMPLE_CHEMICAL", 58, 70], ["anthocyanins", "TREATMENT", 58, 70], ["crude extract", "TREATMENT", 86, 99], ["encapsulated spray dried formulations", "TREATMENT", 141, 178]]], ["Like delphinidin 3,5-diglucoside the next two leads (Scutellarein 7-glucoside, Avicularin) which are glycosidic flavonoids also have less bioavailability with acceptable water solubility limit.", [["delphinidin 3,5-diglucoside", "CHEMICAL", 5, 32], ["Scutellarein 7-glucoside", "CHEMICAL", 53, 77], ["Avicularin", "CHEMICAL", 79, 89], ["glycosidic flavonoids", "CHEMICAL", 101, 122], ["delphinidin 3,5-diglucoside", "CHEMICAL", 5, 32], ["Scutellarein 7-glucoside", "CHEMICAL", 53, 77], ["Avicularin", "CHEMICAL", 79, 89], ["glycosidic flavonoids", "CHEMICAL", 101, 122], ["delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 5, 32], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 53, 77], ["Avicularin", "SIMPLE_CHEMICAL", 79, 89], ["glycosidic flavonoids", "SIMPLE_CHEMICAL", 101, 122], ["water", "SIMPLE_CHEMICAL", 170, 175], ["delphinidin", "TREATMENT", 5, 16], ["Scutellarein", "TREATMENT", 53, 65], ["glucoside", "TREATMENT", 68, 77], ["Avicularin", "TREATMENT", 79, 89], ["glycosidic flavonoids", "TREATMENT", 101, 122], ["delphinidin 3,5", "OBSERVATION", 5, 20], ["glycosidic flavonoids", "OBSERVATION", 101, 122]]], ["Glycosidic flavonoids show less permeability through GIT (Arts et al., 2004).", [["Glycosidic flavonoids", "CHEMICAL", 0, 21], ["Glycosidic flavonoids", "CHEMICAL", 0, 21], ["Glycosidic flavonoids", "SIMPLE_CHEMICAL", 0, 21], ["GIT", "ORGAN", 53, 56], ["Glycosidic flavonoids", "TEST", 0, 21], ["flavonoids", "OBSERVATION", 11, 21], ["less permeability", "OBSERVATION_MODIFIER", 27, 44]]], ["Hollman et al. reported that only aglycone part of flavonoids pass through the intestinal membrane and glycone moiety mostly gets digested in the GIT with time to reach peak concentrations (Tmax) between <0.5 and 9 h (Walle, 2004).", [["intestinal membrane", "ANATOMY", 79, 98], ["GIT", "ANATOMY", 146, 149], ["aglycone", "CHEMICAL", 34, 42], ["flavonoids", "CHEMICAL", 51, 61], ["glycone", "CHEMICAL", 103, 110], ["flavonoids", "CHEMICAL", 51, 61], ["glycone", "CHEMICAL", 103, 110], ["aglycone", "SIMPLE_CHEMICAL", 34, 42], ["flavonoids", "SIMPLE_CHEMICAL", 51, 61], ["intestinal membrane", "MULTI-TISSUE_STRUCTURE", 79, 98], ["glycone moiety", "SIMPLE_CHEMICAL", 103, 117], ["GIT", "ORGAN", 146, 149], ["flavonoids", "TREATMENT", 51, 61], ["glycone moiety", "TREATMENT", 103, 117], ["peak concentrations", "PROBLEM", 169, 188], ["Tmax", "TEST", 190, 194], ["flavonoids pass", "OBSERVATION", 51, 66], ["intestinal membrane", "ANATOMY", 79, 98]]], ["The 3,5-Di-O-galloylshikimic acid (gallotanin with quinic acid core) estimated log S value suggest that it has acceptable water solubility due to presence of polar functional groups, yet its bioavailability score is only 0.11.Results and discussionBoth from docking and ADME analysis, it is clear that the sugar moieties and other polar groups are both responsible for the high binding affinity to Mpro/ACE2 and low oral bioavailability.", [["oral", "ANATOMY", 416, 420], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 4, 33], ["gallotanin", "CHEMICAL", 35, 45], ["quinic acid", "CHEMICAL", 51, 62], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 4, 33], ["gallotanin", "CHEMICAL", 35, 45], ["quinic acid", "CHEMICAL", 51, 62], ["sugar", "CHEMICAL", 306, 311], ["3,5-Di-O-galloylshikimic acid", "SIMPLE_CHEMICAL", 4, 33], ["gallotanin", "SIMPLE_CHEMICAL", 35, 45], ["quinic acid", "SIMPLE_CHEMICAL", 51, 62], ["sugar moieties", "SIMPLE_CHEMICAL", 306, 320], ["Mpro", "GENE_OR_GENE_PRODUCT", 398, 402], ["ACE2", "GENE_OR_GENE_PRODUCT", 403, 407], ["oral", "ORGANISM_SUBDIVISION", 416, 420], ["Mpro", "PROTEIN", 398, 402], ["ACE2", "PROTEIN", 403, 407], ["Di-O-galloylshikimic acid (gallotanin", "TREATMENT", 8, 45], ["quinic acid core", "TREATMENT", 51, 67], ["estimated log S value", "TEST", 69, 90], ["polar functional groups", "PROBLEM", 158, 181], ["its bioavailability score", "TEST", 187, 212], ["ADME analysis", "TEST", 270, 283], ["the sugar moieties", "PROBLEM", 302, 320], ["the high binding affinity", "PROBLEM", 369, 394], ["Mpro/ACE2", "TREATMENT", 398, 407], ["low oral bioavailability", "TREATMENT", 412, 436], ["polar", "ANATOMY_MODIFIER", 158, 163]]], ["Among other natural compounds reported to bind with Mpro and ACE2, Epigallocatechin gallate (EGCG) (Khaerunnisa et al., 2020; Lalit & Vyomesh, 2020; Mittal et al., 2020) and Theaflavin-3,3-digallate (Manish, 2020) also showed very good binding to Mpro and ACE2, but has poor oral bioavailability (ABS-0.17) (Figure 6).", [["oral", "ANATOMY", 275, 279], ["Epigallocatechin gallate", "CHEMICAL", 67, 91], ["EGCG", "CHEMICAL", 93, 97], ["Theaflavin-3,3-digallate", "CHEMICAL", 174, 198], ["Epigallocatechin gallate", "CHEMICAL", 67, 91], ["EGCG", "CHEMICAL", 93, 97], ["Theaflavin-3,3-digallate", "CHEMICAL", 174, 198], ["Manish, 2020", "CHEMICAL", 200, 212], ["Mpro", "SIMPLE_CHEMICAL", 52, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["Epigallocatechin gallate", "SIMPLE_CHEMICAL", 67, 91], ["EGCG", "SIMPLE_CHEMICAL", 93, 97], ["Theaflavin-3,3-digallate", "SIMPLE_CHEMICAL", 174, 198], ["Manish", "SIMPLE_CHEMICAL", 200, 206], ["Mpro", "GENE_OR_GENE_PRODUCT", 247, 251], ["ACE2", "GENE_OR_GENE_PRODUCT", 256, 260], ["oral", "ORGANISM_SUBDIVISION", 275, 279], ["ACE2", "PROTEIN", 61, 65], ["Mpro", "PROTEIN", 247, 251], ["ACE2", "PROTEIN", 256, 260], ["ACE2", "TEST", 61, 65], ["Theaflavin", "TEST", 174, 184], ["ACE2", "TEST", 256, 260], ["poor oral bioavailability", "PROBLEM", 270, 295], ["ABS", "TEST", 297, 300]]], ["Specifically, EGCG has been reported to be broken down in large intestine by the colonic microflora.", [["intestine", "ANATOMY", 64, 73], ["colonic microflora", "ANATOMY", 81, 99], ["EGCG", "CHEMICAL", 14, 18], ["EGCG", "CHEMICAL", 14, 18], ["EGCG", "SIMPLE_CHEMICAL", 14, 18], ["intestine", "ORGAN", 64, 73], ["colonic microflora", "MULTI-TISSUE_STRUCTURE", 81, 99], ["EGCG", "TEST", 14, 18], ["broken", "OBSERVATION", 43, 49], ["large", "ANATOMY_MODIFIER", 58, 63], ["intestine", "ANATOMY", 64, 73], ["colonic", "ANATOMY", 81, 88], ["microflora", "OBSERVATION", 89, 99]]], ["The fraction of EGCG that is absorbed might undergo rapid methylation catalyzed by liver cytosolic catechol-O-methyltransferase which decreases its hydrophilicity (Mereles & Hunstein, 2011), the key feature found responsible for Mpro inhibition.", [["liver cytosolic", "ANATOMY", 83, 98], ["EGCG", "CHEMICAL", 16, 20], ["catechol", "CHEMICAL", 99, 107], ["EGCG", "CHEMICAL", 16, 20], ["catechol", "CHEMICAL", 99, 107], ["O", "CHEMICAL", 108, 109], ["EGCG", "SIMPLE_CHEMICAL", 16, 20], ["liver", "ORGAN", 83, 88], ["catechol-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 99, 127], ["Mpro", "GENE_OR_GENE_PRODUCT", 229, 233], ["liver cytosolic catechol-O-methyltransferase", "PROTEIN", 83, 127], ["Mpro", "PROTEIN", 229, 233], ["rapid methylation catalyzed", "TREATMENT", 52, 79], ["liver cytosolic catechol", "TEST", 83, 107], ["Mpro inhibition", "TREATMENT", 229, 244], ["EGCG", "OBSERVATION", 16, 20], ["liver", "ANATOMY", 83, 88]]], ["Thus a majority of the natural molecules with therapeutic potential against SARS-CoVs require an effective way to get delivered to lung in their native form to bypass degradation and metabolism associated with oral route.ConclusionTraditional medicines in different countries have history of successfully treating several epidemics and endemics.", [["lung", "ANATOMY", 131, 135], ["oral", "ANATOMY", 210, 214], ["SARS", "DISEASE", 76, 80], ["SARS-CoVs", "SIMPLE_CHEMICAL", 76, 85], ["lung", "ORGAN", 131, 135], ["oral", "ORGANISM_SUBDIVISION", 210, 214], ["SARS", "PROBLEM", 76, 80], ["CoVs", "PROBLEM", 81, 85], ["bypass degradation", "TREATMENT", 160, 178], ["oral route", "TREATMENT", 210, 220], ["Traditional medicines", "TREATMENT", 231, 252], ["endemics", "PROBLEM", 336, 344], ["lung", "ANATOMY", 131, 135], ["bypass", "OBSERVATION", 160, 166]]], ["With advanced drug discovery tools in place, it is feasible to screen active ingredients of these natural concoctions for potential antiviral application.", [["advanced drug discovery tools", "PROBLEM", 5, 34], ["these natural concoctions", "TREATMENT", 92, 117], ["potential antiviral application", "TREATMENT", 122, 153]]], ["We attempted to explore this approach by screening selected natural secondary metabolites for their dual binding potential to (1) viral main protease Mpro that has a conserved catalytic cleavage site responsible for post-translational processing of polyproteins required for viral replication in all SARS corona viruses and (2) ACE2 the principle receptor responsible for entry of the viral particles into the host cells.", [["cells", "ANATOMY", 415, 420], ["Mpro", "CHEMICAL", 150, 154], ["Mpro", "GENE_OR_GENE_PRODUCT", 150, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 328, 332], ["host cells", "CELL", 410, 420], ["viral main protease", "PROTEIN", 130, 149], ["Mpro", "PROTEIN", 150, 154], ["catalytic cleavage site", "PROTEIN", 176, 199], ["polyproteins", "PROTEIN", 249, 261], ["ACE2", "PROTEIN", 328, 332], ["host cells", "CELL_TYPE", 410, 420], ["SARS corona viruses", "SPECIES", 300, 319], ["this approach", "TREATMENT", 24, 37], ["viral main protease Mpro", "TREATMENT", 130, 154], ["a conserved catalytic cleavage site", "PROBLEM", 164, 199], ["polyproteins", "PROBLEM", 249, 261], ["viral replication", "PROBLEM", 275, 292], ["all SARS corona viruses", "PROBLEM", 296, 319], ["ACE2 the principle receptor", "TREATMENT", 328, 355], ["viral particles", "OBSERVATION", 385, 400], ["host cells", "OBSERVATION", 410, 420]]], ["The top four leads Delphinidin 3,5-diglucoside, Scutellarein 7-glucoside, Avicularin and 3,5-Di-O-galloylshikimic acid showed encouraging binding affinity with MM-GBSA energies up to \u221274.0 Kcal/mol and \u221279.5 Kcal/mol to Mpro and ACE2, respectively.", [["Delphinidin 3,5-diglucoside", "CHEMICAL", 19, 46], ["Scutellarein 7-glucoside", "CHEMICAL", 48, 72], ["Avicularin", "CHEMICAL", 74, 84], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 89, 118], ["Delphinidin 3,5-diglucoside", "CHEMICAL", 19, 46], ["Scutellarein 7-glucoside", "CHEMICAL", 48, 72], ["Avicularin", "CHEMICAL", 74, 84], ["3,5-Di-O-galloylshikimic acid", "CHEMICAL", 89, 118], ["Delphinidin 3,5-diglucoside", "SIMPLE_CHEMICAL", 19, 46], ["Scutellarein 7-glucoside", "SIMPLE_CHEMICAL", 48, 72], ["Avicularin", "SIMPLE_CHEMICAL", 74, 84], ["3,5-Di-O-galloylshikimic acid", "SIMPLE_CHEMICAL", 89, 118], ["MM-GBSA", "SIMPLE_CHEMICAL", 160, 167], ["Mpro", "GENE_OR_GENE_PRODUCT", 220, 224], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["Mpro", "PROTEIN", 220, 224], ["ACE2", "PROTEIN", 229, 233], ["Delphinidin", "TEST", 19, 30], ["diglucoside", "TREATMENT", 35, 46], ["Scutellarein", "TEST", 48, 60], ["glucoside", "TREATMENT", 63, 72], ["Avicularin", "TREATMENT", 74, 84], ["galloylshikimic acid", "TEST", 98, 118], ["MM", "TEST", 160, 162], ["GBSA energies", "TEST", 163, 176]]], ["However, their theoretical bioavailability score (ABS) of 0.11 or 0.17 makes them ineffective via oral route.", [["oral", "ANATOMY", 98, 102], ["oral", "ORGANISM_SUBDIVISION", 98, 102], ["their theoretical bioavailability score", "TEST", 9, 48], ["ABS", "TEST", 50, 53]]], ["Potential natural leads such as Delphinidin 3, 5-diglucoside, an anthocyanin responsible for the red pigmentation of pomegranate juice, are ingested orally.", [["juice", "ANATOMY", 129, 134], ["Delphinidin 3, 5-diglucoside", "CHEMICAL", 32, 60], ["anthocyanin", "CHEMICAL", 65, 76], ["Delphinidin 3, 5-diglucoside", "CHEMICAL", 32, 60], ["anthocyanin", "CHEMICAL", 65, 76], ["Delphinidin 3,", "SIMPLE_CHEMICAL", 32, 46], ["5-diglucoside", "SIMPLE_CHEMICAL", 47, 60], ["anthocyanin", "SIMPLE_CHEMICAL", 65, 76], ["pomegranate", "ORGANISM", 117, 128], ["juice", "ORGANISM_SUBSTANCE", 129, 134], ["pomegranate", "SPECIES", 117, 128], ["Delphinidin", "TREATMENT", 32, 43], ["diglucoside", "TREATMENT", 49, 60], ["an anthocyanin", "TREATMENT", 62, 76], ["the red pigmentation of pomegranate juice", "TREATMENT", 93, 134], ["natural leads", "OBSERVATION", 10, 23], ["pomegranate juice", "OBSERVATION", 117, 134]]], ["Nonetheless, their viral inhibitory potential is greatly limited by low oral bioavailability.", [["oral", "ANATOMY", 72, 76], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["low oral bioavailability", "PROBLEM", 68, 92]]], ["To overcome this bottleneck, these molecules can be either engineered to withstand GIT degradation and first pass metabolism or can be encapsulated in nano/microparticles towards their site specific pulmonary delivery.", [["GIT", "ANATOMY", 83, 86], ["site", "ANATOMY", 185, 189], ["pulmonary", "ANATOMY", 199, 208], ["GIT", "ORGAN", 83, 86], ["pulmonary", "ORGAN", 199, 208], ["GIT degradation", "PROBLEM", 83, 98], ["nano/microparticles", "TREATMENT", 151, 170], ["pulmonary", "ANATOMY", 199, 208]]]], "10a3d96f8c163b21326407afa9d05a51adc79e47": [], "PMC7215148": [["Case presentation ::: IntroductionOn January 25, 2020, a 48-year-old male who suffered from fever for 3 days went to local hospital to see a doctor.", [["fever", "DISEASE", 92, 97], ["male", "ORGANISM", 69, 73], ["fever", "PROBLEM", 92, 97], ["fever", "OBSERVATION", 92, 97]]], ["His highest body temperature reached 39 \u00b0C, accompanied with chills, cough and fatigue.", [["body", "ANATOMY", 12, 16], ["chills", "DISEASE", 61, 67], ["cough", "DISEASE", 69, 74], ["fatigue", "DISEASE", 79, 86], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["His highest body temperature", "TEST", 0, 28], ["chills", "PROBLEM", 61, 67], ["cough", "PROBLEM", 69, 74], ["fatigue", "PROBLEM", 79, 86], ["chills", "OBSERVATION", 61, 67], ["cough", "OBSERVATION", 69, 74]]], ["Chest radiography, blood routine and 2019-nCoV nucleic acid test was undertaken with suspected novel coronavirus pneumonia (NCP).", [["blood", "ANATOMY", 19, 24], ["nucleic acid", "CHEMICAL", 47, 59], ["coronavirus pneumonia", "DISEASE", 101, 122], ["NCP", "DISEASE", 124, 127], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["coronavirus", "ORGANISM", 101, 112], ["Chest radiography", "TEST", 0, 17], ["blood routine", "TEST", 19, 32], ["nCoV nucleic acid test", "TEST", 42, 64], ["novel coronavirus pneumonia", "PROBLEM", 95, 122], ["coronavirus", "OBSERVATION_MODIFIER", 101, 112], ["pneumonia", "OBSERVATION", 113, 122]]], ["Only stripes of the lower lobe of the left lung was found by the chest radiography (Fig. 1a).", [["lower lobe", "ANATOMY", 20, 30], ["left lung", "ANATOMY", 38, 47], ["chest", "ANATOMY", 65, 70], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 20, 30], ["lung", "ORGAN", 43, 47], ["the chest radiography", "TEST", 61, 82], ["stripes", "OBSERVATION_MODIFIER", 5, 12], ["lower lobe", "ANATOMY_MODIFIER", 20, 30], ["left", "ANATOMY_MODIFIER", 38, 42], ["lung", "ANATOMY", 43, 47], ["chest", "ANATOMY", 65, 70]]], ["One day later, the Centers for Disease Control and Prevention (CDC) of Wenzhou confirmed that the patient's oropharyngeal swabs tested positive for 2019-nCoV.", [["oropharyngeal swabs", "ANATOMY", 108, 127], ["patient", "ORGANISM", 98, 105], ["oropharyngeal swabs", "ORGAN", 108, 127], ["patient", "SPECIES", 98, 105], ["Disease Control", "TREATMENT", 31, 46], ["the patient's oropharyngeal swabs", "TEST", 94, 127], ["oropharyngeal", "ANATOMY", 108, 121]]], ["On January 28, 2020, the patient was admitted to an airborne-isolation unit at local hospital.Case presentation ::: IntroductionThe patient had a history of AS for 2 years and using Tumor Necrosis Factor-\u03b1(TNF-\u03b1)inhibitor to control disease (25mg per times, 8 times for the first month, 4 times for the second month, then reduced to 2 times one month, and recently 1 times every 50 days, the last injection was 50 days ago).", [["AS", "DISEASE", 157, 159], ["patient", "ORGANISM", 25, 32], ["patient", "ORGANISM", 132, 139], ["Tumor Necrosis Factor-\u03b1", "GENE_OR_GENE_PRODUCT", 182, 205], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 206, 211], ["Tumor Necrosis Factor-\u03b1(TNF-\u03b1", "PROTEIN", 182, 211], ["patient", "SPECIES", 25, 32], ["patient", "SPECIES", 132, 139], ["Tumor Necrosis Factor", "TREATMENT", 182, 203], ["\u03b1(TNF-\u03b1)inhibitor", "TREATMENT", 204, 221], ["disease", "PROBLEM", 233, 240], ["Necrosis", "OBSERVATION", 188, 196]]], ["In addition, he had a history of hypertriglyceridemia and hypertension, but no history of smoking.", [["hypertriglyceridemia", "DISEASE", 33, 53], ["hypertension", "DISEASE", 58, 70], ["smoking", "CHEMICAL", 90, 97], ["hypertriglyceridemia", "PROBLEM", 33, 53], ["hypertension", "PROBLEM", 58, 70], ["hypertriglyceridemia", "OBSERVATION", 33, 53], ["hypertension", "OBSERVATION", 58, 70]]], ["The physical examination revealed no obvious abnormalities.", [["The physical examination", "TEST", 0, 24], ["obvious abnormalities", "PROBLEM", 37, 58], ["no", "UNCERTAINTY", 34, 36], ["obvious", "OBSERVATION_MODIFIER", 37, 44], ["abnormalities", "OBSERVATION", 45, 58]]], ["After admission, the patient received supplemental oxygen, antiviral (lopinavir and ritonavir tablets, interferon \u03b12\u03b2) and antibacterial (moxifloxacin) therapy.Case presentation ::: IntroductionOn days 2 through 7 of hospitalization, the patient continued to report a nonproductive cough, fatigued and intermittent fevers, followed by abdominal discomfort and diarrhea.", [["abdominal", "ANATOMY", 335, 344], ["oxygen", "CHEMICAL", 51, 57], ["lopinavir and ritonavir tablets, interferon \u03b12\u03b2", "CHEMICAL", 70, 117], ["moxifloxacin", "CHEMICAL", 138, 150], ["cough", "DISEASE", 282, 287], ["intermittent fevers", "DISEASE", 302, 321], ["abdominal discomfort", "DISEASE", 335, 355], ["diarrhea", "DISEASE", 360, 368], ["oxygen", "CHEMICAL", 51, 57], ["lopinavir", "CHEMICAL", 70, 79], ["ritonavir", "CHEMICAL", 84, 93], ["moxifloxacin", "CHEMICAL", 138, 150], ["patient", "ORGANISM", 21, 28], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["lopinavir", "SIMPLE_CHEMICAL", 70, 79], ["ritonavir", "SIMPLE_CHEMICAL", 84, 93], ["interferon \u03b12\u03b2", "SIMPLE_CHEMICAL", 103, 117], ["moxifloxacin", "SIMPLE_CHEMICAL", 138, 150], ["patient", "ORGANISM", 238, 245], ["abdominal", "ORGANISM_SUBDIVISION", 335, 344], ["patient", "SPECIES", 21, 28], ["patient", "SPECIES", 238, 245], ["supplemental oxygen", "TREATMENT", 38, 57], ["antiviral (lopinavir", "TREATMENT", 59, 79], ["ritonavir tablets", "TREATMENT", 84, 101], ["interferon \u03b1", "TREATMENT", 103, 115], ["antibacterial (moxifloxacin) therapy", "TREATMENT", 123, 159], ["a nonproductive cough", "PROBLEM", 266, 287], ["fatigued", "PROBLEM", 289, 297], ["intermittent fevers", "PROBLEM", 302, 321], ["abdominal discomfort", "PROBLEM", 335, 355], ["diarrhea", "PROBLEM", 360, 368], ["nonproductive", "OBSERVATION_MODIFIER", 268, 281], ["cough", "OBSERVATION", 282, 287], ["intermittent", "OBSERVATION_MODIFIER", 302, 314], ["fevers", "OBSERVATION", 315, 321], ["abdominal", "ANATOMY", 335, 344], ["discomfort", "OBSERVATION", 345, 355], ["diarrhea", "OBSERVATION", 360, 368]]], ["Laboratory results on hospital days 2 showed elevated levels of creatine kinase, ferritin, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), lower percentage of lymphocytes.", [["erythrocyte", "ANATOMY", 120, 131], ["lymphocytes", "ANATOMY", 178, 189], ["creatine", "CHEMICAL", 64, 72], ["creatine", "CHEMICAL", 64, 72], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 64, 79], ["ferritin", "GENE_OR_GENE_PRODUCT", 81, 89], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 91, 109], ["CRP", "GENE_OR_GENE_PRODUCT", 111, 114], ["erythrocyte sedimentation rate", "GENE_OR_GENE_PRODUCT", 120, 150], ["lymphocytes", "CELL", 178, 189], ["creatine kinase", "PROTEIN", 64, 79], ["ferritin", "PROTEIN", 81, 89], ["C-reactive protein", "PROTEIN", 91, 109], ["CRP", "PROTEIN", 111, 114], ["lymphocytes", "CELL_TYPE", 178, 189], ["elevated levels of creatine kinase", "PROBLEM", 45, 79], ["ferritin", "TEST", 81, 89], ["C", "TEST", 91, 92], ["reactive protein", "TEST", 93, 109], ["CRP", "TEST", 111, 114], ["erythrocyte sedimentation rate", "TEST", 120, 150], ["ESR", "TEST", 152, 155], ["lower percentage of lymphocytes", "PROBLEM", 158, 189], ["lower percentage", "OBSERVATION_MODIFIER", 158, 174], ["lymphocytes", "ANATOMY", 178, 189]]], ["Computerized tomography (CT) taken on hospital day 1 showed infiltrates in lower lobe of both lung (Fig. 1b).", [["lower lobe", "ANATOMY", 75, 85], ["lung", "ANATOMY", 94, 98], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 75, 85], ["lung", "ORGAN", 94, 98], ["Computerized tomography (CT)", "TEST", 0, 28], ["infiltrates in lower lobe of both lung", "PROBLEM", 60, 98], ["infiltrates", "OBSERVATION", 60, 71], ["lower lobe", "ANATOMY", 75, 85], ["both", "ANATOMY_MODIFIER", 89, 93], ["lung", "ANATOMY", 94, 98]]], ["A second CT from hospital day 4 showed more obvious evidence of pneumonia (Fig. 1c), and arbidol tablets was added to strengthen antiviral therapy.Case presentation ::: IntroductionA third CT (hospital day 8) showed no obviously improvement of the pneumonia (Fig. 1d).", [["pneumonia", "DISEASE", 64, 73], ["arbidol", "CHEMICAL", 89, 96], ["pneumonia", "DISEASE", 248, 257], ["arbidol", "CHEMICAL", 89, 96], ["arbidol tablets", "SIMPLE_CHEMICAL", 89, 104], ["A second CT", "TEST", 0, 11], ["pneumonia", "PROBLEM", 64, 73], ["arbidol tablets", "TREATMENT", 89, 104], ["strengthen antiviral therapy", "TREATMENT", 118, 146], ["IntroductionA third CT", "TEST", 169, 191], ["the pneumonia", "PROBLEM", 244, 257], ["obvious evidence of", "UNCERTAINTY", 44, 63], ["pneumonia", "OBSERVATION", 64, 73], ["antiviral therapy", "OBSERVATION", 129, 146], ["no", "UNCERTAINTY", 216, 218], ["obviously", "OBSERVATION_MODIFIER", 219, 228], ["improvement", "OBSERVATION_MODIFIER", 229, 240], ["pneumonia", "OBSERVATION", 248, 257]]], ["Then methylprednisolone 80 mg daily was added to alleviate alveolar inflammation, which was reduced regularly.", [["alveolar", "ANATOMY", 59, 67], ["methylprednisolone", "CHEMICAL", 5, 23], ["inflammation", "DISEASE", 68, 80], ["methylprednisolone", "CHEMICAL", 5, 23], ["methylprednisolone", "SIMPLE_CHEMICAL", 5, 23], ["alveolar", "MULTI-TISSUE_STRUCTURE", 59, 67], ["methylprednisolone", "TREATMENT", 5, 23], ["alveolar inflammation", "PROBLEM", 59, 80], ["alveolar", "ANATOMY", 59, 67], ["inflammation", "OBSERVATION", 68, 80]]], ["Rechecked CT (hospital day 10 and day 18) showed the previous infiltrates lesion absorption (Fig. 1e and f).", [["lesion", "ANATOMY", 74, 80], ["Rechecked CT", "TEST", 0, 12], ["the previous infiltrates lesion absorption", "PROBLEM", 49, 91], ["infiltrates", "OBSERVATION", 62, 73]]], ["On hospital day 14, the patient's oropharyngeal swabs tested negative for 2019-nCoV.", [["oropharyngeal swabs", "ANATOMY", 34, 53], ["patient", "ORGANISM", 24, 31], ["oropharyngeal", "ORGANISM_SUBDIVISION", 34, 47], ["swabs", "ORGANISM_SUBSTANCE", 48, 53], ["patient", "SPECIES", 24, 31], ["the patient's oropharyngeal swabs", "TEST", 20, 53], ["oropharyngeal", "ANATOMY", 34, 47]]], ["On hospital day 18, the patient's clinical condition improved significantly.DiscussionThis case of report, to our knowledge, is the first case of 2019-nCoV infection in a AS patient who was a regular TNF-\u03b1 inhibitor user.", [["infection", "DISEASE", 156, 165], ["patient", "ORGANISM", 24, 31], ["2019-nCoV", "ORGANISM", 146, 155], ["patient", "ORGANISM", 174, 181], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 200, 205], ["TNF", "PROTEIN", 200, 203], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 174, 181], ["nCoV infection", "PROBLEM", 151, 165], ["a regular TNF-\u03b1 inhibitor user", "TREATMENT", 190, 220], ["infection", "OBSERVATION", 156, 165]]], ["The dosing interval was a bit longer than usual usage due to low disease activity of AS.", [["low disease activity of AS", "PROBLEM", 61, 87], ["low", "OBSERVATION_MODIFIER", 61, 64], ["disease", "OBSERVATION", 65, 72]]], ["We found low incidence of NCP in rheumatic disease patient, and the reason remain unclear.DiscussionRecent study reported that the pathological of 2019-nCoV manifested with increased CCR4+ Th17 cells which may lead to high levels of cytokine [3].", [["CCR4+ Th17 cells", "ANATOMY", 183, 199], ["NCP", "DISEASE", 26, 29], ["rheumatic disease", "DISEASE", 33, 50], ["patient", "ORGANISM", 51, 58], ["CCR4", "GENE_OR_GENE_PRODUCT", 183, 187], ["CCR4", "PROTEIN", 183, 187], ["Th17 cells", "CELL_TYPE", 189, 199], ["cytokine", "PROTEIN", 233, 241], ["patient", "SPECIES", 51, 58], ["NCP in rheumatic disease", "PROBLEM", 26, 50], ["DiscussionRecent study", "TEST", 90, 112], ["increased CCR4+ Th17 cells", "PROBLEM", 173, 199], ["low incidence", "OBSERVATION_MODIFIER", 9, 22], ["NCP", "OBSERVATION_MODIFIER", 26, 29], ["rheumatic disease", "OBSERVATION", 33, 50], ["Th17 cells", "OBSERVATION", 189, 199]]], ["Some studies also found patients infected with 2019-nCoV had high amounts of cytokine, including IL2, IL10, and TNF\u03b1 [4].", [["patients", "ORGANISM", 24, 32], ["2019-nCoV", "ORGANISM", 47, 56], ["IL2", "GENE_OR_GENE_PRODUCT", 97, 100], ["IL10", "GENE_OR_GENE_PRODUCT", 102, 106], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 112, 116], ["cytokine", "PROTEIN", 77, 85], ["IL2", "PROTEIN", 97, 100], ["IL10", "PROTEIN", 102, 106], ["TNF\u03b1", "PROTEIN", 112, 116], ["patients", "SPECIES", 24, 32], ["Some studies", "TEST", 0, 12], ["cytokine", "TREATMENT", 77, 85], ["IL2, IL10", "TREATMENT", 97, 106]]], ["Pulmonary epithelia damage leading to respiratory distress syndrome (ARDS) can be a consequence of a cytokine storm, consist of IL-1\u03b2, TNF [5].", [["Pulmonary epithelia", "ANATOMY", 0, 19], ["respiratory", "ANATOMY", 38, 49], ["Pulmonary epithelia damage", "DISEASE", 0, 26], ["respiratory distress syndrome", "DISEASE", 38, 67], ["ARDS", "DISEASE", 69, 73], ["Pulmonary epithelia", "TISSUE", 0, 19], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 128, 133], ["TNF", "GENE_OR_GENE_PRODUCT", 135, 138], ["cytokine", "PROTEIN", 101, 109], ["IL-1\u03b2", "PROTEIN", 128, 133], ["TNF", "PROTEIN", 135, 138], ["Pulmonary epithelia damage", "PROBLEM", 0, 26], ["respiratory distress syndrome", "PROBLEM", 38, 67], ["ARDS", "PROBLEM", 69, 73], ["a cytokine storm", "PROBLEM", 99, 115], ["IL", "TEST", 128, 130], ["epithelia", "ANATOMY_MODIFIER", 10, 19], ["damage", "OBSERVATION", 20, 26], ["respiratory distress", "OBSERVATION", 38, 58]]], ["Anti-TNF\u03b1 may have a protect effect as a decrease in serum TNF-\u03b1 and IL-1\u03b2 is associated with decreased lung injury and lethality in rats [6].", [["serum", "ANATOMY", 53, 58], ["lung", "ANATOMY", 104, 108], ["lung injury", "DISEASE", 104, 115], ["Anti-TNF\u03b1", "GENE_OR_GENE_PRODUCT", 0, 9], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 59, 64], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 69, 74], ["lung", "ORGAN", 104, 108], ["rats", "ORGANISM", 133, 137], ["TNF\u03b1", "PROTEIN", 5, 9], ["TNF", "PROTEIN", 59, 62], ["IL-1\u03b2", "PROTEIN", 69, 74], ["rats", "SPECIES", 133, 137], ["Anti-TNF", "TREATMENT", 0, 8], ["a decrease", "PROBLEM", 39, 49], ["serum TNF", "TEST", 53, 62], ["IL", "TEST", 69, 71], ["decreased lung injury", "PROBLEM", 94, 115], ["lethality in rats", "PROBLEM", 120, 137], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["associated with", "UNCERTAINTY", 78, 93], ["decreased", "OBSERVATION_MODIFIER", 94, 103], ["lung", "ANATOMY", 104, 108], ["injury", "OBSERVATION", 109, 115], ["lethality", "OBSERVATION_MODIFIER", 120, 129]]], ["And earlier infliximab (anti-TNF\u03b1 monoclonal antibody) administration is associated with better therapeutic result and prognosis in patient with dermatomyositis with acute interstitial pneumonia [7].", [["interstitial", "ANATOMY", 172, 184], ["infliximab", "CHEMICAL", 12, 22], ["dermatomyositis", "DISEASE", 145, 160], ["interstitial pneumonia", "DISEASE", 172, 194], ["infliximab", "SIMPLE_CHEMICAL", 12, 22], ["anti-TNF\u03b1", "GENE_OR_GENE_PRODUCT", 24, 33], ["patient", "ORGANISM", 132, 139], ["TNF\u03b1 monoclonal antibody", "PROTEIN", 29, 53], ["patient", "SPECIES", 132, 139], ["earlier infliximab", "TREATMENT", 4, 22], ["anti-TNF\u03b1 monoclonal antibody) administration", "TREATMENT", 24, 69], ["dermatomyositis", "PROBLEM", 145, 160], ["acute interstitial pneumonia", "PROBLEM", 166, 194], ["dermatomyositis", "OBSERVATION", 145, 160], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["interstitial", "ANATOMY_MODIFIER", 172, 184], ["pneumonia", "OBSERVATION", 185, 194]]], ["Since no-specific treatment has been recommended for 2019-nCoV infection, anti-TNF\u03b1 therapy may be a potential treatment for NCP.DiscussionDespite its anti-inflammation effect, exposed to anti-TNF agent may increase risk of all infections, markedly bacterial and fungal opportunistic infections [8,9].", [["infection", "DISEASE", 63, 72], ["TNF\u03b1", "CHEMICAL", 79, 83], ["NCP", "DISEASE", 125, 128], ["infections", "DISEASE", 228, 238], ["bacterial and fungal opportunistic infections", "DISEASE", 249, 294], ["anti-TNF\u03b1", "GENE_OR_GENE_PRODUCT", 74, 83], ["TNF\u03b1", "PROTEIN", 79, 83], ["no-specific treatment", "TREATMENT", 6, 27], ["nCoV infection", "PROBLEM", 58, 72], ["anti-TNF\u03b1 therapy", "TREATMENT", 74, 91], ["a potential treatment", "TREATMENT", 99, 120], ["NCP", "PROBLEM", 125, 128], ["anti-TNF agent", "TREATMENT", 188, 202], ["all infections", "PROBLEM", 224, 238], ["markedly bacterial and fungal opportunistic infections", "PROBLEM", 240, 294], ["infection", "OBSERVATION", 63, 72], ["all", "OBSERVATION_MODIFIER", 224, 227], ["infections", "OBSERVATION", 228, 238], ["bacterial", "OBSERVATION_MODIFIER", 249, 258], ["fungal", "OBSERVATION_MODIFIER", 263, 269], ["opportunistic", "OBSERVATION_MODIFIER", 270, 283]]], ["This patient had normal levels of cytokine, which may due to his pervious injection of TNF\u03b1.", [["patient", "ORGANISM", 5, 12], ["TNF", "GENE_OR_GENE_PRODUCT", 87, 90], ["cytokine", "PROTEIN", 34, 42], ["TNF", "PROTEIN", 87, 90], ["patient", "SPECIES", 5, 12], ["his pervious injection of TNF", "TREATMENT", 61, 90]]], ["But the true role of TNF\u03b1 in NCP remain unknown, and whether anti-TNF therapy is benefit for NCP need more real world data.ConclusionIn the study, we presented a case of patient with rheumatic disease under anti-TNF\u03b1 therapy infected with 2019-nCoV.", [["NCP", "DISEASE", 29, 32], ["rheumatic disease", "DISEASE", 183, 200], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 21, 25], ["NCP", "CANCER", 29, 32], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 61, 69], ["patient", "ORGANISM", 170, 177], ["anti-TNF\u03b1", "GENE_OR_GENE_PRODUCT", 207, 216], ["TNF\u03b1", "PROTEIN", 21, 25], ["TNF", "PROTEIN", 212, 215], ["patient", "SPECIES", 170, 177], ["anti-TNF therapy", "TREATMENT", 61, 77], ["the study", "TEST", 136, 145], ["rheumatic disease", "PROBLEM", 183, 200], ["anti-TNF\u03b1 therapy", "TREATMENT", 207, 224], ["nCoV", "TREATMENT", 244, 248], ["rheumatic", "OBSERVATION", 183, 192]]], ["Anti-TNF therapy may have positive effect in NCP.", [["NCP", "DISEASE", 45, 48], ["TNF", "GENE_OR_GENE_PRODUCT", 5, 8], ["TNF", "PROTEIN", 5, 8], ["Anti-TNF therapy", "TREATMENT", 0, 16], ["positive effect in NCP", "PROBLEM", 26, 48], ["positive", "OBSERVATION_MODIFIER", 26, 34], ["effect", "OBSERVATION_MODIFIER", 35, 41]]]]}